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Metastasis, the process of cancer dissemination, is responsible for at least 90% of cancer
deaths. Treating or preventing metastasis remains a long-standing aim in cancer research,
however tumours are a complex mixture of cancer cells which precludes the success of ther-
apy. To understand what factors contribute to metastasis and treatment response, it is critical
to characterise the tumour microenvironment (non-cancerous cells in the tumour tissue).
Ovarian cancer offers a unique opportunity to study the tumour microenvironment because
diagnosis often occurs at advanced stages when metastasis has already taken place. This
thesis presents a comprehensive analysis of an long-term (>10 years) survivor of metastatic
ovarian cancer (5 tumours) who exhibited differential progression/regression of different
tumour lesions. Regressing tumours showed a higher expression of genes related to immune
cell infiltration and activation, while progressing tumours showed high expression of genes
associated with blocking immune infiltration. This demonstrates co-existence of tumour mi-
croenvironments within a patient. Then a follow-up study is presented where different tumour
microenvironments within patients with metastatic ovarian cancer at diagnosis are charac-
terised (8 patients and 38 tumours). Co-existence of different tumour microenvironments
within patients was corroborated, and genes associated with immune exclusion appeared
highly expressed in some tumours. Evaluation of the effect of neoadjuvant chemotherapy was
assessed in an independent cohort with matched and unmatched pre/post therapy samples (40
patients and 80 tumours). This study showed that chemotherapy induces immune activation,
and paradoxically, that low levels of immune activation pre-chemotherapy correlate with
immune activation upon chemotherapy treatment. Importantly, these observations were only
detected when intra-patient tumour microenvironment differences were considered. Finally,
computational tools that predict cell types in tumours using cell-type specific gene sets were
benchmarked and a consensus approach (ConsensusTME) was developed. ConsensusTME
outperforms other methods in estimating immune infiltration levels in ovarian cancer and
in most tumour types. This study provides a comprehensive examination of the tumour
microenvironment in ovarian cancer at diagnosis and in response to chemotherapy, and
generated a resource for a consensus computational approach for estimation of immune cells
in tumours using gene expression profiles.

Abstract
The tumour microenvironment comprises the non-cancerous cells present in the tumour mass
(fibroblasts, endothelial, and immune cells), as well as signalling molecules and extracellular
matrix. Tumour growth, invasion, metastasis, and response to therapy are influenced by the
tumour microenvironment. Therefore, characterising the cellular and molecular components
of the tumour microenvironment, and understanding how they influence tumour progression,
represent a crucial aim for the success of cancer therapies. High-grade serous ovarian cancer
provides an excellent opportunity to systematically study the tumour microenvironment due
to its clinical presentation of advanced disseminated disease and debulking surgery being
standard of care.
This thesis first presents a case report of a long-term survivor (>10 years) of metastatic
high-grade serous ovarian cancer who exhibited concomitant regression/progression of the
metastatic lesions (5 samples). We found that progressing metastases were characterized
by immune cell exclusion, whereas regressing metastases were infiltrated by CD8+ and
CD4+ T cells. Through a T cell - neoepitope challenge assay we demonstrated that pre-
dicted neoepitopes were recognised by the CD8+ T cells obtained from blood drawn from
the patient, suggesting that regressing tumours were subjected to immune attack. Immune
excluded tumours presented a higher expression of immunosuppressive Wnt signalling, while
infiltrated tumours showed a higher expression of the T cell chemoattractant CXCL9 and
evidence of immunoediting. These findings suggest that multiple distinct tumour immune
microenvironments can co-exist within a single individual and may explain in part the hetero-
geneous fates of metastatic lesions often observed in the clinic post-therapy.
Second, this thesis explores the prevalence of intra-patient tumour microenvironment het-
erogeneity in high-grade serous ovarian cancer at diagnosis (38 samples from 8 patients),
as well as the effect of chemotherapy on the tumour microenvironment (80 paired samples
from 40 patients). Whole transcriptome analysis and image-based quantification of T cells
from treatment-naive tumours revealed highly prevalent variability in immune signalling and
distinct immune microenvironments co-existing within the same individuals at diagnosis.
xii
ConsensusTME, a method that generates consensus immune and stromal cell gene signatures
by intersecting state-of-the-art deconvolution methods that predict immune cell populations
using bulk RNA data was developed. ConsensusTME improved accuracy and sensitivity of
T cell and leukocyte deconvolutions in ovarian cancer samples. As previously observed in
the case report, Wnt signalling expression positively correlated with immune cell exclusion.
To evaluate the effect of chemotherapy on the tumour microenvironment, we compared
site-matched and site-unmatched tumours before and after neoadjuvant chemotherapy. Site-
matched samples showed increased cytotoxic immune activation and oligoclonal expansion
of T cells after chemotherapy, unlike site-unmatched samples where heterogeneity could not
be accounted for. In addition, low levels of immune activation pre-chemotherapy were found
to be correlated with immune activation upon chemotherapy treatment. These results cor-
roborate that the tumour-immune interface in advanced high-grade serous ovarian cancer is
intrinsically heterogeneous, and that chemotherapy induces an immunogenic effect mediated
by cytotoxic cells.
Finally, the different deconvolution methods were benchmarked along with ConsensusTME
in a pan-cancer setting by comparing deconvolution scores to DNA-based purity scores,
leukocyte methylation data, and tumour infiltrating lymphocyte counts from image analysis.
In so far as it has been benchmarked, unlike the other methods, ConsensusTME performs
consistently among the top three methods across cancer-related benchmarks. Additionally,
ConsensusTME provides a dynamic and evolvable framework that can integrate newer de-
convolution tools and benchmark their performance against itself, thus generating an ever
updated version.
Overall, this thesis presents a systematic characterisation of the tumour microenvironment
of high grade serous ovarian cancer in treatment-naive and chemotherapy treated samples,
and puts forward the development of an integrative computational method for the systematic
analysis of the tumour microenvironment of different tumour types using bulk RNA data.
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Chapter 1
Introduction
Cancer is more than one disease, more than a disease of the genome, and more than a group
of cells that proliferate uncontrollably. Instead, the word cancer as a concept, comprises a
number of different tumour types that relate to their tissue and cell of origin. It also includes
de-regulation of multiple molecular systems in the cells besides the genome, including the
epigenome, the transcriptome, the proteome, the secretome, etc. Finally, tumours are complex
semi-organised tissues that interact with their surrounding microenvironment and, therefore,
consist of a network of heterotypic interactions between cancerous and non-cancerous cells.
Altogether, cancer cannot and should not be understood, conceived, or thought only as a
disease of the genome any more.
Studying the tumour niche and how the non-cancerous cells interact with the tumour has be-
come a central paradigm in cancer research. As such, integrating different data types beyond
genome sequencing through computational systematic approaches is a central endeavour
towards gaining a comprehensive understanding of cancer. Additionally, due to the com-
plexity of tumours, it is foreseeable that accounting for the different layers of heterogeneity
and differences across tumour types, patients with the same tumour type, and even between
tumours within the same patient, would become common practice both for cancer researchers
and clinicians.
By employing computational and statistical analyses of tumours from patients with ovarian
cancer, this doctoral thesis explores and illustrates how the TME interacts and shapes tumour
development, and contributes to the field of immunogenomics of cancer by trying to improve
stromal and immune cell estimations using bulk RNA data in a pan-cancer setting.
2 Introduction
1.1 The tumour microenvironment
It has been proposed that cancer development can be rationalised as a multi-step process
by which cancer cells acquire several traits that allow them to proliferate indefinitely in an
uncontrolled manner (Hanahan and Weinberg, 2011). Following this rationale, for cancer
cells to succeed at establishing a consolidated tumour, the following traits have been proposed
to be sufficient:
1. Constitutive proliferative signalling




6. Cell death resistance
7. Cellular metabolism adaptation
8. Immune evasion
Furthermore, two traits have been proposed to be consequential of neoplastic development
but also facilitators of the carcinogenic process, thus constituting feedback loop traits, these
are:
1. Genome instability and mutation acquisition
2. Innate immune tumour-promoting inflammation
These 10 traits together comprise what has been termed "The Hallmarks of Cancer" (Hanahan
and Weinberg, 2011). To note, angiogenesis induction, immune evasion, and innate immune
tumour-promoting inflammation involve other cells other than the cancer cells themselves,
since tumour progression requires the interaction with extrinsic elements as well. In this
sense, the collection of the non-cancerous cellular and non-cellular components present in
the tumour niche are defined as the TME.
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1.1.1 Cellular composition of the tumour microenvironment
As previously noted, tumours are considered as tissue-like entities that, in terms of complex-
ity, closely resemble healthy tissues and organs composition. Therefore, to comprehensively
understand tumour progression it is necessary to study the different cell types present in
the tumour mass and the TME. The TME consists of signalling molecules and extracellular
matrix, but most importantly the non-cancerous cells which can have passive or actively roles
in tumour progression as described in the next section.
In the interest of clarity, throughout the text the terms tumour microenvironment, niche,
and stroma refer to the non-cancerous elements of the tumour. In addition, despite signalling
molecules and extracellular matrix being elements of the TME, they are not directly discussed
in this thesis.
A great variety of stromal cell types populate tumours, as they do in healthy organs. These
can be classified according to their developmental origin and their functional interactions
(Figure 1.1):
1. Fibroblasts and adipocytes
2. Neuroendocrine cells
3. Endothelial cells and pericytes
4. Innate immune cells
5. Innate/adaptive immune cells
6. Adaptive immune cells
Each of the cell types and differentiation states that constitute the categories listed above
perform distinct functions and promote, maintain, restrict, or counteract tumour progression
differently [reviewed in Wang et al. 2017]. The listed TME cell-type categories are critical
for various "Hallmarks of Cancer" through heterotypic interactions between cancer cells and














































































































































































































































Fig. 1.1 Cells of the tumour microenvironment. Summary of cellular origins and differentiation
processes of cells present in the tumour microenvironment with gene classical gene markers. Markers
in black are expressed, while markers in red are not.
1.1.2 Cancer and tumour microenvironment cellular interactions
The cellular components of the TME play an active role in tumour progression through
constant interactions that evolve into complex interactive networks involving both secreted
and membrane-bound molecules (Wang et al., 2017). However, the interactions between
the cancer cells and cells of each of the TME cell-type categories are different, as the effect
of such interactions. The known effects these TME cells produce in tumours in relation to
the "Hallmarks of Cancer" are briefly summarised in this following section. The adaptive
immune cell compartment, is described in more detail since the adaptive TME compartment
resulted the main focus of the research performed in this thesis.
Fibroblasts and adipocytes
Fibroblasts
Fibroblasts can induce angiogenesis, recruit immune cells, stimulate cancer cell proliferation
[reviewed in Kalluri and Zeisberg 2006; Wiseman 2002], and induce epithelial mesenchymal
transition (EMT) of cancer cells (Eberlein et al., 2014; Jung et al., 2013).
Adipocytes
Adipocytes are involved in the physiology of energy homeostasis by regulating its storage
and release (Kajimura, 2017). Epidemiological studies have shown that the risk of developing
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cancer is higher in obese individuals (Calle et al., 2003). Multiple lines of evidence also sug-
gest that adipocytes influence cancer initiation and progression. However, most interactions
are related to inflammation [reviewed in Wang et al. 2017], except for the observation that
adypocites can induce EMT in breast cancer cells (Devarajan et al., 2012; Pinilla et al., 2009;
Zimmerlin et al., 2011).
Neuroendocrine cells
Neuroendocrine cells are present in many organs, where their function is to secrete hormones
as a response to a neuronal input. Similar to adipocytes, many independent studies have
observed tumour induced effect of neuroendocrine cells. However, most of these associations
relate to immune cell recruitment and no systematic analyses have been conducted to critically
assess the direct effect of neuroendocrine cells on cancer cells [reviewed in Wang et al. 2017].
Therefore, the active role of neuroendocrine cells in the tumour niche seems to be more
related to the cross-talk with other TME cells so far.
Endothelial cells and pericytes
Endothelial cells
Endothelial cells are responsible for the vasculature in the body, both blood and lymphatic
vessels. In tumours, therefore, they are the main contributors of the angiogenic switch
[reviewed in Hanahan and Folkman 1996].
Pericytes
Pericytes also contribute to the formation of blood vessels in tumours providing more stable
vascularity [reviewed in Bergers et al. 2005; Gaengel et al. 2009; Pietras and Östman 2010].
The main effect of vascularisation in tumours is the nutrition supply through the blood, which
is required by cancer cells to survive and proliferate, as well as for non-cancerous cells in
the tumour niche. However, a consequence of vascularisation in tumours is that it can also
facilitate metastatasis [reviewed in Gerhardt and Semb 2008; Raza et al. 2010].
Innate immune cells
The fact that the immune system is crucial in the protection against cancer is well supported
[reviewed in Schreiber et al. 2011]. For example, experiments have shown that immunodefi-
cient mice have an increased susceptibility to develop cancer compared to immunocompetent
mice (Dighe et al., 1994). However, the immune system consists of numerous different cell
types and their interaction with cancer cells and with other cells in the TME is different for
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each cell type.
Innate immune cells are characterised by mounting a non-specific, memoryless, quick
response to pathogens and cancer. Innate immune cells include dendritic cells, monocytes,
macrophages, neutrophils, eosinophils, and mast cells [reviewed in Angell and Galon 2013].
Dendritic cells
Dendritic cells are professional antigen presenting cells that are critical for antitumor im-
munity, as they can de-novo recruit other immune cells (particularly T cells) and induce an
adaptive immune response [reviewed in Corrales et al. 2017; Veglia and Gabrilovich 2017],
however they can also contribute to an immune suppressive TME (Tesone et al., 2016).
Monocytes and macrophages
Monocytes are usually found in the blood stream and are the direct precursors of macrophages.
Monocytes differentiate into macrophages once they are recruited to a tissue, which includes
tumours (Bayik et al., 2017). It has been recognised that macrophages can have anti-tumour
or pro-tumorigenic effects, and a simplistic conceptualisation of this dichotomy has been ren-
dered as the M0/M1/M2 macrophage framework, where M0 represent neutral macrophages,
M1 anti-tumour macrophages, and M2 immune suppressive macrophages [reviewed in
Martinez and Gordon 2014; Shapouri-Moghaddam et al. 2018]. However, this M1/M2
categorisation could also be an oversimplification, since tumour associated macrophages can
have dual roles in tumour progression depending on the context [reviewed in Martinez and
Gordon 2014].
Neutrophils
Neutrophils migrate to sites of infection through chemotaxis and amplify inflammation by the
release of cytokines in the site of infection. Neutrophils also phagocyte, de-granulate proteins
with anti-microbial properties, and generate neutrophil extracellular traps, which are web-like
structures of DNA that trap and kill extracellular microorganisms. The role of neutrophils
in cancer depends on several different factors and is not completely understood [reviewed
in Ocana et al. 2017]. However, it has been shown that neutrophils can induce angiogen-
esis (Antonio et al., 2015), tumour growth, and metastasis [reviewed in Swierczak et al. 2015].
Eosinophils
Eosinophil functions include de-granulation of anti-microbial proteins, production of reactive
oxygen species, secretion of pro-inflammatory cytokines, growth factors, and enzymes at
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the site of inflammation. In cancer, eosinophil infiltration has been associated with better
prognosis in general, however the mechanisms behind eosinophil infiltration are still largely
unknown and seems to be tumour-type dependent [reviewed in Davis et al. 2014].
Mast cells Similarly, mast cells are important in the inflammatory process. Mast cells
can either selectively or rapidly de-granulate pro-inflammatory factors. Mast cells have been
associated with pro- and anti-tumourigenic effects, or simply bystanders depending on their
surrounding microenvironment and the tumour type [reviewed in Varricchi et al. 2017].
Innate/adaptive immune cells
Natural killer cells
Natural Killer cells (NK) have been originally considered to be part of the innate immune
system, as they largely comply with the innate immunity functional characteristics (non-
specific, memoryless, rapid response). However, NK cells are more closely related to
adaptive immune cells in their differentiation pathway (Hanahan and Weinberg, 2011). In-
deed, NK cells interactions with cancer cells occur through different mechanisms: one is
called antibody-dependent cellular cytotoxicity, where NK cells bind antibodies that have
recognised antigens on the cell surface of cancer cells; another well known mechanism
depends on the presence of activating ligands and lack of human leukocyte antigen (HLA)
molecules which are essential for T cell recognition as below [reviewed in Lowry and Zehring
2017]; lastly expression of "stress" related ligands that are related to HLA molecules are
also recognised and activate NK cells, γδ T cells, and CD8+ T cells (Bauer et al., 1999). In
addition, the ability to generate memory has been observed in NK cells against viral infec-
tions [reviewed in O’sullivan et al. 2015]. Despite the type of response, NK cell immunity
has been mainly associated with anti-tumour response [reviewed in Lowry and Zehring 2017].
γδ T cells
Similarly, γδ T cells belong to the lymphoid branch of the immune system, express specific
rearranged T cell receptor (TCR) genes and develop immunological memory. However, they
also express invariant receptors like NK cells, which recognise ligands on stressed epithelial
cells without specificity or memory [reviewed in Fleming et al. 2017]. Unlike, NK cells, γδ
T cells have been associated with both anti- and pro-tumourigenic effects, and although still
under investigation, the different effect seems to be related to which subset of γδ T cells are
present in the TME [reviewed in Fleming et al. 2017; Wu et al. 2016].
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Innate lymphoid cells
Innate Lymphoid Cells (ILC) are a type of lymphoid cells that have been defined more
recently, and have been associated with both tumour promoting and suppressing phenotypes
[reviewed in Wagner et al. 2017]. Although very similar to NK cells, ILCs have been
characterised to be less anti-tumourigenic (Gao et al., 2017). ILCs lack rearrangement of
specific receptors [reviewed in Mattner and Wirtz 2017], but secrete cytokines that regulate
the immune response, including the regulation of T cell infiltration into tumours (Crome et al.,
2017). However, the understanding of the function of ILCs in tumours is still incomplete
(Wagner et al., 2017).
Adaptive immune cells
The adaptive immunity is characterised by being specific, creating memory, and provide an
enhanced response to specific antigens after an initial encounter. Adaptive immunological
memory allows long-lasting protection against specific antigens, and thus vaccination is
possible. B and T cell lymphocytes are responsible for the adaptive immune response.
B cells
B cells are lymphocytes express specific B cell receptor (BCR) on their plasma membrane,
which when activated is secreted resulting in an antibody. In addition, B cells also present
antigens and regulate immunity through cytokine secretion. B cells mature in the bone
marrow and are characterised by the expression of their BCR on the membrane. Given
the right microenvironment, when a BCR recognises an antigen, B cells become activated
and differentiate into plasma cells, which finally produce and secrete large amounts of the
antibody that recognises the specific antigen, and become memory B cells [reviewed in
Cooper 2015]. The secreted antibodies can then bind the antigens on the cancer cells and
then be targeted by macrophages, or used as an anchor for NK cell mediated killing. Despite
this clear anti-tumourigenic effect, B cells have been also associated with pro-tumourigenic
phenotypes, since they secrete cytokines that regulate infiltration of T cell lymphocytes
[reviewed in Yuen et al. 2016].
T cells
T cells can be broadly classified in two groups: CD4+ (helper) and CD8+ (cytotoxic) T cells.
CD4+ T cells are specialised in the secretion of cytokines that stimulate and regulate the
immune response. Besides, CD8+ T cells are specialised in the secretion of perforin and
granzyme proteins, which produce pores in the plasma membrane and/or activates the Fas
receptor on the target cell leading to the activation of caspases and apoptosis of the target
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cell [reviewed in Smith-Garvin et al. 2009]. Furthermore, many studies have shown that T
cells play an important role in the recognition and elimination of cancer [reviewed in van der
Woude et al. 2017].
T cell specificity
T cell receptor
The expression of TCR genes, and their translocation to the membrane, is what characterise
T cells. The T cell receptors are vastly diverse within an individual (over 108 different TCRs)
(Arstila et al., 1999) because they are generated by somatic genetic recombination of multiple
variable immunoglobulin genes [reviewed in Von Essen et al. 2012]. The molecular process
that generates this vast TCR diversity is similar to that for antibodies and B cell antigen
receptors. The TCR diversity is generated in the thymus by the genetic recombination of the
variable, joining, and sometimes diversity gene segments (V(D)J segments) in individual T
cells through RAG1 and RAG2 recombinases. To ensure high affinity of the TCR, unlike
B cells which undergo “affinity maturation” through somatic hypermutation of their BCR
genes, T cells increase their antigen responsiveness through the sustained expression of genes
involved in T cell response once they have encountered an antigen, this process is called
“functional avidity maturation” [reviewed in Von Essen et al. 2012]. Each recombined TCR
has a unique antigen specificity, which is determined by the tertiary protein structure of
the antigen-binding site formed by the α and β chains of αβ T cells or γ and δ chains of
γδ T cells. Both the α and γ chains are generated by the recombination of VJ segments,
while β and δ chains are generated by VDJ recombination. The intersection of the VJ or
and VDJ chains correspond to the complementary-determining region 3 (CDR3), the most
variable region of the TCR and important for antigen recognition on the Human Leukocyte
Antigen (HLA). The unique combination of the V(D)J segments in the CDR3 region, along
with the palindromic and random nucleotide additions are responsible for the enormous TCR
diversity [reviewed in Alcover et al. 2018].
HLA and epitope determinants
T cells use their TCR which recognise peptides bound to Major Histocompatibility Com-
plex (MHC) molecules, called Human Leukocyte Antigen (HLA) system in humans, on the
plasma membrane of other cells. Peptides bound to HLAs are called epitopes, as they can
be recognised by a TCR. There are two types of HLA molecules: HLA class I molecules
are expressed in every nucleated cell and display intracellular peptides, whereas HLA class
II molecules are expressed by Antigen Presenting Cells (APC)s (e.g. dendritic cells and
macrophages) and display peptides from extracellular origin after being phagocyted by the
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APC. The expression level of HLA-I molecules differs among different cell types, and it
is subject to regulation by various cytokines. The process by which a peptide is displayed
on the plasma membrane is slightly different for HLA-I and HLA-II molecules [reviewed
in Neefjes et al. 2011]. For the HLA-I system, proteins are degraded in the cytoplasm of
cells by the proteosome, then the generated peptides are translocated into the endoplasmic
reticulum (ER) by transporter associated with antigen processing molecules (TAP) (Reits
et al., 2000; Schubert et al., 2000). Once in the ER, peptides form non-covalent interactions
with HLA-I molecules, and if the affinity between the peptide and the HLA is strong enough
to form a stable complex, the complex leaves the ER through the secretory pathway to reach
the cell surface [reviewed in Vyas et al. 2008]. For the HLA-II system, extracellular proteins
are phagocyted by APCs, enzymatically processed in the early endosome, and transported
trough vesicle traffic into the MHC class II compartment. Finally, stable complexes are
transported to the plasma membrane. CD8+ T cells recognise HLA-I, while CD4+ T cells
recognise HLA-II molecules. To allow T cells to differentiate non-self from self epitopes,
T cells undergo a process of maturation and selection in the thymus where positive (HLA
recognition) and negative selection (tolerance against self-proteins) take place [reviewed
in Parkin and Cohen 2001]. Therefore, a diverse and ample repertoire of T cells, each one
with a different TCR, surveys a sample of the body’s proteome. If a T cell recognises an
epitope as non-self and co-stimulatory signals take place, the T cell becomes activated and
the epitope is considered an antigen (Aptsiauri et al., 2008; Hamaï et al., 2010).
HLA variability
HLA molecules are polymorphic in the human population with 13,680 HLA-I and 5,091
HLA-II different alleles identified so far (August 2018) (http://www.ebi.ac.uk/ipd/imgt/hla/
stats.html). There are 3 classical HLA-I genes (A, B, C) and 6 main HLA-II (DRA, DRB,
DQA1, DQB1, DPA1, DPB1) genes. HLA-I genes form heterodimers with β2-microglobulin,
while HLA-II form homodimers. HLA genes are co-dominantly expressed, thus each person
can express up to 6 different HLA-I and 12 HLA-II alleles (Figure 1.2) [reviewed in Shiina
et al. 2009].
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Fig. 1.2 HLA nomenclature system. Each HLA
allele has a unique name composed of the HLA
prefix, the gene name (A, B, or C) and up to four
sets of digits (fields) separated by colons.
Patterns of epitope presentation
HLA molecules are able to present a wide
range of epitopes, because only two or
three amino acid positions in the peptide
interact directly with the HLA, thus all
the other amino acids can vary. Each
HLA allele binds different sets of pep-
tides with particular characteristics, however
general binding patterns have been eluci-
dated.
HLA-I molecules bind peptides of length 8-11 (Eichmann et al., 2014), most often 9 amino
acids, while HLA-II molecules bind peptides 14-20 amino acids [reviewed in Mohan and
Unanue 2012]. Certain amino acid positions in the peptides interact through non-covalent
bonds with the HLA molecule, for example positions 2-3 and positions 8-10 usually interact
with HLA-I (Fritsch et al., 2014), while amino acids in the middle arch up and away from
the HLA and are more visible to the TCR. Likewise, certain amino acid physicochemical
properties that facilitate non-covalent bonds tend to be enriched in such positions. Thus
HLA-I molecules are constantly displaying a sample of peptides of all proteins expressed
within the cell, and extracellular proteins through HLA-II molecules on APCs.
T cell development
HLA-I restriction and self-tolerance is possible because during their development, T cells
are positively (HLA-I restriction) and negatively (self-tolerance) selected in the thymus
[reviewed in Parkin and Cohen 2001]. Once the receptor rearrangement has occurred in
the bone marrow, T cells move to the thymus where CD8+ and CD4+ T cells that recognise
self HLA-I and HLA-II molecules, respectively, are positively selected. Then, T cells with
high affinity to self-epitopes die by apoptosis (negative selection). Therefore, T cells that
recognise HLA molecules with an epitope but are self-tolerant leave the thymus.
T cell activation
Therefore, every T cell has an antigen specific and clonally restricted receptor, which means
that a T cell can become active only when it finds an epitope that is recognised as non-self
[reviewed in Huppa and Davis 2003]. Importantly, the TCR is associated with co-receptors
needed for a full activation; without these co-signals the T cell becomes anergic or dies by
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apoptosis. When a cytotoxic T cell becomes active, it secretes perforin and granzymes to the
target cell, and/or activates the fas and TRAIL receptors on the target cell; both strategies
lead to the activation of caspases and the death of the target cell by apoptosis [reviewed in
Smith-Garvin et al. 2009].
Neoepitopes
T cells react against non-self epitopes, like viral or bacterial epitopes, but also to some self-
epitopes which could lead to autoimmunity. In cancer, three classes of self-epitopes have been
defined: 1) Proteins that are expressed only during early development before the immune
system has matured and therefore are ectopically expressed by cancer cells, 2) over-expressed
proteins, and 3) mutant proteins [reviewed in Vigneron 2015]. Particularly, mutant proteins
play an important role in the detection of cancer mediated by T cells because mutant proteins
arise from somatic mutations in cancer cells and are presented HLA molecules, thus being
encountered as new peptide sequences by T cells. Epitopes that originate from non-silent
somatic mutations are called neoepitopes, and if a T cell reacts against a neoepitope, then the
neoepitope is considered a neoantigen (Figure 1.3). Any expressed mutation that produces a
change in the protein sequence could, in principle, generate neoepitopes, including missense
mutations (point mutation that causes change of one amino acid) which occur frequently in

























Fig. 1.3 Endogenous HLA-I epitope presentation pathway. Expressed genes, including mutated
genes, are degraded by the proteosome in the cytosol as part of the normal protein turn-over. The
peptides with and without the mutation are generated, and translocated into the endoplasmic reticulum
(ER) by the transporter associated with antigen processing (Reits et al., 2000; Schubert et al., 2000).
The HLA-I peptide binding takes place in the lumen of the ER. If the complex is stable, the loaded
HLA-I molecule leaves the ER through the secretory pathway to reach the cell surface where the
epitope can be recognised by a CD8+ T cell. An analogous process occurs in antigen presenting cells,
using HLA-II molecules and presenting both to CD8+ and CD4+ T cells.
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Immunoediting and the 3 Es
As explained above, T cells are able to selectively recognise neoepitopes displayed by cancer
cells, and these neoepitopes can be predicted. However, this selective recognition imposes a
natural selection process where preferential elimination of immunogenic cancer clones leave
less immunogenic cancer cells to progress, which may partly explain why cancer occurs in
immunocompetent individuals (Matsushita et al., 2012). Moreover, chronic inflammation
generated by the constant interaction between cancer and immune cells often lead to im-
munosuppressive signals from the tumour microenvironment allowing cancer cells to further
proliferate and finally evade the immune system [reviewed in Teng et al. 2015]. The process
that comprises both tumour suppression and promotion is termed cancer immunoediting
(Schreiber et al., 2011), in which neoepitopes play a crucial role as they are one of the key
elements of selective recognition mediated by T cells (Mittal et al., 2014; Schreiber et al.,
2011). Immunoediting involves three different phases: Elimination of cancer cells by the
immune system, equilibrium of cancer and immune compartments in the TME, and escape of
cancer cells. Nevertheless, the dynamics of immunoediting throughout tumour progression
and the consequence of constant interactions between cancer and immune cells are still
largely unknown.
Plenty of evidence supports the role of molecular interactions between cancer cells and
the TME on tumour initiation, progression, and metastasis. These interactions shape and
constrain tumour evolution, which can lead to resistance to therapy and immune evasion.
However, still the role of various cell types is unclear or, so far, seems to be tumour type
related. New definitions of cell types or cellular states further complicate the elucidation
of their true biological role in different cancer types. In addition, cancer heterogeneity, an
intrinsic feature of cancer, poses a remarkable challenge to the study of the effect of each of
the components of TME in tumour progression.
1.1.3 Tumour heterogeneity at a multi-scale level
Tumours are not only comprised by various different cell types, cellular states, and cellular
interactions, but cancer cells themselves acquire new and different mutations as the tumour
develops, leading to a natural state of intra-tumour heterogeneity (ITH), both spatially
and temporally [reviewed in McGranahan and Swanton 2017]. Indeed, heterogeneity in
cancer spans multiple dimensions: at the molecular level with the presence of genetic
ITH (Campbell et al., 2010; Gerlinger et al., 2012; Shah et al., 2009), the cellular level with
variability observed in infiltration and recruitment of non-tumour cell populations in the TME
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(Natrajan et al., 2016), and the spatial and population levels where variability is observed
both within tumours of the same individual with disseminated disease (Jiménez-Sánchez
et al., 2017) and between tumours of different patients (McGranahan et al., 2016; Patch et al.,
2015). However, the extent of TME heterogeneity and its dynamics with ITH have not been
systematically characterised in metastatic disease. The heterogeneous nature of tumours
has halted the potential success of cytotoxic chemotherapy and targeted therapies, specially
in the more advanced stages of disease. Therefore, studying and understanding the driving
forces of TME heterogeneity along with ITH, and accounting for such variations are critical
aims to achieve in cancer research both from the basic and clinical point of view.
1.1.4 Therapy targeting the tumour microenvironment
As expected, most traditional cancer therapeutic strategies were originally conceived to target
the cancer cells of the tumour. The main aim is to maximise the effect of therapy against the
cancer cells, and minimise its effect to normal cells. Therefore, the rationale behind cytotoxic
chemotherapy and radiation therapy for instance, was to take advantage of the fact that cancer
cells are continuously dividing, and therefore are more susceptible to the DNA damaging
effects of radiotherapy and chemotherapy. However, these therapies also damage healthy
tissue and side effects become a limiting factor for the increase of dosage or therapy duration.
In addition, disease recurrence is common in patients with most cancers after cytotoxic
and radiation therapy, since residual disease is difficult to detect. More recently, with the
advent of high-throughput sequencing technologies, mutations were thought to provide a
source for selective therapeutic target as non-cancer cells do not have such genetic alterations.
Particularly, targeting critical proliferation or survival pathways that have been altered in
the cancer cells are subject of intense research, clinical trials, and therapies. Indeed, this
strategy has improved patient outcomes in various tumour types, however response duration
is often limited [reviewed in Fisher et al. 2011]. The reason behind resistance to targeted
therapy is thought to be mainly due to cancer heterogeneity. As explained above, tumours
are dynamic complex semi-organised tissues that become more heterogeneous during the
course of disease. Genetically, ITH results in a non-uniform distribution of distinct cancer
sub-clones, sharing clonal mutations but harbouring distinct sub-clonal ones [reviewed in
Dagogo-Jack and Shaw 2017]. Therefore, if a sub-clonal mutation is the target of therapy, re-
currence is almost inevitable. In addition, most mutations are difficult to target, and knowing
all sub-clones in a tumour, is clinically impractical and contradictory, because that would
require the resection of the complete tumour mass [reviewed in McGranahan and Swanton
2017]. Overall, the heterogeneous nature of tumours has limited the efficacy of cytotoxic
chemotherapy and targeted therapies, especially in the more advanced stages of the disease.
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Observations on the effect of different cells of the TME has shifted the attention towards
targeting non-cancerous cells that promote tumour progression, inducing the infiltration or
enhancing the activation of anti-tumour immune cells. For instance, anti-angiogenic therapy
aims to inhibit the formation of blood vessels in the tumour and reduce the blood supply and
nutrient distribution to cancer cells through reducing production, inhibiting or blocking the
action of pro-angiogenic factors secreted by the tumour cells (e.g. vascular endothelial growth
factor). Anti-angiogenic therapies elicit survival benefits in many tumour types, however the
clinical response is transient and resistance emerges [reviewed in Bergers and Hanahan 2008].
Another approach when targeting cells of the TME is to enhance the anti-tumour effect
of immune cells, in particular T cells. These therapies have been focused on inducing T
cell proliferation, survival, and differentiation (e.g. interleukin-2 stimulation) [reviewed in
Rosenberg 2014], increasing the number of anti-tumour T cells ex vivo and re-infuse them
into the patient (e.g. adoptive cell therapy) (Dudley et al., 2002; Rosenberg and Restifo,
2015; Rosenberg et al., 2011), and interfering with molecular mechanisms that inhibit T cell
function (e.g. checkpoint-blockade inhibitors) [reviewed in Sharma and Allison 2015]. By
far, checkpoint-blockade immunotherapies have showed the greatest success rate, since these
therapies have showed objective response rates in ∼ 10 different tumour types, ranging from
15% (Head and Neck, Gastroesophageal, and Bladder cancer) to 87% (Hodgkin’s disease)
objective response rates [reviewed in Ribas and Wolchok 2018]. Most importantly, when
successful, checkpoint-blockade immunotherapy has shown durable long-lasting response
[reviewed in Sharma and Allison 2015]. However, most tumor types have not yet responded
to checkpoint-blockade immunotherapy, and for tumours that show response, there is still a
subset of patients that have not received benefit [reviewed in Sharma et al. 2017]. Indeed,
research has started shed light on the effect of ITH and response to checkpoint blockade
immunotherapy, where it has been shown that less heterogeneous tumours tend to have a
slightly better response (McGranahan et al., 2016; Miao et al., 2018).
Recent preclinical and clinical data has shown that the partial success of conventional
chemotherapies can be to some extent attributed to immune-stimulatory mechanisms [re-
viewed in Gotwals et al. 2017]. Thus, the exploration of combination strategies where cancer
cells and TME cells are targeted, with special focus on understanding the underlying variables
behind response or lack or response, has become an area of intense research in the last years
[reviewed in Gotwals et al. 2017; Khan and Kerbel 2018; Sharma et al. 2017]. However, a
different avenue towards increasing response rates is to achieve a better understanding of
cancer and the TME at diagnosis and in response to standard of care using systematic and
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unbiased approaches (Binnewies et al., 2018; Miao and Van Allen, 2016; Valkenburg et al.,
2018).
1.1.5 Immunogenomics of the tumour microenvironment
Different strategies have been applied to study the TME: in vitro studies of cell-cell com-
munication [reviewed in Byrne et al. 2014; Wu and Swartz 2014], in vivo studies with
model organisms trying to recreate the human disease [reviewed in Gómez-Cuadrado et al.
2017; Li et al. 2018; Lindner 2014], patient-derived xenografts (Zhao et al., 2018), and
finally using tumours from clinical samples [reviewed in Binnewies et al. 2018]. All these
approaches provide different levels of information and complement each other. By employ-
ing high-throughput sequencing technologies and with the help of computational analyses,
more systematic studies on human data can be performed. Indeed, the generation of thou-
sands of publicly available genomic, epigenomic, transcriptomic, and proteomic data of
primary tumours in 33 tumour types through the TCGA project, and some metastatic tumours
has allowed an exhaustive characterisation of tumours, including their immune landscape
(Thorsson et al., 2018). Despite this massive enterprise, questions related to intra-patient
TME heterogeneity, TME response to therapy, and proper benchmarks and computational
methods for the characterisation of the TME in cancer remain unsolved. To overcome this
limitation, further analyses on multiple tumours from the same patient, longitudinal studies,
and integrative computational methods are required.
This PhD work has been focused on immunogenomic analyses of a case study of metastatic
HGSOC, treatment-naive HGSOC patients with disseminated pelvic disease, the effect of
chemotherapy on the TME of HGSOC, and the development of an integrative approach for
the estimation of TME cells using bulk expression data along with a systematic pan-cancer
benchmarking system.
1.2 High grade serous ovarian cancer
Ovarian cancer spans several different sub-types according to their histology. Importantly,
each sub-type has different risk factors, cells of origin, genomic alterations, clinical features
and treatments options. However, ∼90% of ovarian cancers fall in the category of epithelial
cancers, of which high-grade serous ovarian cancer (HGSOC) is the most commonly diag-
nosed and lethal of the ovarian cancer subtypes. high-grade serous ovarian cancer (HGSOC)
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originates from the fallopian tubes, not from the ovaries themselves [reviewed in Bowtell
et al. 2015].
1.2.1 Epidemiology
Ovarian cancer is the 7th most commonly diagnosed cancer among women in the world
[reviewed in Brett M. et al. 2017]. Currently, the risk for a woman to develop ovarian cancer
is 1 in 75, and the probability of dying of the disease is 1 in 100 (https://seer.cancer.gov/
archive/csr/1975_2013/). The disease is usually diagnosed at late stage when the 5-year
relative survival is 29%. Only 15% of cases are diagnosed at stage I, when the 5-year survival
rate is 92%. World wide the overall 5-year survival rate ranges between 30% and 40%,
and unfortunately only 2% to 4% increase has been achieved since 1995 (Allemani et al.,
2015). These alarming statistics put forward the need for more research in every angle of
ovarian cancer, from early detection, to new therapeutic strategies. Nevertheless, a better
understanding of the disease is crucial to increase the survival rates.
1.2.2 Molecular features
Early detection strategies in ovarian cancer have not been effective. However, genetic risk
factors have been identified. Germline mutations in genes that encode proteins involved in
homologous recombination DNA damage repair (e.g. BRCA1/BRCA2) increase the risk of
developing ovarian cancer [reviewed in Matulonis et al. 2016]. Approximately 20% HGSOC
cases harbour germline or somatic mutations in BRCA1 or BRCA2. Mutations or epigenetic
silencing of other homologous recombination DNA damage repair related genes also increase
risk of developing HGSOC, but are less prevalent in the population (TCGA, 2011). However,
so far genomic stratification has been limited only to homologous recombination deficiency
(Fong et al., 2010; Gelmon et al., 2011; Swisher et al., 2017).
In general, HGSOC is characterised by a preponderance of DNA copy-number alterations
with highly complex genomic profiles (Hoadley et al., 2014; Macintyre et al., 2018), and a
modest somatic missense mutation burden (∼61 per exome) (Ciriello et al., 2013; Patch et al.,
2015; TCGA, 2011). However, recurrent oncogenic mutations and copy number alterations
are uncommon (Hoadley et al., 2014), except for TP53 mutations which are ubiquitous in
HGSOC (Ahmed et al., 2010). Analyses of whole-genomes have shown that loss of RB1,
NF1, and PTEN by gene breakage are common (Patch et al., 2015), as well as amplification
associated fold-back inversions in tumours lacking alterations in homologous recombination
genes (Wang et al., 2017). In addition, analysis of gene expression profiles has shown
18 Introduction
predominantly differences related to the TME, although reliable only in a subset of patients
(Chen et al., 2018; Verhaak et al., 2012). Importantly, it has been shown that, genetically,
HGSOC is a very heterogeneous disease, even at diagnosis (Bashashati et al., 2013; De
Mattos-Arruda et al., 2014; Lee et al., 2015).
1.2.3 Treatment
HGSOC is usually diagnosed at late stages, when the disease has already started to spread.
In patient with symptoms, diagnosis involves physical pelvic and recto-vaginal examination,
and radiographic imaging [trans-vaginal and/or abdominal ultrasonography, Computarised
Tomography (CT), Magnetic Resonance Imaging (MRI), and/or Positron Emission Tomog-
raphy (PET)]. The biomarker CA125 (also known as mucin-16), which is preferentially
expressed by ovarian cancer cells, is also commonly used for diagnosis and to follow-up
treatment response. Surgery with removal of all visible disease is recommended (Demir
and Marchand, 2012), and further histological analysis is performed. Finally, ovarian can-
cer diagnosis is confirmed after a tissue biopsy is analysed [reviewed in Matulonis et al. 2016].
The therapeutic strategy for newly diagnosed HGSOC involves primary surgical cytore-
duction (tumour debulking) followed by platinum-based chemotherapy or neoadjuvant
chemotherapy Neoadjuvant Chemotherapy (NACT) - administration of chemotherapy be-
fore surgery -, then followed by interval surgery and additional chemotherapy after surgery.
Currently, the most active therapeutics against newly diagnosed HGSOC are platinum (cis-
platin or carboplatin) with taxane analogues (paclitaxel or docetaxel) [reviewed in Matulonis
et al. 2016]. Unfortunately, resistance to chemotherapy is developed by nearly all patients
diagnosed at late stages of the disease. Anti-angiogenic treatments, DNA damage repair
blocking agents (poly(ADP-ribose) polymerase (PARP) inhibitors), and immunotherapy
are strategies that have been used or researched for patients with recurrent disease which
usually presents platinum resistance [reviewed in Cojocaru et al. 2018; Matulonis et al. 2016].
Overall, despite surgical, chemotherapy, and targeted therapeutic interventions, most patients
relapse and develop resistance to therapy, which leads to premature death (Bowtell et al.,
2015; Cannistra, 2004).
Analysis of data from various cancer types studied by the TCGA consortium, including
ovarian cancer, has demonstrated that the number of somatic mutations and neoepitopes
(see Neoepitopes in section 1.1.2 under T cell specificity) correlate with overall survival
(Brown et al., 2014). Similarly, mutation burden and response to checkpoint-blockade im-
munotherapy correlate (Yarchoan et al., 2017). In HGSOC, the low somatic point mutation
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load, high aneuploidy levels and high copy number alterations have been associated with
lack of immunogenicity, thus HGSOC has been considered as a non-immunogenic tumour
type (Bowtell et al., 2015; Zhang et al., 2018). Despite the low intrinsic immunogenicity, T
cell infiltration plays a major role in predicting HGSOC survival in a primary disease setting
(Ovarian Tumor Tissue Analysis (OTTA) Consortium et al., 2017; Zhang et al., 2003), and
recent studies have started to shed light on the interplay between ITH and T cell interactions
(Zhang et al., 2018), as well as the potential effect of chemotherapy on T cell infiltration
in HGSOC (Böhm et al., 2016). Yet, check-point blockade immunotherapy has not been
successful in this disease (Homicsko et al., 2016). Different mechanisms or genomic features
could be at play to explain the lack of response, but besides the low intrinsic immunogenic
feature of HGSOC, the high ITH in HGSOC could also be a limiting factor. This is because
tumour heterogeneity increases the likelihood of selection of subclones that escape the
immune system (Bhang et al., 2015; Su et al., 2012; Turke et al., 2010), in addition to the
the low number of potential neoepitopes. Additionally, little is known about the effect of
other treatments like chemotherapy on the cancer-immune interactions. For example, some
studies suggest that chemotherapy may promote immune activation (Carson et al., 2004;
Gavalas et al., 2010; Pfirschke et al., 2016), but chemotherapy may also increase genetic
heterogeneity (McGranahan et al., 2016). Thus, a unified model of the effect of chemotherapy
on the tumour heterogeneity and immune-tumour interactions has not yet been reached.
Importantly, due to the sample acquisition from surgical debulking as standard of care
of HGSOC, this clinical setting offers the opportunity to explore and characterise systemati-
cally the TME at diagnosis and in response to treatment. Moreover, the intrinsic heterogenous
nature of HGSOC provides an ideal framework for the analysis of TME heterogeneity in
tumours. By integrating genomic, transcriptomic, and multiplexed imaging analyses, through
state-of-the-art computational analyses, cancer-TME dynamics will start to be understood
and potentially inferred.
1.3 Computational approaches for the analysis of tumour-
stroma interactions
While the study of ITH has been facilitated by computational approaches to estimate the
distribution and co-existence of different tumour clones from large-scale somatic mutation
data, bioinformatics analysis of TME heterogeneity poses considerable technical difficulties
due to the huge diversity of cell types present. This section presents a brief summary of data
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types, algorithms, computational methods, and statistical approaches employed in this thesis
for the study of the TME.
1.3.1 Genomics
Whole-exome sequencing
Whole Exome Sequencing (WES) sequencing targets the exons of all genes in the genome,
although 100% coverage of exons is not achieved. The exome constitutes up to ∼1% of
the genome. The process begins with the extraction of DNA from the cells, followed by its
fragmentation. Then synthetic DNA linkers are added to the end of the fragments and coding
sequences are selected, replicated and amplified through several rounds. The amplified
fragments are then sequenced in a series of reactions in which complementary nucleotides
coupled with different fluorescent dyes per base are added to clusters of identical DNA
molecules. The fluorescent colour released during the elongation is imaged with a laser
camera coupled with a microscope, then the fluorescent indicator is removed, and the cycle
is repeated. Nucleotide sequence reads that are between 75 to 150 nucleotides in length
are generated. The sequence reads are aligned to a reference genome (haploid mosaic of
different DNA sequences from multiple donors, which is periodically revised), and finally
each position in the exome is compared to the reference genome, and the sequences generated
[reviewed in Biesecker and Green 2014]. Through this process, genetic alterations (single
nucleotide variant, insertion/deletions, structural variants) in exonic regions of tumours can
be sought.
Mutation calling
Mutation calling refers to the computational exercise of identifying mutations in an exome
or genome and differentiating them from sequencing errors. In principle, given enough
sequencing read depth (the number of times a fragment has been sequenced) and coverage
(how many regions in the exome/genome are sequenced), all mutations could be observed.
However, still calling the mutations, i.e. distinguishing mutations from sequencing errors
and noise, has to be performed. First, low quality reads and sequencing linkers (synthetic
adapters) are trimmed using read processing algorithms. Second, the cleaned reads are
mapped and aligned to the reference genome. It is recommended to the perform PCR
de-duplication, indel-realignment, and base quality recalibration (DePristo et al., 2011;
McKenna et al., 2010). Variant calling is the last step, where real variants are discriminated
from artefacts generated during library preparation, sample enrichment, sequencing, and
mapping/alignment. Mutations with low variant allele frequency, due to impure sample or
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small subclone population, are the most challenging to discriminate from noise [reviewed in
Xu 2018].
Matched tumour-normal mutation calling is the preferred procedure for mutation calling,
where the idea is to identify somatic from germline variants and artefacts using the matched
normal sample. Multiple different algorithms have been developed following heuristic,
Bayesian, expectation-maximisation, machine learning algorithms (random forest, Bayesian
adaptive regression tree, support vector machine, and logistic regression), or a combination
of approaches. Independent benchmarks have shown that MuTect (Cibulskis et al., 2013)
is among the most reliable single nucleotide variant (SNV) mutation callers. MuTect was
designed to improve calling low-allelic-fraction mutations (variant allele frequency (VAF) ≤
0.1) by applying a Bayesian classifier. In short, MuTect models the variant allele fraction
and does not assumes a heterozygous diploid event unlike other methods. MuTect identifies
variants by analysing each site under two alternative models: (1) a reference model M0,
which assumes there is not variant at the site and any observed non-reference bases are due to
random sequencing errors, and (2) an alternative model Mmf , which assumes the site contains
a true variant allele m at allele fraction f in addition to sequencing errors. The allele fraction
f is unknown and is estimated as the fraction of tumour sample reads that support m. Then
m is considered a candidate variant if the log-likelihood ratio of the data under the variant
and reference models exceeds a predefined threshold that depends on the expected mutation
frequency and the desired false positive rate. The threshold can be changed to control the
trade-off between specificity (Number of not called variants that are artefacts) and sensitivity
(Number of called variants that are mutations) (Cibulskis et al., 2013).
Copy number alteration calling
Copy Number Alterations (CNA) are commonly assessed through different technologies
other than WES, like comparative genomic hybridization, single nucleotide polymorphism
arrays, and low-coverage whole-genome sequencing (Scheinin et al., 2014; TCGA, 2011;
Wang et al., 2004). However, performing these analyses increase cost significantly. Different
methods have been developed to derived CNA from WES, and two different approaches
have been followed: (i) using on-target reads or (ii) off-target reads. The advantage of using
off-target reads over on-target reads is that information from non-exonic regions is captured,
and the variation in the efficiency of capture baits in off-target regions presents low variation
compared to on-target reads. Different statistical methods have been employed to overcome
the large variation when using on-target reads (principal component analysis (PCA), hidden
Markov models, singular value decomposition) (Tan et al., 2014). Nevertheless, the accuracy
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of CNA calling using WES is poor compared to dedicated technologies (Tan et al., 2014).
Since targeted WES targeted sequencing generally achieve between 40% to 60% efficiency
(Samuels et al., 2013), off-targets reads represent a great source to calculate CNA. This is
achieved by CopywriteR using the following steps: (1) exome-enriched reads are used as
input (e.g. WES), (2) low quality and anomalous read pairs are removed, (3) genomic regions
enriched for sequencing reads are identified and discarded in sample and reference (these
correspond to exonic regions). (4) Then CopywriteR looks at the background reads and maps
them into bins, (5) then compensation in removed peak regions is performed, (6) depth of
coverage is corrected for GC-content and mappability, (7) then median normalisation and
log2 transformation of the corrected and compensated depth of coverage is performed. (8)
Finally, substraction of log2 transformed, corrected, and compensated depth of coverage of
the normal sample is used to create relative copy number profiles (Kuilman et al., 2015).
This approach showed more accuracy at calling CNA from WES than other methods based
on on-target reads, and a comparable copy number detection to the obtained through CNA
detection dedicated methods (Kuilman et al., 2015).
Tumour similarity
As noted before, tumours are a complex mixture of cancer and non-cancer cells. Moreover,
cancer cells in the tumour are not all equal or equivalent, they are genetically heterogeneous.
Leaving aside non-cancer cells, tumours are composed by a complex mixture of different
subclonal cancer populations. This genetic diversity within tumours acts as a substrate
for natural selection to operate and thus, tumour evolution to take place. As such, tumour
evolution intervenes in immune evasion, metastasis, and resistance to therapy [reviewed
in McGranahan and Swanton 2017]. Using WES of multiple regions from a tumour or
from different metastasis from a patient various studies have tried to reconstruct the tumour
phylogeny [reviewed in Alves et al. 2017]. However, due to the extensive ITH, unless CNA,
mutation clonality, and tumour purity are properly accounted for, and clonal trees inferred,
sample trees using presence/absence mutation data only provide genomic similarity between
tumours or regions, but not a tumour phylogeny [reviewed in Alves et al. 2017]. Making
the correct interpretation of both type of analyses could be a powerful and complementary
strategy.
In this work a similarity presence/absence mutation analysis was performed using only non-
synonymous mutations. A common method used for presence/absence similarity dendogram
is employing unweighted pair group method with arithmetic mean (UPGMA) hierarchical
clustering followed by the parsimony ratchet analysis (Nixon, 1999; Schliep, 2011). First, the
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UPGMA algorithm constructs a dendogram that reflects the structure present in the pairwise
similarity matrix, where the nearest two clusters are combined into a higher-level cluster.
The distance between any two clusters is the mean distance between elements of each cluster.
With the clusters and distance calculated, a dendogram can be generated, where the length
of the branches are proportional to the similarity between clusters, and corresponds to the
number of mutations between the tumours analysed. This dendogram is then passed as start-
ing point for the parsimony ratchet heuristic method which (1) randomly selects a subset of
characters, (2) each of which is given additional weight, (3) then branches are swapped using
the re-weighted matrix keeping only one tree. (4) Then set all weights for the characters to
the original weights, (5) followed by branch swapping. Finally return to step (2) and re-start
the cycle iteratively 50 to 200 times. The last selected tree is the most likely parsimonious
solution, and branch lengths are then calculated and proportional to mutation counts. As
explained above, strictly speaking this approach does not provide a true phylogeny, but a
similarity dendrogram based on the mutation data obtained. This is because tumour samples
comprise a mixture of sub-clones and multi-regional trees built from bulk mutational profiles
do not consider this heterogeneity. Thus, evolutionary inferences can be mistaken, timing of
somatic mutations erroneously assigned leading to spurious parallel mutation events and/or
incorrect chronological ordering of metastatic events. Importantly, this phylogeny versus
dendrogram distinction in cancer has not been yet clarified at the time of the publication in
chapter 2, so in that publication the analysis was mistakenly referred to as "Phylogenetic




Tumour purity can be assessed using genomic and/or transcriptomic data. Using WES data
genomic characterisation methods and mutation callers do not consider tumour purity and
overall ploidy. Thus mutation callers provide useful information in terms of presence/absence
of mutations and and estimate of VAF, but information regarding tumour cellularity requires
the integration of CNA data too. ABSOLUTE is an algorithm that integrates mutation VAF
data, relative CNA data, and common common tumour specific karyotypes to estimate tumour
purity, absolute CNA, subclonal estimations, and ploidy of bulk tumour samples (Carter
et al., 2012). In short, (1) ABSOLUTE jointly estimates tumour purity and ploidy directly
from observed relative copy profiles and somatic mutation VAF if available. (2) A large and
diverse sample collection of tumour specific karyotypes is used to resolve ambiguous cases.
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(3) It accounts for subclonal copy-number alterations and somatic point mutations, which are
common in heterogeneous tumours.
(Neo)epitope predictions
The binding affinity between HLA and epitopes depends on the position and physico-chemical
properties of the anchor amino acids. Therefore, different approaches have been taken to
predict if a peptide may bind or not bind to a particular HLA molecule. These approaches can
be classified according to the data used to develop the prediction method: 1) Modelling-based
methods use only sequence and structure data of peptides and HLAs (Schafroth and Floudas,
2004; Schiewe and Haworth, 2007; Tong et al., 2004), 2) Binding pattern recognition models
trained on boolean data (binders versus non-binders) (Lauemøller et al., 2001; Mamitsuka,
1998; Nielsen et al., 2004; Reche et al., 2002), and 3) Quantitative binding affinity models,
which are trained on HLA-peptide binding affinity datasets generated through biochemical
assays (Andreatta and Nielsen, 2015; Nielsen et al., 2007; Zhang et al., 2007). Among the
different methods and algorithms developed, the quantitative binding affinity model based on
artificial neural network (ANN) called NetMHC has shown to be the most accurate and is
a widely tool used in the community (Gulukota et al., 1997; Lin et al., 2008; Peters et al.,
2006; Roomp et al., 2010; Yu et al., 2002).
ANNs are statistical supervised machine learning models that emulate the function of bi-
ological neurons to recognise linear and non-linear patterns in a set of data [reviewed in
Manning et al. 2013]. The function of a neural network is to give an output after an input
has been given, for example in the NetMHC algorithm, the inputs are a sequence of amino
acids and the HLA subtype, and the output is a binding affinity value (Nielsen et al., 2003).
This is possible because neural networks are “trained” using a set of data with known output
(HLA-peptide binding affinity for NetMHC), and when the training data sets are sufficiently
large, continuous data can be approximated. During the training data set processing, the
neural networks adjust iteratively their error rate. Thus, with an accurate and large training
set, neural networks can be used to predict outputs based on a new set of input data. How-
ever, because the learning process occurs as the networks adjust their output iteratively, the
elements they recognise cannot be directly interpreted, thus neural networks operate as a
black-box [reviewed in Manning et al. 2013].
For HLA-I epitope prediction, the NetMHC algorithm includes, besides the ANN algo-
rithm, a combination of regression and hidden Markov models, sparse encoding, and Blosum
encoding, which together have increased the accuracy of the predictions (Nielsen et al., 2003).
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The original training set consisted of 528 HLA-peptide binding affinities from biochemical
assays using 9 long peptides and 78 different HLAs allowing NetMHC to predict IC50 bind-
ing affinity values (Nielsen et al., 2003). However, because only 9mers were included, the
prediction of HLA binding affinites of shorter or longer peptides was inaccurate, and further
training using data sets from the Immune Epitope Database and Analysis Resource (IEDB)
(Vita et al., 2015), the SYFPEITHI database (Rammensee et al., 1999), and new experimental
data were included (Lundegaard et al., 2008a,b). To evaluate the accuracy of the predictions
performed by NetMHC, 6,452 9mers covering 32 HLA alleles were used. 76% peptides
were correctly predicted as binders using an IC50 < 500. The NetMHC algorithm for HLA-II
epitope predictions is based on an artificial neural network-based alignment model trained on
a large data set of more than 14,000 quantitative binding affinity values covering 14 HLA-DR
alleles. The performance was evaluated on six independent datasets being comparable to the
best publicly available HLA-II prediction methods (Nielsen and Lund, 2009). The principal
caveats of the ANNs methods are: 1) the elements used for pattern recognition are usually
uninterpretable, 2) reliable predictions are limited to the type of data used in the training set,
which are mainly 9mers for NetMHC-I, and a subset of HLA subtypes, 3) peptide processing
is not taken into account directly, 4) only primary peptide sequence information is used, and
5) machine learning algorithms always have an intrinsic error rate [reviewed in Manning
et al. 2013].
Exome sequencing of tumours and identification of exonic mutations provides a source
for neoepitope prediction and cancer-immune recognition analyses (Segal et al., 2008). A
neoepitope prediction pipeline from sequencing data consists, briefly, of the following: 1)
filtering and quality processing of sequencing reads, 2) detection and filtering of non-silent
mutations, 3) mapping of mutated genes to their protein sequence, 4) in silico generation of
mutant peptides, 5) typing of patient HLA alleles, and 6) prediction of HLA specific binding
affinities (Figure 1.4).
Immunoediting estimation
The central paradigm of immunoediting is that it occurs during the evolution of the tumour,
where negative selection of clones with mutations that bind HLA molecules could be expected.
Thus, a lower number of neoepitopes than expected would suggest that an immunoediting
process has occurred. A previous study by (Rooney et al., 2015) using exome sequencing and
RNA sequencing of TCGA data have shown that, relative to other cancers, colorectal and
kidney clear cancers have a higher neoepitope depletion in general. More recently, Mlecnik
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Fig. 1.4 Neoepitope prediction pipeline. Mutations detected in exome-sequencing data can be stored
and organised in Mutation Annotation Format files (MAF). The missense mutations are filtered and
peptide 17mers were generated using the Uniprot/Swiss-Prot human proteome as a reference. The
middle amino acid (position 9th) of the generated reference peptides is changed with the annotated
mutated amino acid. HLA-I binding affinities are predicted for wild type (reference) and mutant
peptides with NetMHC. Peptides with IC50 values below 500nM are considered potential epitopes
(Dark blue and dark red). An epitope is counted if a peptide had an IC50 <500 for at least one of the
six HLAs as shown in the example. Mutations are represented in red.
hypermutated samples had more tumour infiltrating T cell and neoepitope depletion. These
analyses together with the observation that high mutation and predicted neoepitope loads
correlate with higher patient survival rate in general (Brown et al., 2014) and better response
to immunotherapy (Rizvi et al., 2014; Snyder et al., 2014) evidence that computational
analyses of sequencing data and neoepitope prediction could be exploited to understand
better how cancer-immune interactions occur in different tumour types and how they affect
clinical outcome. However, this is still an emerging field of research and negative selection
of cancer clones with specific mutations using sequencing data needs to be further verified.
Estimation and deconvolution of TME cell populations
Traditionally, cells from the TME in tumours have been quantified using immunohisto-
chemistry (IHC), immunofluorescence (IF), and flow cytometry. However, these methods,
although highly accurate, are expensive, labour intensive, and only provide cell quantifi-
cations. More recently, single cell RNA sequencing (scRNA-seq) technologies have been
implemented to study the TME, offering the advantage of physically separating each individ-
ual cell and allowing the measurement of each individual cell transcriptome [reviewed in
Gawad et al. 2016]. For instance, seminal studies have started to shed light on tumour and
immune heterogeneity at single cell resolution (Amir et al., 2013; Azizi et al., 2018; Tirosh
1.3 Computational approaches for the analysis of tumour-stroma interactions 27
et al., 2016). Also, integration of scRNA-seq with spatial localization through traditional
immunohistochemistry has been done (Puram et al., 2017), and molecular mechanisms of re-
sponse to immunotherapy have also been conducted using mass cytometry (Wei et al., 2017).
However, the interplay and integration of ITH, TME heterogeneity, spatial localization, and
their influence to response to therapy in tumour samples remains unexplored [reviewed in
Yuan et al. 2017]. Moreover, the computational methods to compare dynamics of distinct cell
populations at the single cell resolution still do not conform with the statistical properties
of scRNA-seq data. Thus, scRNA-seq is still an emerging field and the analysis of several
tumours or different tumour types is still prohibitive due to high costs. On the contrary,
the great access and lower cost of bulk transcriptomics data has incited the possibility of
estimating cellular populations of the TME using bioinformatics approaches. In brief, the
principle behind the computational approaches to estimate TME cell populations is using
a selected set of specific marker genes or expression signatures for each cell type to be
estimated [reviewed in Finotello and Trajanoski 2018].
The most common approach for the analysis of marker genes is gene set enrichment analy-
sis (GSEA), and its derivation single sample gene set enrichment analysis (ssGSEA). GSEA-
based methods generate an enrichment score (ES) that is high when the genes specific for a
cell type are amongst the top highly expressed in the sample of interest, and low otherwise.
ssGSEA computes an ES representing the degree to which genes in a particular gene set are
coordinately high- or low expression levels within a single sample compared to a random
distribution of genes in the gene expression profile of the same sample (Barbie et al., 2009).
With respect to the original GSEA, ssGSEA ranks the genes by their absolute expression in
a sample and computes ES by integrating the differences between the empirical cumulative
distribution functions of the gene ranks.
Unlike GSEA-based approaches that are semi-quantitative, deconvolution methods are quan-
titative. Deconvolution based methods estimate the unknown cell fractions using a signature
matrix describing the cell-type-specific expression profiles. Deconvolution algorithms use
a system of equations that describe the expression of each gene in a heterogeneous sample
as a linear combination of the expression levels of that gene across the different cell sub-
sets present in the sample, weighted by their relative cell fractions. However, whether the
relationship between the expression levels of pure and heterogeneous samples is linear or
not, is currently unknown. A crucial limitation of deconvolution methods is that cell types
with higher amount of total RNA will contribute more to the cumulative expression of a
heterogeneous sample and would be over-estimated as a result. Since different cell types have
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different sizes and different quantities of RNA, the final quantifications may be completely
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within a single individual
and may help to explain
the heterogeneous fates of
metastatic lesions often ob-
served post-therapy.
Highlights
• Differential progression of metastases during off-treatment period.
• Co-existence of distinct tumour-immune microenvironments within the same individual.
• Tumour regression and progression correlated with T cell infiltration and exclusion.
• Clonal neoepitopes elicited reactivity of circulating CD8+ T cells.
Video abstract




We present an exceptional case of a patient with high-grade serous ovarian cancer, treated
with multiple chemotherapy regimens, who exhibited regression of some metastatic lesions
with concomitant progression of other lesions during a treatment-free period. Using im-
munogenomic approaches, we found that progressing metastases were characterised by
immune cell exclusion, whereas regressing and stable metastases were infiltrated by CD8+
and CD4+ T cells and exhibited oligoclonal expansion of specific T cell subsets. We also
detected CD8+ T cell reactivity against predicted neoepitopes after isolation of cells from a
blood sample taken almost 3 years after the tumours were resected. These findings suggest
that multiple distinct tumour immune microenvironments co-exist within a single individual
and may explain in part the heterogeneous fates of metastatic lesions often observed in the
clinic post-therapy.
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2.3 Introduction
Several studies of smaller cohorts of patients with metastatic ovarian cancer have found
that primary and metastatic lesions exhibit heterogeneity at the genomic level (Bashashati
et al., 2013; De Mattos-Arruda et al., 2014; Lee et al., 2015). Supporting these findings,
functional MRI-based analysis has revealed that ovarian tumours and metastatic peritoneal
implants are already phenotypically heterogeneous at diagnosis (Sala et al., 2012). As tumour
heterogeneity increases so does the likelihood of presence of subclones able to escape the
immune system (Bhang et al., 2015; Su et al., 2012; Turke et al., 2010). Thus, immune
control may be particularly challenging in ovarian cancer due to extensive heterogeneity and
the low number of potential mutation-derived epitopes. The clinical challenge of tumour
heterogeneity has been demonstrated recently in the context of immunotherapy: patients with
less heterogeneous tumours, and hence with more clonal neoepitopes, were more likely to
respond to checkpoint blockade immunotherapy than patients with heterogeneous tumours
(McGranahan et al., 2016). In some settings, chemotherapy promotes immune cell homeosta-
sis and activation (Carson et al., 2004; Gavalas et al., 2010; Pfirschke et al., 2016), tumour
antigen release (Zitvogel et al., 2008), and decreased numbers of myeloid-derived suppressor
cells in the tumour microenvironment (Suzuki et al., 2005). Furthermore, effector T cells have
recently been implicated to play a role in abrogating fibroblast-mediated chemoresistance in
a mouse model of ovarian cancer (Wang et al., 2016). Despite these findings, a unified model
describing the effect of chemotherapy on the tumour heterogeneity and immune-tumour
interactions has not yet been reached. A critical step toward understanding the effect of
chemotherapy on advanced metastatic diseases and the immune response in humans is to
analyse intra-patient matched primary and metastatic tumours (Brabletz et al., 2013).
Here we present a case study of a high-grade serous ovarian cancer patient whose different
metastases exhibited concomitant regression and progression after treatment with multiple
types of chemotherapy. We used whole-exome sequencing, RNA expression data, immuno-
histochemistry, neoepitope prediction, in situ T cell receptor sequencing of tumour-infiltrating
immune cells, and T cell-neoepitope challenge assays with Intra-Cellular Staining (ICS) to
investigate the genetic, molecular, and cellular components that potentially underlie this
differential growth. In this heavily chemotherapy-treated patient, immune cell infiltration
with clonal expansion of T cells, but not mutation or neoepitope number, correlated with
tumour progression/regression status. Our immunogenomic analysis paints a portrait that
immune infiltration and activation are different in each tumour at 2 years post-chemotherapy.
Inter-site immune heterogeneity represents an important clinical challenge in the development
of treatment modalities to overcome tumour heterogeneity.
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2.4 Methods
Contact for reagent and resource sharing
Further information and requests for resources and reagents should be directed to and will be
fulfilled by Dr Martin L. Miller (martin.miller@cruk.cam.ac.uk).
Experimental model and subject details
Human subjects research
⊙
Patient samples were collected and analysed after informed consent to the institutional tissue
collection protocol, and approval by the Internal Review Board of Memorial Sloan Kettering
Cancer Center (MSKCC). The biological sex of the patient is female (XX). The age of the
patient at the time the primary sample was resected was 53 years old, and 60 years old at the




Whole exome sequencing was performed using the Illumina protocol at the Broad Institute
of MIT and Harvard, Cambridge, MA, USA. Illumina sequencing of exomes was employed
targeting approximately 37.7 Mb of mainly exonic territory made up of all targets from Broad
Institute’s Agilent exome design (Agilent SureSelect All Exon V2), all coding regions of
Gencode V11 genes, and all coding regions of RefSeq gene and KnownGene tracks from
the UCSC genome browser (http://genome.ucsc.edu). Data were analysed using the Broad
Picard Pipeline which includes de-multiplexing and data aggregation.
The Illumina exome sequencing uses Illumina’s in-solution DNA probe based hybrid selection
method that uses similar principles as the Broad Institute-Agilent Technologies developed
in-solution RNA probe based hybrid selection method (Fisher et al., 2011; Gnirke et al.,
2009) to generate Illumina exome sequencing libraries. Pooled libraries were normalized to
2 nM and denatured using 0.2 N NaOH prior to sequencing. Flow cell cluster amplification
and sequencing were performed according to the manufacturer’s protocols using either the
HiSeq 2000 v3 or HiSeq 2500. Each run was a 76 bp paired-end with a dual eight-base index
barcode read. The sequencing depths of the samples were: normal blood sample (90% at 20
X), primary (82% at 50 X), spleen 78% at 50 X), right upper quadrant (RUQ) (60% at 50X),
liver (89% at 50 X), and vaginal cuff (77% at 50 X) tumours.
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Gene expression
RNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples using the Re-
coverAll Total Nucleic Acid Isolation from Thermo Fisher Scientific (Catalogue Number:
AM1975). RNA expression was assessed using the human Affymetrix Clariom D Pico assay.⊙
Arrays were analysed using the SST-RMA algorithm in the Affymetrix Expression Console
Software. Expression was determined by using the Affymetrix Transcriptome Analysis
Console, and for genes displaying inconsistent expression between probes, the SRY gene
signal was used as a cut-off. local regression (LOESS) normalisation across samples was
implemented before differential expression analysis and ssGSEA (Tables C2S2A and C2S2C)
using:
# R 3.4.0




The immunofluorescent staining and cell counting were performed at Molecular Cytology
Core Facility of Memorial Sloan Kettering Cancer Center using Discovery XT processor
(Ventana Medical Systems) by a cytologist blinded to the sample identifiers and conditions.
The tissue sections were deparaffinised with EZPrep buffer (Ventana Medical Systems),
antigen retrieval was performed with CC1 buffer (Ventana Medical Systems). Sections were
blocked for 30 min with Background Buster solution (Innovex) followed by avidin/biotin
blocking for 8 min. Pseudocolors were applied as follows: CD4 A594, FOXP3 A488,
CD8 A647; CD68 and CD3 A594 and PD-L1 A488. Cells were detected using the DAPI
image, which was processed and segmented using ImageJ/FIJI (U.S. National Institutes
of Health). Appropriate threshold values were set for all other markers, and the number
of cells with positive signal above the threshold was counted for all single and double staining.
For multiplex staining, each marker was added consecutively in separate staining runs
as follows. CD4/FoxP3/CD8: Sections were incubated with anti-CD4 (Ventana, Catalogue
Number: 790-4423, 0.5 mg/ml) for 5 hr, followed by 60 min incubation with biotinylated goat
anti-rabbit IgG (Vector Laboratories, Catalogue Number: PK6101) at 1:200 dilution. The
detection was performed with Streptavidin-HRP D (part of DABMap kit, Ventana Medical
Systems), followed by incubation with Tyramide Alexa 488 (Invitrogen, Catalogue Number:
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T20922) prepared according to manufacturer instruction with predetermined dilutions. Next,
slides were incubated with anti-FoxP3 (Abcam, Catalogue Number: ab20034, 5 mg/ml) for
4 hr, followed by 60 min incubation with biotinylated horse anti-mouse IgG (Vector Labo-
ratories, Catalogue Number: MKB-22258) at 1:200 dilution. The detection was performed
with Streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by
incubation with Tyramide Alexa Fluor 568 (Invitrogen, Catalogue Number: T20914) pre-
pared according to manufacturer instruction with predetermined dilutions. Finally, sections
were incubated with anti-CD8 (Ventana, Catalogue Number: 790-4460, 0.07 mg/ml) for 5
hr, followed by 60 min incubation with biotinylated goat anti-rabbit IgG (Vector, Catalogue
Number: PK6101) at 1:200 dilution.
PDL1/CD68 or CD3: First, sections were incubated with anti-PDL1 (Cell Signaling, Cata-
logue Number: 13684, 5 mg/ml) for 5 hr, followed by 60 min incubation with biotinylated
goat anti-rabbit IgG (Vector, Catalogue Number: PK6101) at 1:200 dilution. The detection
was performed with Streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems),
followed by incubation with Tyramide Alexa 488 (Invitrogen, Catalogue Number: T20922)
prepared according to manufacturer instruction with predetermined dilutions. Next, slides
were incubated with anti-CD68 (DAKO, Catalogue Number: M0814, 0.02 mg/ml) for 5
hr, followed by 60 min incubation with biotinylated horse anti-mouse IgG (Vector Labs,
Catalogue Number: MKB-22258) at 1:200 dilution, or with anti-CD3 (DAKO, Catalogue
Number: A0452, 1.2 mg/ml) for 4 hr, followed by 60 min incubation with biotinylated horse
anti-rabbit IgG (Vector Labs, Catalogue Number: PK6101) at 1:200 dilution. The detection
was performed with Streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems),
followed by incubation with Tyramide Alexa Fluor 568 (Invitrogen, Catalogue Number:
T20914) prepared according to manufacturer instruction with predetermined dilutions. After
staining slides were counterstained with DAPI (Sigma Aldrich, Catalogue Number: D9542,
5 mg/ml) for 10 min and cover-slipped with Mowiol.
Sequenced-based HLA typing
⊙
HLA class I and class II 6-digit typing was performed at the New York Blood Center by
sequence-based typing and specific sequence primers.
TCR sequencing
⊙
High-throughput sequencing of the T cell receptors present in the samples and blood of the
patient was done using the immunoSEQ assay platform (Adaptive biotechnologies).
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The predicted peptides were synthesized (Genscript Corporation). peripheral blood mononu-
clear cell (PBMC) were cultured in complete RPMI (Core Media Preparation Facility
MSKCC) with peptides at 1 mg/mL, peptide vehicle (DMSO, Sigma-Aldrich) and CEF
peptide pool (2 mg/ml, C.T.L) for 21 days with peptide re-stimulation at day 7 and day 14.
IL-2 (Proleukin, Chiron) and IL-15 Peprotech, Catalogue Number: 200-15) were added
every 3 days at 10 IU/mL and 10 ng/mL respectively. Intracellular Cell Staining (ICS) was
performed at day 14, and day 21 after 6 hr re-stimulation in the presence of monensin for 5 hr
(GolgiStop, BD). Cells were then stained for 15 min with viability dye (LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit, ThermoFisher) at 4C followed by 30 min incubation with CD45-
APC-H7 (BD PharMingen, clone 2D1), CD3-Pacific Blue (BD PharMingen, clone UCHT1),
CD4-PerCP-Cy5.5 eBioscience, clone OKT4), CD8-PE (BD Biosciences, clone SK1). Cells
were then fixed and permeabilised with BD Cytofix/Cytoperm (BD Biosciences) for 20 min
at 4C and washed with BD Perm/Wash (BD Biosciences). The ICS was performed in BD
Perm/Wash with IFN-g-FITC (eBioscience, clone GZ-4) and TNF-a-PE-Cy (eBioscience,
clone MAb11) at 4C for 30 min. Samples were acquired on a BD LSRII flow cytometer (BD
Biosciences) and the analysis was performed on FlowJo software (FlowJo, LLC).
Quantification and statistical analysis
Tumour volume calculation
The two axes of the CT scan measurements and the equation for the ellipsoid volume were





Where a and b are the two axes, and c is their mean.
Mutation calling
Reads with mapping quality below 30 in the BAM files were filtered out before mutation
calling. SNV were called using MuTect version 1.4 (Cibulskis et al., 2013). Identified
missense mutations were manually reviewed using the Integrative Genomics Viewer version
2.3.61 (Robinson et al., 2011; Thorvaldsdóttir et al., 2013).
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Phylogenetic tree inference
The phylogenetic tree was generated as described in Murugaesu et al.. A binary pres-
ence/absence matrix of all non-silent mutations was used as input for the R package phangorn
version 2.0.2 (Schliep, 2011). UPGMA hierarchical clustering followed by the parsimony
ratchet analysis (Nixon, 1999) were implemented to build the unrooted tree, and the acctran
function was used to determine branch lengths.
Relative copy-number alterations
To extract copy number information based on the sequenced exomes of the samples, Copy-
writeR version 2.2.0 (Kuilman et al., 2015) was employed in R version 3.2.3. To perform the
analysis, mappability information based on the hg19 human reference genome, 20 kb bin
size, and default parameters were used.
Absolute copy-number alterations and tumour purity
The absolute copy number profiles and the tumour content of the samples were inferred
using the computational method ABSOLUTE version 1.0.6 (Carter et al., 2012) in R ver-
sion 3.2.3. ABSOLUTE integrates segmented copy number data, pre-computed statistical
models of recurrent cancer karyotypes, allelic fractions of somatic SNVs, and a proba-
bilistic model framework to jointly estimate candidate tumour purity, ploidy values, ab-
solute copy number data, and subclonal single nucleotide variants (Carter et al., 2012).
Tumour purity and absolute copy numbers were obtained using ABSOLUTE default pa-
rameters, segmented copy number data derived from CopywriteR, and variant allele fre-
quencies estimated by MuTect (Cibulskis et al., 2013). Best model selection was based
on the guidelines provided by GenePattern and the Broad Cancer Genome Analysis group
(http://www.broadinstitute.org/cancer/software/genepattern/analyzing-absolute-data). Am-
plifications and deep deletions were defined as copy-number alterations with at least ± 2
median absolute deviations for each sample copy-number distribution as shown in Figure
S1C.
Mutation cellular prevalence
Variant allelic cellular prevalence was estimated using PyClone version 0.13.0 (Roth et al.,
2014) in Python version 2.7.11. The PyClone pipeline analysis was performed jointly on
all samples with their tumour purity and absolute copy number alterations estimated by
ABSOLUTE. Total copy number prior probability estimate and the PyClone binomial model
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were used in the analysis. The mutation variant allele frequencies, closest integer copy
number alterations, and tumour purity were used as input. Mutations not present or called in
the sample were set to 0. Agglomerative hierarchical cluster analysis with Euclidean distance
metric and average linkage clustering was performed on the cellular prevalence values and
samples. The SREBF2S120* nonsense mutation was not included in the PyClone pipeline
because its copy number data was closest to 0.
Single-sample gene set enrichment analysis
Single-sample gene set enrichment analysis (Barbie et al., 2009), a modification of standard
gene set enrichment analysis (Subramanian et al., 2005), was performed on RNA measure-
ments for each sample using the GSVA package version 1.24.1 (Hänzelmann et al., 2013)
in R version 3.3.2 with parameters: method="ssgsea", and tau=0.25. Normalised enrich-
ment scores were generated for gene sets belonging to KEGG (Kanehisa and Goto, 2000;
Kanehisa et al., 2015) and Reactome (Fabregat et al., 2016). The gene sets were obtained
from MSigDB database version 5.2 (Liberzon et al., 2011). In order to identify significantly
up- and down-regulated gene sets, a p-value was calculated for each gene set based on
comparison of the enrichment score with 10,000 permutations of randomly sampled gene sets
of the same size. All genes listed in the expression array were used to derive the permutated
gene sets. Finally, the p-values were corrected using Benjamini and Hochberg method (BH).
Enrichment scores were normalized across samples (Tables C2S2D and C2S2F) using:
# R 3.4.0
data_norm<-as.data.frame(scale(data,center=T,scale=T))
Immune cell gene-expression signatures
Tumour purity and total immune component in the tumour samples were analysed using the
ESTIMATE algorithm method version 1.0.13 (Yoshihara et al., 2013) on the gene expression
data using the option: platform="affymetrix" in R version 3.4.0. Then, selection of
probes with the highest variance for each gene was performed to deconvolute cell type
specific immune signatures. The deconvolution was achieved using CIBERSORT Jar version
1.05 (https://cibersort.stanford.edu/) with the standard LM22 signature gene file, and 1000
permutations to calculate deconvolution p-values (Newman et al., 2015).
Whole-exome sequencing-based HLA inference
The HLA genotyping algorithms OptiType version 1.0 (Szolek et al., 2014) and POLY-
SOLVER version 1.0 (Shukla et al., 2015) with default parameters were employed for HLA
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class I 4-digit inference. POLYSOLVER HLA-I typing and mutation calling were performed
using samtools version 0.1.19 and novocraft 3.02.05 for the alignment, and MuTect version
1.1.7 for the variant calling.
Neoepitope predictions
In silico mutant peptide generation: To predict neoepitopes, “wild-type” petide 17mers
(for HLA-I) and 29mers (for HLA-II) with the affected amino acid in the middle for
each missense mutation were retrieved from the GRCh37.74 human reference proteome
(http://ftp.ensembl.org/pub/release-74/fasta/homo_sapiens/pep/). To generate “mutant” pep-
tides, the affected amino acid was replaced in silico with the corresponding mutant amino
acid.
HLA class I epitope binding predictions: Mutant peptides were used as input for the T
Cell Epitope Prediction Tools included in the IEDB 3.0 (http://www.iedb.org/) (Vita et al.,
2015). The HLA class I epitope binding predictions were performed using the HLA-I IEDB
algorithms Consensus (Kim et al., 2012) and the artificial neural network (NetMHC) version
3.4 (Lundegaard et al., 2008b; Nielsen et al., 2003) independently, yielding same conclusions.
For Consensus method – which combines NetMHC, the stabilized matrix method (Peters
and Sette, 2005), and the combinatorial peptide libraries method (Sidney et al., 2008) – 9
mers with a relative percentile rank ≤ 1% for each HLA-I allele were considered binders to
cover most of the potential immune responses as previously suggested (Kotturi et al., 2007;
Moutaftsi et al., 2006). For NetMHC, different cut-off values were evaluated independently
and compared between each other. 9mers with absolute IC50 affinity values ≤ HLA-I specific
cutoffs were considered binders (http://help.iedb.org/entries/23854373) (Paul et al., 2013).
HLA-I specific cut-offs were not available for HLA-I C alleles, therefore an IC50 ≤ 500 nM
was used instead. All mutant predicted binders were considered for the analyses, i.e., for
each missense mutation, up to six binders for HLA-I (A, B, C alleles) and up to four binders
for HLA-II (DQ and DR alleles). Since NetMHC gives actual nM binding affinities, and
HLA-I specific cutoffs have been estimated, we used NetMHC predictions.
HLA class II epitope binding predictions: HLA class II epitope binding predictions on
15mers were performed using the HLA-II IEDB algorithms Consensus (Wang et al., 2008,
2010), NetMHCII version 2.2 (Nielsen and Lund, 2009), and Sturniolo (Sturniolo et al., 1999)
since these were the only available methods for the patient HLA-II alleles. The Consensus
method used the relative percentile ranks of NetMHCII and Sturniolo, and 15mers with
percentile ranks ≤ 1% were considered binders. 15 mers with NetMHCII IC50 ≤ 500 nM or
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Sturniolo percentile rank ≤ 1% were considered binders, which are more stringent cut-off
values than the IEDB recommended 1000 nM for NetMHCII and ≤ 10% percentile rank
for Sturniolo. In the authors’ knowledge, HLA-II specific NetMHCII cut-offs have not been
reported.
Neoepitope depletion analysis
TCGA ovarian cancer null model: To analyse neoepitope depletion across the different
samples, we followed the method developed by Rooney and colleagues using only expressed
mutations. Commonly mutated genes were not included as indicated (Rooney et al., 2015).
The method compares the samples to a data driven null model. To generate the null model
and estimate neoepitope depletion, the nucleotide sequences flanking each mutation (context
of the mutation) are taken into account, thus 192 possible codon mutations are considered:
(64 codons)(3 possible mutations) = 192 possible changes. To control for tumour type
differences, we used TCGA ovarian cancer samples to generate the null model (TCGA,
2011). Context of the mutations for the TCGA ovarian cancer samples and the case study
tumour samples were obtained from the assembly of the Genome Reference Consortium
Human Reference 37. Only TCGA ovarian cancer samples with mutation context in all
missense and silent mutations were included (n = 150). We predicted HLA-I neoepitopes
of TCGA ovarian cancer samples using the same approach as for the case study samples
described above.
Neoepitope depletion for each sample was calculated as follows. First, the expected number
of missense mutations per silent mutation (Ns) and the expected number of predicted neoepi-
topes per missense mutation (Bs) were calculated using all samples (TCGA ovarian cancer
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missenseT T T→T GT








, . . . ,
neoepitopeT T T→T GT
missenseT T T→T GT
) (2.3)
Therefore, each component of the vector Ns corresponds to the fraction of missense muta-
tions per silent mutation, and each component of the vector Bs corresponds to the number of
predicted neoepitopes per missense mutation. In both vectors, Ns and Bs, each component
corresponds to the ratio of a particular codon change. The components of Ns can be computed
because the counts of the mutations take into account the three possible reading frames.
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Second, the count of silent mutations for each codon change (Ss) was calculated for each
sample. Thus, Ss is a vector with 192 components where each component is the number of
silent mutations with a particular type of codon change for a given sample:
Ss = (silentAAA→ACA,silentAAA→AGA, . . . ,silentT T T→T GT ) (2.4)
Third, the expected number of missense mutations (N pred) and the expected number of











m ∈ (AAA → ACA,AAA → AGA, . . . ,T T T → T GT )
Where Silent represents the number of silent mutations.
Fourth, the expected and observed numbers of neoepitopes per missense mutation for each









Where Nobs is the observed number of missense mutations and Bobs the predicted num-
ber of neoepitopes for each sample.






Each sample has a ratio R, thus a distribution of log2 ratios is generated as shown in Fig-
ure S4C top panel. Empirical two-sided p-value thresholds were calculated because the
ratios do not follow a normal distribution (Shapiro-Wilk test, D’Agostino-Pearson’s test, and
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Kolmogorov-Smirnov test) The calculations can be found in Tables C2S4E-C2S4G.
Permutation null model: To compare the levels of neoepitope depletion only between the
patient’s samples, we generated sample specific null models based on 150 random unique
permutations (redundant permutations excluded) of the samples and their mutations (Table
C2S4H). The number of permutations was selected based on the number of samples used
in the TCGA ovarian cancer neoepitope depletion analysis (n = 150). Permutated and real
samples were analysed together using the same approach as for the TCGA ovarian cancer
neoepitope depletion analysis described above. A permutation-based null model for each
sample was used to control for the number of mutations. Empirical two-sided p-value
thresholds were calculated for each distribution because the ratios do not follow a normal
distribution (Shapiro-Wilk test, D’Agostino-Pearson’s test, and Kolmogorov-Smirnov test).
The calculations can be found in Figure 7.4 and Table C2S4I.
Immunogenicity predictions
Immunogenic properties of HLA class I epitopes were estimated in silico using the IEDB
resource tool “MHC I Immunogenicity” (http://tools.iedb.org/immunogenicity/), which com-
bines the chemical and physical properties of the amino acids, their position in the epitope,
and the HLA-I subtype allele to estimate the immunogenicity of a given neoepitope-HLA
complex (Calis et al., 2013). To compare clonal and sub-clonal predicted immunogenic
properties, we used two approaches:
Absolute score comparison: Two-sided Mann-Whitney rank tests were calculated to compare
absolute scores between clonal and sub-clonal predicted binders and non-binders. In figures
7.5A-C, n refers to the number of peptides in each category. The Mann-Whitney rank test
was employed because the absolute score distributions do not follow a normal distribution
(Shapiro-Wilk test, D’Agostino-Pearson’s test, and Kolmogorov-Smirnov test), and because
the number of peptides in each category is different a Wilcoxon signed-rank test could not be
calculated.
Binomial immunogenicity comparison: Generalised Linear Model (GLM) were used to
compare the probability of a peptide having immunogenic properties or not according to
it clonal status and HLA binding affinity. The binomial GLM approach was considered
appropriate for this setting because immunogenicity can be considered a binomial process,
immunogenic or non-immunogenic. In this scenario, however, the binomial process corre-
sponds to whether an epitope has biochemical properties associated with immunogenicity
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(score ≥ 0) that outweigh properties associated with no immunogenicity (score < 0). Im-
portantly, predicted immunogenicity scores < 0 can still elicit an immunogenic response,
but overall they have less immunogenic properties than positive scores (Calis et al., 2013).
To further explain variation in the intrinsic immunogenic predictions we included HLA-I
binding affinity (nM) as an explanatory variable. We then calculated the probability of a
peptide having a positive immunogenic score or not based on the samples’ neoepitope data.
No interaction between clonality and HLA-I binding affinity was found, thus the interaction




Analysis of the sequences was performed on the immunoSEQ ANALYZER 3.0 (Adaptive
biotechnologies). T cell rearrangements that are differentially abundant between samples
were detected using the Differential Abundance tool by two-sided binomial tests with Ben-
jamini and Hochberg multiple test correction, q-value < 0.01 was considered statistically
significant.
Data and Software Availability
Requests for additional data and custom code should be directed to Dr Martin L. Miller
(martin.miller@cruk.cam.ac.uk).
Whole-exome sequencing data
The accession numbers for the whole exome sequences reported in this chapter are BioSam-
ple: SAMN06199513, SAMN06199514, SAMN06199515, SAMN06199516, SAMN06199517, and
SAMN06199518.
Microarray data
The microarray data discussed in this study have been deposited in NCBI’s Gene Expression
Omnibus (Edgar, 2002), and the accession number is GEO: GSE92780.
TCR sequencing data
The TCR sequencing data discussed will be provided upon request Dr Martin L. Miller.
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The patient presented here was diagnosed with stage IV HGSOC, which typically exhibits
a 5 year survival of 17% (National Cancer Institute, SEER Data Base), and underwent an
optimal surgical debulking followed by paclitaxel combined with first cisplatin and then
carboplatin. The patient experienced recurrence after 7 months, and during a period of 3
years she was treated with multiple regimens of chemotherapy with progression of disease
after each therapy (Figures 2.1A and 2.1B). Her cancer was growing radio-graphically, and
her CA125 was rising during treatment with topotecan when she then transitioned to best
supportive care and was followed clinically with regular CA125 biomarker evaluation.
After chemotherapy treatment was stopped, she experienced an atypical course: her CA125
decreased, and after 2 years of clinical follow up, CT scans showed evidence of differential
growth of metastatic lesions including a new complex cystic mass in the vaginal cuff. Because
of her long treatment-free interval and abdominal discomfort, she opted to undergo another
debulking procedure, which found a substantial disease burden including tumour implants
on the liver capsule, the splenic hilum, right upper quadrant (RUQ), and rectovaginal space
(Figures 2.1A and 2.1B). Samples of the primary and four metastatic tumours were submitted
for whole-exome sequencing, microarray RNA quantification, staining for protein markers
by immunofluorescence, and in situ T cell receptor sequencing.
2.5.2 Phylogenetic analysis of somatic alterations in tumours
We performed whole-exome sequencing of normal blood and the resected samples to identify
somatic mutations in the primary tumour and the metastases. Of all samples, we detected
the highest mutation load in the liver and vaginal cuff metastases (Figure 2.1C). To infer the
evolutionary relationship between the tumour samples, we used a binary presence/absence
matrix of the non-silent mutations to perform a phylogenetic reconstruction based on the par-
simony ratchet analysis method with branch lengths proportional to the number of non-silent
mutations (Nixon, 1999; Schliep, 2011) (Figures 2.1D and 8.1A). The liver and vaginal cuff
tumours were genetically more heterogeneous and harboured more mutations.
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Fig. 2.1 Metastatic tumours exhibit heterogeneous growth and somatic mutation patterns after
multi-line chemotherapy. (A) Representative CT scans showing concomitant progression/regression
of the different resected metastatic tumours. RUQ = right upper quadrant. “Spleen” refers to the
tumour deposit adjacent to the spleen. (B) CT-based volume of metastatic lesions represented with
the solid vertical lines and dynamics of quantified CA125 levels with the red line indicating the
CA125 upper limit of normal (35 units/ml). The x axis at the bottom shows a time-line of therapeutic
interventions and clinical follow up. (C) Number of missense, silent, and nonsense mutations. (D)
The phylogenetic tree represents the relationship of the samples based on binary calls of non-silent
point mutations. Length of the branches is proportional to the number of mutations. Potential driver
mutations are indicated. (E) Hierarchical cluster analysis (Euclidean distance metric and "average"
linkage method) of the cellular prevalence of point mutations (n=299) estimated with PyClone (Roth
et al., 2014).
To estimate the proportion of cancer cells identified with a given mutation (cellular preva-
lence), we applied PyClone (Roth et al., 2014) using CopywriteR-inferred (Kuilman et al.,
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2015) DNA copy-number changes (Figures 7.1B and 7.1C) and ABSOLUTE-inferred
(Carter et al., 2012) tumour purity and absolute copy numbers. As expected, truncal and
shared mutations were generally clonal with high cellular prevalence, whereas private mu-
tations had medium to low cellular prevalence indicating sub-clonal status (Figure 8.1E).
Focusing on the specific genes that were mutated across all samples, we found among the trun-
cal mutations potential oncogenic driver alterations, including WNK3P1728R, PAX4P287L, and
TP53N247I (Figure 7.1D). TP53N247I was detected with a high cellular prevalence indicating
loss of heterozygosity, which was supported by our DNA copy-number analysis. Additionally,
we identified other putative truncal events, including deletion of BRCA1, BRCA2, and PTEN
and amplification of CCNE1 (Figure 7.1B), which are commonly altered in serous ovarian
cancer (Bowtell et al., 2015; Patch et al., 2015). Among the private mutations we detected
several potential driver mutations including RUNX3P246S in the growing splenic lesion and
CSMD1G1770R in the primary tumour. Several private and shared branch mutations were
found in different Rho GTPase-activating genes (ARHGAP), which inactivate Rho and Rac
signalling involved in the control of cellular motility (Bernards and Settleman, 2004; Li et al.,
2014).
2.5.3 Immune-related pathways are over-expressed in regressing tu-
mours
To evaluate whether genes involved in chemotherapy resistance were differentially altered
between tumours and associated with regression and progression status, we analysed somatic
alterations and gene-expression data (Affymetrix transcript array) across the samples. After
analysing chemotherapy-resistance genes identified in HGSOC (Patch et al., 2015), as well
as gene sets for multi-drug resistance (ABC transporters), apoptosis, and DNA-damage
response, we found no clear evidence of gene-expression or somatic-alteration patterns (mu-
tations, DNA amplification, and deep deletion) that differed between progressing (primary,
vaginal cuff, and spleen) and regressing/stable tumours (RUQ and liver) (Figures 7.2A–C).
Interestingly, there was a trend that the ABC transporter TAP1, which is known for its
function as a transporter of cytosolic peptides to the endoplasmic reticulum for HLA class I
presentation (Bahram et al., 1991; Neefjes et al., 1993; Powis et al., 1991; Suh et al., 1994),
was expressed at a higher level in the regressing tumours (Figure 2.2A).
To further identify potential differences between samples, we analysed gene sets and path-
ways in an unbiased manner with ssGSEA (Barbie et al., 2009; Subramanian et al., 2005).
Using permutation-based false-discovery rate, we estimated the significance of the enrich-
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ment score for each pathway and performed an outlier analysis relating gene-set significance
to the relative change in enrichment score between a given sample and the rest of the samples
(Figure 2.2B, Tables C2S2D-F). The most significant and differentially enriched pathway
found was the immune system pathway with a higher enrichment in the spleen and RUQ
metastases and a lower enrichment in the primary and vaginal cuff tumours (Table C2S2H).
Further indicating immune activation, the systemic lupus erythematosus pathway was highly
enriched in the RUQ and liver metastases (Table C2S2I), whereas TCR signalling pathways
were preferentially enriched in the RUQ sample alone (Table C2S2J). Cancer and prolifera-
tion pathways, as well as Wnt signalling, were more enriched in the primary and vaginal cuff
tumours (Table C2S2K). No outlier gene sets were identified for the negatively enriched
pathways (Figure 7.2E and Tables C2S2D-F).
To investigate the gene-expression differences between the samples on an unbiased in-
dividual gene level, we calculated the coefficient of variation of the expression levels for
each gene across samples (Table C2S2A). We found that among the most variably expressed
genes, besides lipid metabolic process related genes in the liver, the T cell chemo-attractant
CXCL9 was predominantly expressed in the RUQ and liver metastases, as well as STAT1,
which has been implicated in the regulation of CXCL9 expression (Liao et al., 1995; Satoh
and Tabunoki, 2013) (Figure 7.2D). No relevant mutations in immune-related molecules
were identified except for truncal mutations in the MHC class I polypeptide-related sequence
B (MICB) (Table C2S1A), which is a stress-induced ligand recognized by NKG2D receptors
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Fig. 2.2 Differential expression of immune-related pathways in heterogeneously growing tu-
mours. (A) Expression levels and genetic alterations of genes associated with chemotherapy resis-
tance in HGSOC (Patch et al., 2015) and multi-drug resistance. Amplification and deep deletion were
defined as at least ± 2 median absolute deviations of copy-number alterations for each sample (Figure
7.1). (B) Single-sample gene set enrichment analysis (Barbie et al., 2009; Subramanian et al., 2005)
of up-regulated pathways using the KEGG (Kanehisa and Goto, 2000; Kanehisa et al., 2015) and
REACTOME (Fabregat et al., 2016) databases. Significantly enriched pathways (q < 0.05) with at
least ± 1 log2 change relative to the median of the other samples are coloured. FDR adjusted p-value
(q-value) was calculated using the BH method.
2.5.4 Heterogeneous immune infiltration in growing and regressing le-
sions
To investigate the immune infiltration status of the tumours, we used ESTIMATE to analyse
tumour purity and overall stromal and immune components (Yoshihara et al., 2013). The
lowest tumour purities and highest immune infiltration scores were found in the RUQ, liver,
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and spleen samples (Figure 2.3A). Furthermore, we deconvoluted the gene-expression data
using CIBERSORT (Newman et al., 2015) as a first approach to dissect infiltration of specific
immune cell subsets in the tumours. We found that the largest immune cell components cor-
responded to CD8+and CD4+ T cells in RUQ, liver, and spleen tumours, although the overall
CIBERSORT deconvolution p-value was only significant for RUQ and liver tumours (Figure
2.3B). In contrast, the primary and vaginal cuff tumours had low immune cell ESTIMATE
scores and insufficient levels of immune cell transcripts to confidently apply CIBERSORT
(Tables C2S3A-B), together suggesting a low or absent immune component present in these
tumours.
Following this analysis, samples were immuno-fluorescently co-stained for T cell mark-
ers CD4, CD8, and the T regulatory cell marker FOXP3, double stained for PD-L1 and
macrophage marker CD68, as well as double stained for PD-L1 and the T cell marker CD3
(Figures 2.3C and 7.3A). Consistent with the transcriptomic deconvolution analyses, the
primary tumour demonstrated no T cell infiltration and was negative for PD-L1 and CD68
(Figures 2.3C, 2.3D, and 7.3A, and Table C2S3C). The vaginal cuff lesion, which was
growing at the time of surgical resection, did display a T cell population; however, these cells
bordered but did not infiltrate the tumour. The splenic lesion, which was also progressing
at the time of resection, albeit at a much more modest rate than the vaginal cuff lesion,
demonstrated a CD8+ infiltrate. Finally, the RUQ and liver metastases, which were regress-
ing and stable, respectively, at the time of surgical resection, displayed a strong CD4+ and
CD8+ infiltrate. In summary, the transcript and IF analyses suggested that each tumour site












































































































































































































Fig. 2.3 Immune infiltration status shows heterogeneous microenvironments across tumour
samples. (A) Tumour purity and immune component estimated by analysing Affymetrix-based
transcriptomics (Yoshihara et al., 2013). (B) Fractions of immune cell subsets in tumour samples
inferred from gene-expression data using CIBERSORT (Newman et al., 2015). Width of bars is
proportional to the −log10 p-value of the deconvolution. CIBERSORT empirical p-value, ∗ p < 0.05.
(C) Representative images of H&E staining of tumour samples and IF staining for DAPI, cytotoxic T
cells (CD8+), helper T cells (CD4+FOXP3-), T cells (CD3+), Tregs (CD4+FOXP3+), macrophages
(CD68+), and immune-checkpoint PD-L1. Complete slides are shown in Figure 7.3. (D) Image-based
cell quantification of whole slides.
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Fig. 2.4 Higher HLA expression and T cell
oligoclonal expansion detected in regressing tu-
mours. (A) HLA-I and II gene differential ex-
pression across samples. (B) Number of predicted
neoepitopes per sample. (C) TCR sequencing
of FFPE tumour samples and blood. The most
prevalent TCR clonotypes (top 5 for each sam-
ple and blood) are shown. The blood sample
was collected from the patient 550 days after sec-
ondary debulking (Figure 7.5A). Inset shows de-
tection of the most frequent TCR rearrangement
(CASSNDEYRGPTYEQYF) and its abundance compar-
ison between samples (two-sided binomial tests
with BH multiple test correction, q-value < 0.001
***).
It is known that genetic alterations in HLA-
I molecules are associated with escape of
cancer cells from CD8+ T cell recognition
(Shukla et al., 2015). The patient’s HLA alle-
les were determined experimentally by con-
ventional polymerase chain reaction (PCR)-
based HLA typing and computationally on
exome data by OptiType (Szolek et al., 2014)
and POLYSOLVER (Shukla et al., 2015)
independently, yielding the same results
(Table C2S4A). We searched copy-number
alterations as well as mutations by applying
POLYSOLVER, a specific computational
pipeline for HLA-I typing and mutation de-
tection in the HLA-I genes; however, no ge-
netic alterations were detected. We then
assessed gene expression and found that
all HLA-I genes were expressed in the tu-
mours (Tables C2S2A-C); however, com-
pared to primary and vaginal cuff samples,
an overall higher expression of HLA genes
was observed in the RUQ and liver samples,
with a lesser extent seen in the spleen sam-
ple (Figure 2.4A). We next estimated the
neoepitope landscape of the samples by map-
ping missense mutations to their amino acid
sequences, in silico generating the mutant
peptide sequences, and predicting the mu-
tant peptide-HLA binding affinities to the
patient’s HLAs. The predictions were per-
formed using the NetMHC algorithm with
HLA specific cut-offs for HLA-I (Lunde-
gaard et al., 2008b; Nielsen et al., 2003; Paul
et al., 2013) and consensus scores for HLA-
II (Kim et al., 2012; Kreiter et al., 2015).
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The tumours with the highest mutation and neoepitope loads for both HLA class I and HLA
class II were the liver and vaginal cuff, which also had the highest number of missense
mutations (Figure 2.4B). We also investigated whether there were shared neoepitopes or mu-
tations present in the RUQ (regressing) and liver (stable) metastases alone, i.e., not present in
the other tumours. No shared mutations between RUQ and liver alone were detected (Figure
7.4A); therefore, it did not appear that a shared neoepitope or mutation alone explained the
behaviour of the non-progressing tumours sites.
As an active CD8 T cell infiltration can exert a selective pressure at the neoepitope level
(DuPage et al., 2012; Matsushita et al., 2012; Teng et al., 2015; Tran et al., 2016; Verdegaal
et al., 2016), we further interrogated the neoepitope landscape by analysing potential evi-
dence of neoepitope depletion using an approach adopted from a report analysing TCGA
data (Rooney et al., 2015). Relative to the other samples from the patient, the regressing
RUQ tumour showed a consistent yet non-significant—tendency of neoepitope depletion
(p-value < 0.1 by two-sided empirical p-value; Figures 7.4B and 7.4C). This result is in
line with a recent report showing neoepitope depletion in tumours with higher levels of
immune signatures in colorectal cancer (Davoli et al., 2017). We then predicted the intrinsic
immunogenicity of neoepitopes by analysing the biochemical properties of peptides that
are predicted to be associated with T cell epitope recognition. Positive immunogenicity
scores have biochemical properties associated with higher immunogenicity that outweigh
properties associated with lower immunogenicity, and vice versa for negative scores (Calis
et al., 2013). We observed that there was a significant effect of neoepitope clonality on the
probability of a neoepitope having immunogenic properties, with clonal neoepitopes showing
a lower probability of having immunogenic properties than sub-clonal predicted binders
(p-value = 0.02 by chi-square test; Figures 2.5A–D). Using the predicted non-binders instead
of binders in a control analysis (NetMHC score > HLA-I specific cut-off), the opposite
trend was observed, clonal neoepitopes show a higher probability of having immunogenic
properties, as there was a small but significant effect of clonal mutations being predicted as
more immunogenic (p-value=0.003 by chi-square test; Figure 2.5F), as well as peptides with
higher HLA-I affinities (chi-square test, p-value=0.0001), although the absolute differences
are minor. No significant interaction between clonality and predicted HLA-I binding affinity
was detected for either binders or non-binders. Although preliminary, these analyses indicate
a potential negative selection process at the neoepitope level.
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Fig. 2.5 Predicted immunogenicity of HLA class I neoepitopes. (A) Predicted immunogenic
properties of trunk (clonal) and private HLA-I neoepitopes. Horizontal lines within violin plots show
the median and interquartile range of the data distribution. (B and C) Comparison between clonal and
sub-clonal (including shared between two or more samples but not all) predicted immunogenicity
of predicted binders and non-binders (two-sided Mann-Whitney rank test). Horizontal lines within
violin plots show the median and interquartile range of the data distribution. (D–F) Probability of
an HLA-I neoepitope having immunogenic properties considering its clonality and HLA-I binding
affinity using the neoepitope data in (A), (B), and (C), respectively. GLM = generalized linear model.
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To evaluate a T cell response in the tumours, we investigated whether T cell clonal expansion
could be detected in the tumour samples. To this end, we performed in situ TCR sequencing
on each sample and on peripheral blood from the patient sampled 550 days after tumour
resection (Figures 2.4C and 7.5A, and Table C2S5A). We detected a T cell expansion in
the RUQ metastasis with a dominant clone accounting for 13% of all productive T cell
receptors sequenced. The expanded clone was also detected in the liver and spleen metastases
and strikingly also in the blood of the patient. However, the clonal frequency in the RUQ
metastasis was significantly higher than that in the other samples (q-value < 0.001 by two-
sided binomial tests with BH correction). In contrast, no T cell receptors were detected in
the primary and vaginal cuff tumours, further supporting their lack of T cell infiltrate.
2.5.6 Peripheral blood CD8+ T cells react against predicted neoepi-
topes
Since expanded T cell clones detected in the tumours were still detected in the patient’s blood
sampled 1 year 6 months (550 days) after resection, we decided to test whether circulating
T cells could react against any of the predicted neoepitopes. We sampled blood from the
patient again, this time at 2 years 8 months (978 days) after resection, and isolated PBMCs
(Figure 7.5A). We performed an ICS assay lasting 21 days, where PBMCs were cultured
with each of the mutant peptides (n = 43) predicted to have at least one HLA-I neoepitope,
as a mutant peptide (17-mer) can have more than one predicted binder (9-mer) (Figure
7.5B). Importantly, the likelihood of observing T cell reactivity by the ICS assays is low
due to the low frequency of T cell precursors in the blood and the limited representation of
the total TCR repertoire in each peptide challenge experiment (5×105 cells per well) (?).
Despite the high false-negative rate generally observed with the ICS assay, we found CD8+
T cells reactive against several mutant peptides showing cytokine activation levels (IFN-γ
and TNF-α) similar to the positive control consisting of a mixture of viral-derived epitopes
(Figures 2.6A and 2.6B and Table C2S5A). Of the top five reactive peptides detected, all
had a higher mutant to wild-type predicted HLA-I binding affinity (inset, Figure 2.6B).
With limited material available, we focused on the top hits and repeated the ICS experiment
and again found reactivity with peptide 12, which was derived from a clonal mutation in
FLG2E1608K (Table C2S1A), and peptide 6, which was derived from a private mutation in
LRRC8EC629Y in the splenic tumour.
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Fig. 2.6 Predicted neoepitopes with higher mutant than wild-type HLA-I binding affinity elicit
a T cell response. (A) Representative scatter-plots of TNF-α and IFN-γ intracellular cytokine
staining of CD8+ T cells after 21 days of culture with CEF peptides or DMSO as positive and negative
controls or the predicted mutant peptides (Figure 7.5B). CEF = Cytomegalovirus, Epstein-Barr virus,
Influenza virus. (B) Percentage of CD8+ T cells with double-positive intracellular staining (TNF-α
and IFN-γ) after incubation with each of the 43 predicted HLA-I neoepitopes, and HLA-I predicted
binding affinity wild-type to mutant ratio. Mutation in gene FLG2E1608K (P12) was found to be
clonal after manual inspection in IGV.
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2.6 Discussion
The natural history of ovarian cancer typically features remissions of decreasing length,
leading to premature death (Bowtell et al., 2015). In this unusual case, the divergent fates
of the tumours show an overall association with multiple molecular and cellular features
at the tumour-immune interface (Figure 2.7). For example, the shrinking RUQ tumour
was heavily infiltrated with CD4+ and CD8+ T cells and had evidence of active CD8+ T
cell surveillance with expansion of specific TCR clonotypes. The stable liver tumour also
exhibited immune infiltration, but at a lower level and with fewer expanding T cell clones.
The spleen tumour was growing modestly at the time of resection and presented with in-
termediate tumour-immune microenvironment features. Finally, the growing vaginal-cuff
and the primary tumour exhibited complete immune cell exclusion. The TCR clone most
prevalent in the non-progressing tumours was also detected in the blood of the patient 18
months after the metastases were resected, and clonal neoepitopes induced a CD8+ T cell
response from PBMCs obtained nearly 3 years after surgery. The two most extreme tumours,
the RUQ and the vaginal cuff, had a consistently divergent pattern of molecular features
associated with immune activation (HLA expression, IFN-γ , CXCL9, TAP1, etc.) and im-
mune suppression (Wnt signalling), respectively. Importantly, the observed features that
relate to progression/regression status are correlative and do not per se prove any bona fide
mechanism nor negate the fact that chemotherapy could have influenced the divergent fates.
In sum, we find evidence of distinct tumour-immune microenvironments among differentially
growing metastases within the same individual.
Beyond the co-existence of tumour microenvironments across different metastases in a patient
with advanced HGSOC, different questions remained unsolved, namely:
• Does intra-patient tumour-immune heterogeneity occur at baseline (i.e. before treatment
intervention)?
• What are the molecular and cellular mechanisms behind the intra-patient TME heterogene-
ity observed?
• Which cells induce or impede immune cell infiltration in a treatment-naive setting?
• What is the effect of chemotherapy in the TME?
• What are the clinical implications of TME heterogeneity?
• Can immune-exclusion be reverted therapeutically?
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Fig. 2.7 Overall associations between tumour fates and tumour-immune microenvironmental
features. Cellular and molecular associations with change in tumour growth. Change in tumour
growth (y axis) was calculated by dividing the tumour volume at CT scan 11 by the tumour volume at
CT scan 10 (Figure 2.1B). Fitted curves are 2nd order polynomial regression lines plotted for trend
visualization rather than prediction purposes. Caspase 1 and 4 are considered inflammatory caspases
involved in a type of apoptosis related to immune response called pyroptosis. The enrichment score x
axis and the q-values come from the ssGSEA analysis. HLA-I genes include HLA-A, B, C, E, and F.
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• Intra-patient tumour-immune heterogeneity is highly prevalent in patients with high-grade
serous ovarian cancer.
• Consensus gene set signatures improve tumour microenvironment cell estimation.
• Myc and Wnt signalling pathways are enriched in immune excluded tumours.
• Neoadjuvant chemotherapy induces NK cell infiltration and T cell activation.
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3.2 Summary
In metastatic cancer, the role of heterogeneity at the tumour-immune microenvironment, its
molecular underpinnings and clinical relevance remain largely unexplored. To understand
tumour-immune dynamics at baseline and upon chemotherapy treatment, we performed
unbiased pathway and cell type-specific immunogenomics analysis of treatment-naive (38
samples from 8 patients) and paired chemotherapy treated (80 paired samples from 40 pa-
tients) high-grade serous ovarian cancer (HGSOC) samples. Whole transcriptome analysis
and image-based quantification of T cells from treatment-naive tumours revealed ubiqui-
tous variability in immune signalling and distinct immune microenvironments co-existing
within the same individuals and within tumour deposits at diagnosis. To systematically ex-
plore cell type composition of the tumour microenvironment using bulk mRNA, we derived
consensus immune and stromal cell gene signatures by intersecting state-of-the-art estima-
tion/regression/enrichment methods (ConsensusTME v1.0), providing improved accuracy and
sensitivity when compared to HGSOC immunostaining and leukocyte methylation data sets.
Cell-type estimation and pathway analyses revealed that Myc and Wnt signalling associate
with immune cell exclusion in untreated HGSOC. To evaluate the effect of chemotherapy on
the intrinsic tumour-immune heterogeneity, we compared site-matched and site-unmatched
tumours before and after neoadjuvant chemotherapy. Transcriptomic and T-cell receptor
sequencing analyses showed that site-matched samples had increased cytotoxic immune
activation and oligoclonal expansion of T cells after chemotherapy, which was not seen
in site-unmatched samples where heterogeneity could not be accounted for. These results
demonstrate that the tumour-immune interface in advanced HGSOC is intrinsically heteroge-
neous, and thus requires site-specific analysis to reliably unmask the impact of therapy on
the tumour-immune microenvironment.
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3.3 Introduction
It is unclear how the complex interplay between tumour cells and the TME and their inter-
actions affect treatment outcome in metastatic cancer (Janssen et al., 2017; Kitamura et al.,
2015; Robinson et al., 2017). Investigating this interplay in an advanced disease setting is
complicated by the difficulty of obtaining multiple-site tumour samples and the finding that
different tumours within the same individual can harbour distinct immune microenvironments
(Jiménez-Sánchez et al., 2017; Reuben et al., 2017; Sridharan et al., 2016; Zhang et al., 2018).
Moreover, interactions between different cell populations of the TME are plastic and can
change dependent on extrinsic perturbations such as therapy (Wang et al., 2016).
HGSOC is ideally suited to the study of TME heterogeneity owing to its clinical presentation
with multi-site abdominal disease and standardised treatment with either optimal surgical
debulking at diagnosis or delayed primary surgery after NACT (Bowtell et al., 2015). Thus,
in HGSOC there is a unique opportunity to study the characteristics of the TME at multiple
sites, to observe variation at baseline (diagnosis), and following therapy. Furthermore, since
HGSOC is typically diagnosed when dissemination has already taken place in the peritoneal
cavity, this malignancy provides the basis for evaluating the ubiquitousness of intra-patient
TME heterogeneity in an advanced, metastatic disease setting.
To characterise heterogeneity at the level of the TME and to begin to identify the molecular
and cellular underpinnings of immune infiltration variability at diagnosis and after pertur-
bation by chemotherapy in HGSOC, we performed a systematic analysis of >100 HGSOC
samples from treatment-naive and NACT patient cohorts. Our findings confirm that HGSOC
is a disease characterised by highly prevalent TME heterogeneity with distinct immune
microenvironments co-existing in different tumour nests within the same individuals at
diagnosis. We leverage our rich data sets to create an ensemble computational approach that
integrates and improves upon existing immune and stromal cell cell-type specific estimation
methods, thus enabling us to systematically characterise the TME of HGSOC before and
after treatment. We identify oncogenic signalling pathways such as Myc and Wnt that
associate with immune cell exclusion when comparing tumours with high cancer cell fraction
(high purity) vs low cancer cell fraction (low purity). We find that NACT induces immune
activation and specific T cell clonal expansions in local TMEs, however, intra-patient TME
immune heterogeneity can mask such effects. Consequently, systemic immunomodulatory
therapies may be ineffective in a subset of tumour sites, thus preventing overall patient
benefit. Together, these results show that intra-patient TME heterogeneity is highly prevalent
in HGSOC, which could confound clinical outcomes.
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Contact for reagent and resource sharing
Further information and requests for resources and reagents should be directed to and will be
fulfilled by Dr Martin L. Miller (martin.miller@cruk.cam.ac.uk).
Experimental model and subject details
Human subjects research
⊙
All patients had stage IIIC or IV HGSOC as assessed by a pathologist specialized in gynaeco-




For the treatment-naive cohort, 25 patients were consented to the study between August
2014 and March 2016. Out of these patients, 17 were excluded as they either a) withdrew
from the study (n=3); b) the final pathology was not HGSOC (n=5); c) the patients had
disease progression upon review of study imaging and underwent neoadjuvant chemotherapy
instead of primary cytoreductive surgery (n=5); d) inadequate image-guided tissue sam-
pling due to friable tissue (n=2); e) research imaging studies not performed due to patient
cancellation (n=2). The final treatment-naive study population consisted of 8 patients with
histopathologically-confirmed diagnosis of HGSOC (Table C3S1A-B). Each patient under-
went multi-parametric MRI of the abdomen and pelvis and 18F-FDG PET/CT within 7 days
immediately preceding the primary cytoreductive surgery. Volumetric regions of interest
were outlined on both axial T2-weighted MR images and PET images, covering both the
primary and metastatic lesions, using ImageJ/FIJI (U.S. National Institutes of Health) by
a board certified radiologist with special expertise in ovarian cancer imaging. The tumour
regions outlined on MRI were co-registered with those outlined on PET.
Neoadjuvant chemotherapy cohort
⊙
For the neoadjuvant chemotherapy cohort a previously established institutional database
identified 152 patients with HGSOC who underwent neoadjuvant chemotherapy between
2008 and 2013. Of these patients, 149 went on to interval debulking surgery. 48 of these
patients had adequate pre and post treatment formalin fixed paraffin embedded tissue samples
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available. All pretreatment specimens were obtained either through core biopsy or laparo-
scopic biopsy, and all post treatment specimens were obtained at the time of laparotomy for
interval debulking surgery. Choice of chemotherapy was at the clinician’s discretion, but all
patients in the cohort received a platinum and taxane based regimen (Table C3S5A). 40 of
these paired samples yielded data for analysis, 17 of these pairs were site-matched, meaning
that pre-treatment and post-treatment specimens were taken from the same anatomic site,
while 23 were site-unmatched. Gene expression and T cell receptor sequencing (TCR-seq)
data were generated for 28 and 37 pairs respectively (Table C3S5B). Samples with very low
TCR sequences (n=5 samples, 10 pairs) were not included in the downstream analyses as the
confidence of TCR clonality is low.
Method details
Image acquisition and analysis
⊙
The quantitative diffusion parameters D (diffusion coefficient) and f (volume fraction of
blood flowing through micro-vessels) derived from the intravoxel incoherent motion MRI
(Le Bihan et al., 1988) and dynamic contrast-enhanced MRI (Tofts, 1997) parameter Ktrans
(volume transfer constant between the blood plasma and the extravascular extracellular space)
were generated voxel-wise using a dedicated in-house software written in Matlab (Mathworks
Inc., Natick, MA, USA). The standarised uptake value (SUV) of the voxels contained within
each lesion on PET were also calculated (Kinahan et al., 2009). k-means clustering algorithm
(Carano et al., 2004) of the D, f , Ktrans and SUV voxels, with the number of clusters (k)
being fixed to k=3 was used to identify imaging clusters/habitats. The mean and standard
deviation (mean±std. dev.) of these parameters for each cluster were calculated. To establish
coherence across patients (i.e. to label each cluster with the α , β , γ greek letters, such that
across patients clusters would have similar imaging features), the intra-cluster distance was
calculated for each cluster. The greek letter of the clusters for each patient was assigned
based on the relative value of the intra-cluster distance. Specifically, for each patient, β was
assigned to the cluster which had the highest intra-cluster distance for that patient; γ was
assigned to the cluster with intermediate intra-cluster distance, and α to the cluster with the
lowest intra-cluster distance.
Custom made 3D tumour Moulds
⊙
For each patient, custom made 3 dimensional (3D) moulds [REF:Weigelt B, Vargas AH,
Selenica P, Geyer FC, Mazaheri Y, Blecua P, Conlon N, Hoang LN, Jungbluth AA, Snyder
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A, Ng CKY, Papanastasiou AD, Sosa RE, Soslow RA, Chi DS, Gardner GJ, Shen R, Reis-
Filho JS, Sala E. Radiogenomics analysis of intra-tumour heterogeneity in high-grade serous
ovarian cancer. BJC (under review).] were printed based on manual segmentation of the
ovarian mass and metastatic implants on axial T2-weighted magnetic resonance images. The
lesions were outlined on every axial slice and automatically converted into 3D models using
open source software (MIPAV, National Institutes for Health, Center for Information Tech-
nology). The final 3D models of each lesion were imported into OpenSCAD (OpenSCAD,
The OpenSCAD Developers), a 3D CAD modelling software, which was used to create an
internal cavity that exactly shaped each lesion according to the MRI shape and contour. The
custom-made 3D tumour moulds were printed using a 3D printer (MakerBot Replicator 2,
MakerBot, Brooklyn, NY). The slits for slicing each lesion were placed and labelled into
the molds at 10mm intervals corresponding to the slice thickness and locations of the axial
T2W-weighted MR images. The mould was also labelled with left, right, anterior, posterior,
superior and inferior markers to allow for proper orientation when collecting samples in the
operating room.
Cluster guided specimen sampling
⊙
All 3D moulds containing the specimens were taken to the histopathology department where
each lesion was sampled by a pathology fellow. Each tumour was sectioned through the
mould and samples were taken according to the imaging habitats/clusters defined above. Half
of the sample was sent for histopathology and the other one for immunogenomic analysis.
Immunofluorescent Staining
⊙
The immunofluorescent staining was performed at Molecular Cytology Core Facility of
MSKCC using Discovery XT processor (Ventana Medical Systems). The tissue sections
were deparaffinised with EZPrep buffer (Ventana Medical Systems), antigen retrieval was
performed with CC1 buffer (Ventana Medical Systems). Sections were blocked for 30
minutes with Background Buster solution (Innovex), followed by avidin-biotin blocking for
8 minutes (Ventana Medical Systems).
Multiplex immunofluorescence stainings were performed as previously described (Yarilin
et al., 2015). Slides were incubated with anti-FoxP3 (Abcam, Catalogue Number: ab20034,
5 ug/ml) for 4 hours, followed by 60 minutes incubation with biotinylated horse anti-mouse
IgG (Vector Labs, Catalogue Number: MKB-22258) at 1:200 dilution. The detection was
performed with Streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems),
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followed by incubation with Tyramide Alexa Fluor 488 (Invitrogen, Catalogue Number:
T20922) prepared according to manufacturer instruction with predetermined dilutions. Next,
sections were incubated with anti-CD4 (Ventana, Catalogue Number: 790-4423, 0.5 ug/ml)
for 5 hours, followed by 60 minutes incubation with biotinylated goat anti- rabbit IgG
(Vector, Catalogue Number: PK6101) at 1:200 dilution. The detection was performed with
Streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incuba-
tion with Tyramide Alexa 568 (Invitrogen, Catalogue Number: T20914) prepared according
to manufacturer instruction with predetermined dilutions. Finally, sections were incubated
with anti-CD8 (Ventana, Catalogue Number: 790-4460, 0.07 ug/ml) for 5 hours, followed
by 60 minutes incubation with biotinylated goat anti-rabbit IgG (Vector, Catalogue Number:
PK6101) at 1:200 dilution. The detection was performed with Streptavidin-HRP D (part of
DABMap kit, Ventana Medical Systems), followed by incubation with Tyramide Alexa 647
(Invitrogen, Catalogue Number: T20936) prepared according to manufacturer instruction
with predetermined dilutions. After staining slides were counter-stained with DAPI (Sigma
Aldrich, Catalogue Number: D9542, 5 ug/ml) for 10 min and cover-slipped with Mowiol.
Stained slides were digitized using Pannoramic Flash 250 (3DHistech, Hungary) using
20x/0.8NA objective. Regions of interest were drawn on the scanned images using Panno-
ramic Viewer (3DHistech, Hungary) and exported into tiff images. ImageJ/FIJI was used to
segment DAPI-stained nuclei and count the cells with positive signal.
Nucleic Acid Isolation and Quantification
⊙
DNA and RNA were extracted from tumour areas delineated as tumour nests on H&E slides
reviewed by a pathologist specialized in gynecologic malignancies using the DNeasy® and
RNeasy® (Qiagen) assays, respectively. RNA expression was assessed using the human
Affymetrix Clariom D Pico assay (Thermo Fisher Scientific).
T-Cell Receptor Sequencing
⊙
High-throughput in-situ sequencing of the T cell receptors present in the samples and blood of
the patient was performed using the immunoSEQ assay platform (Adaptive Biotechnologies).
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Quantification and statistical analysis
Gene expression analysis
RNA expression was assessed using the human Affymetrix Clariom D Pico assay. Arrays
were analysed using the SST-RMA algorithm in the Affymetrix Expression Console Software.
Expression was determined by using the Affymetrix Transcriptome Analysis Console. Local
Regression (LOESS) normalisation across samples was implemented (Gautier et al., 2004)
using:
# R 3.5.0
library(affy) # version 1.58.0
data_norm<-normalise.loess(data,family.loess="gaussian")
Single-sample gene set enrichment analysis
Single-sample gene set enrichment analysis (Barbie et al., 2009), a modification of standard
GSEA (Subramanian et al., 2005), was performed on RNA measurements for each sample
using the GSVA package version 1.28.0 (Hänzelmann et al., 2013) in R version 3.5.0
with parameters: method="ssgsea", and tau=0.25. normalised enrichment scores were
generated for the hallmark gene sets (Liberzon et al., 2015), immune and stromal signatures
(Yoshihara et al., 2013), TME cell gene sets obtained from previous publications (Bindea
et al., 2013; Davoli et al., 2017), as well as ConsensusTME gene sets (Figure 8.3A). Hallmark
gene sets were obtained from MSigDB database version 6.1 (Liberzon et al., 2011).
Tumour purity and immune cell gene-expression score
Tumour purity and total immune component in the tumour samples were analysed using
the ESTIMATE algorithm method version 1.0.13 (Yoshihara et al., 2013) on the gene
expression data using the option: platform="affymetrix" for the cohort samples and
platform="illumina" for TCGA OV samples, in R version 3.5.0.
Dimensionality reduction
The t-distributed stochastic neighbor embedding (t-SNE) and PCA dimensionality reduction
methods were implemented in python version 3.6.5 using the sklearn.manifold.TSNE and
sklearn.decomposition.PCA functions from the sklearn version 0.19.1 package. PCA
was computed after sample wise standardization. Functions were used as follows:
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Analysis of T cell infiltration between cases, sites, and habitats
A linear mixed effects model analysis was performed to evaluate if there were significant
differences in T cell infiltration subsets between patients, sites within patients, and habitats
within tumours, and to assess whether the differences were other than random. Due to data
nested dependency we employed a linear mixed effects model under the lme4 R package
(Bates et al., 2015). Cases were considered a random factor, while sites and habitats were
considered fixed factors as follows:
# R 3.5.0
library(lme4) # version 1.1-17
glmer.fit<-glmer(cbind(cd8_counts,total_cells-cd8_counts)∼
site*habitats+(1|case),family=binomial,data=data)
TME cell estimation and enrichment methods
Cell estimation and enrichment methods were used to estimate levels of non-cancerous
cells in the TME. The methods employed were CIBERSORT (Newman et al., 2015), MCP-
counter (Becht et al., 2016), TIMER (Li et al., 2016), xCELL (Aran et al., 2017), as well
as gene sets collected from two previous publications (Bindea et al., 2013; Davoli et al., 2017).
CIBERSORT:
# R 3.5.0
















TIMER: The TIMER web server (https://cistrome.shinyapps.io/timer/) was used for regres-
sion of TME cells (Li et al., 2017c).
xCELL: The xCELL web server version 1.1 (http://xcell.ucsf.edu/) was used to calculate
enrichment of TME cells.
For the Bindea et al. and Davoli et al. gene sets, standard ssGSEA analysis was performed as
previously described.
ConsensusTME version 1.0 gene sets
To generate the ConsensusTME gene sets we identified cell types that were estimated by at
least 2 different methods, leading to 18 different cell types. We then intersected the gene sets
that the different methods considered for the estimation of such cell types. To intersect genes
used in CIBERSORT, we first filtered out genes whose weight was below 1.96 standard
deviations of the mean for each of CIBERSORT cell types. In addition we combined activated
states into the corresponding cell type. The only activated stated included was cytotoxic cells,
which would include CD8 T cells and/or NK cells in their activated stated. The intersected
genes were used to represent each cell type, and genes with a higher Pearson’s correlation
coefficient than -0.2 and a p-value ≤ 0.05 with tumour purity as defined by TIMER were
filtered out from the gene sets (Li et al., 2016). Finally, ssGSEA was employed to calculate
normalised enrichment score (NES) for each cell type as described above (Figure 8.3A).
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TME cell estimation benchmarks
T cell subsets immunofluorescent staining benchmark: We correlated the CD8+, CD4+, Tregs
infiltration counts with the scores generated by ESTIMATE, CIBERSORT, MCP-counter,
Bindea et al., Davoli et al., TIMER, xCELL, and the consensus TME scores. For the immune
score comparison, all the genes used for the estimation for each method were aggregated to-
gether into one single gene set per method except for CIBERSORT. CIBERSORT estimation
−log10(p− values) were used as a metric for immune score comparison. CD8, CD4, and
Treg counts from IF-stained data were summed and used for the comparison. Because the
methods have different scoring systems and ranges we standardized (z-score) the scores to
be able to compare the results across methods together. For each tumour, multiple IF-stained
sections were quantified for tumour infiltrating lymphocyte (TIL)s, and we correlated all the
regions quantified with the scores of each tumour, explaining the vertical patterns observed
in figure 8.3A. Spearman’s rank correlation was performed for each comparison and FDR
p-value correction was applied.
TCGA OV leukocyte methylation benchmark: As an independent benchmark we used leuko-
cyte methylation scores of TCGA ovarian cancer samples (TCGA, 2011). TCGA ovarian
cancer RNA sequencing (RNA-seq) data were retrieved from the cBioPortal (Cerami et al.,
2012; Gao et al., 2013) web server version 1.6.2 (http://www.cbioportal.org/).
First, estimation of cell types was performed using the different methods listed above.
Spearman’s rank correlations were calculated between CD8 T cell scores and the leukocyte
methylation score of TCGA ovarian cancer samples, and FDR p-value correction was applied.
We further fitted multiple linear regression models to each method estimated cell types
(Figure 8.3B). We compared the proportion of leukocyte methylation score variance that
is explained by the unsupervised selected immune cells (adjusted R-squared), as well as
the relative quality of the models by considering goodness of fit and model simplicity after
BoxCox transformation of the leukocyte methylation scores to meet the normality of residuals
assumption. As a sensitivity analysis we log transformed the leukocyte methylation scores be-
fore performing the linear regression models. In both analyses (BoxCox and log-transform),
stepwise Akaike Information Criterion (AIC) variable selection was performed once nor-
mality and heteroscedasticity assumptions were checked. AIC and Bayesian Information
Criterion (BIC) were employed independently to compare the fitted models for each method.
Both AIC and BIC quantify information loss and penalize the number of variables. Thus,
the trade-off between goodness of fit and model simplicity across methods was evaluated,
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allowing us to quantify and minimize information loss. The R version and packages used for
this analysis were R version 3.5.0, gamlss_5.0-8 (Stasinopoulos et al., 2007), leaps_3.0,
car_3.0-0 (Fox and Weisberg, 2011), and MASS_7.3-50 (Venables and Ripley, 2002).
Differential expression analysis
Tumour samples from the treatment-naive cohort were divided into high and low purity
classes taking as a cut-off the median of tumour purity calculated for the tumour samples
using ESTIMATE (Yoshihara et al., 2013). Then a differential expression analysis was
performed using the R packages limma_3.36.1 (Ritchie et al., 2015) and Biobase_2.40.0
(Huber et al., 2015). Patient dependency was taken into account as follows:
# R 3.5.0
library(limma) # version limma_3.36.1
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# Make design matrix
design<-model.matrix(~0+clinical)
colnames(design)<-levels(clinical)
# estimate correlation between measurements on same subjects
corfit<-duplicateCorrelation(eset,design,block=patient_data$case)










Gene ontology analysis of significantly up or down-regulated genes was performed using the
Gene Ontology Consortium (Ashburner et al., 2000; The Gene Ontology Consortium, 2017)
web server (http://www.geneontology.org/). P-value FDR corrections were calculated for
this analysis.
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ssGSEA of differential expression analysis
Further, p-values for each gene were retrieved and multiplied by -1 if the log2 change was
negative. The list of genes with their associated p-value was used to calculate hallmark and
consensus TME NES through ssGSEA. Hallmark gene sets’ NES were normalised by taking
the exponential function. ConsensusTME gene sets’ NES approached normality by taking the
natural logarithm. The modified z-score (ẑx) was calculated to detect outliers in the hallmarks
and ConsensusTME NES independently, as the ẑx uses the median and the median absolute
deviation (x̂(|xi − x̂|) to robustly measure central tendency and dispersion in small data sets
(Iglewicz and Hoaglin, 1993).
ẑx =
0.6745× (xi − x̂)
x̂(|xi − x̂|)
(3.1)
Paired gene set comparisons
Volcano plots: For each of the 52 hallmark and 18 ConsensusTME gene sets paired com-
parisons before and after NACT were performed. Equality of variance (Bartlett’s test) and
normality (Shapiro test, Kolmogorov-Smirnov test, and D-Agostino-Pearson’s test) assump-
tions were checked to select the corresponding paired test (Paired T-test, Welch’s T-test, or
Wilcoxon signed-rank test). The analysis was performed using python 3.6.5 and scipy 1.1.0
(http://www.scipy.org/) (Oliphant, 2007).
Hotelling’s T2 distribution test: Multivariate Hotelling’s T2 test was performed to com-
pare difference of CD8, NK, and cytotoxic ConsensusTME gene sets NES between pre- and
post-NACT tumours as follows:
# R 3.5.0
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Analysis of the sequences was performed on the immunoSEQ ANALYZER 3.0 (Adaptive
biotechnologies). T cell counts and TCR clonality were retrieved for statistical comparisons.
T cell counts are derived from quantitative immunoSequencing of the TCR β -chain loci, in
which the internal controls allow precise quantitation of sequence counts based on reads.
Nucleated cell counts are determined by sequencing housekeeping genes. The fraction of T
cells is determined by dividing the T cell count by the nucleated cell counts. Values for TCR
productive clonality range from 0 to 1. Values near 1 represent samples with one or a few
predominant rearrangements (monoclonal or oligoclonal samples) dominating the observed
repertoire. TCR productive clonality values near 0 represent more polyclonal samples. TCR
productive clonality is calculated by normalizing productive entropy using the total number
of unique productive rearrangements and subtracting the result from 1.
LASSO regression and post-selection inference
least absolute shrinkage and selection operator (LASSO) regression analysis was performed
using the glmnet R package (Friedman et al., 2010). Hallmark and ConsensusTME cell type
NES of pre-NACT samples were used independently as explanatory variables, and the log2
of the ratio post/pre NACT TCR clonality as response variable.
# R 3.5.0



















library("selectiveInference") # version selectiveInference_1.2.4
postselinf_h=fixedLassoInf(h,y,beta_hat[-1],lambda,family="gaussian")
postselinf_c=fixedLassoInf(c,y,beta_hat[-1],lambda,family="gaussian")
Data and Software Availability
Requests for additional data and custom code should be directed to Dr Martin L. Miller
(martin.miller@cruk.cam.ac.uk).
Supplementary tables
Supplementary tables can be accessed through:
https://github.com/cansysbio/immunogenomics/tree/master/AJSPhDThesis/AppendixB/Tables/
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3.5 Results
3.5.1 Intra-patient transcriptomic heterogeneity is largely explained
by immune signalling
To investigate the TME of HGSOC in a treatment-naive context, we analysed the transcrip-
tome of 38 primary and metastatic tumour samples from 8 treatment-naive patients collected
prospectively (Figure 3.1A, Table C3S1A and Table C3S1B). Primary tumour masses and
peritoneal metastases were resected and placed on patient-specific 3D moulds created based
on tumour segmentation using high resolution T2-weighted magnetic resonance magnetic
resonance (MR) images. Each specimen was placed in the custom-made 3D mould in the
operating theatre and was further dissected into sub-specimens according to three multi-
parametric imaging-based phenotypically distinct clusters, hereafter referred to as “habitats”.
Habitats were obtained from MR and 18F-FDG-PET imaging and were defined based on
quantitative imaging features that measure water diffusion, micro-capillary perfusion, per-
meability and metabolic activity (see Methods). We first performed an unbiased clustering
analysis of the whole transcriptome. We observed that overall gene expression of tumour sam-
ples was highly patient specific, irrespective of anatomical site using t-distributed stochastic
neighbor embedding (t-SNE) which accounts for non-linear relationships (Figure 3.1B). To
focus on well-defined biological processes and signalling pathways, we performed ssGSEA
(Hänzelmann et al., 2013) using the hallmark gene sets (Liberzon et al., 2015), stromal and
immune gene signatures, and tumour cell fraction (purity) using the ESTIMATE algorithm
(Yoshihara et al., 2013). We categorised the gene sets into five classes: oncogenic, cellular
stress, immune, stromal, and other.
Principal component analysis (PCA) showed that most of the gene set expression varia-
tion between samples (60% of variation) could be explained by oncogenic, immune, and
stroma-associated gene sets (Figure 3.1C, 8.1A). In contrast to the full transcriptome analy-
sis, the patient specific clustering was less evident, indicating that tumours from different
patients share common patterns of pathway activation and non-cancer cell infiltrates. To
investigate which gene sets explained most of the observed variance, we computed the
principal component feature loadings and displayed them in a variable factors map (Figure
3.1D). This analysis showed that PC1 (40% of variation) is largely explained by tumour
purity, since immune and stromal vectors had an opposite direction to oncogenic vectors and
tumour purity (immune vs oncogenic: p-value = 3×10−05; stromal vs oncogenic: p-value =
1.3×10−03), and PC2 (20% of variation) further showed a separation of immune, stromal,
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and cellular stress vectors (immune vs stromal: p-value = 0.046; immune vs stress: p-value =
0.041; Figure 8.1B).
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Fig. 3.1 Immune signalling contributes to the majority of the transcriptional variance observed
across multiple tumour samples from treatment-naive HGSOC patients. (A) Flowchart of sam-
ple acquisition and analysis. Peritoneal metastases other than omentum were defined as “Other”. (B)
t-SNE analysis of overall transcription profiles of multiple HGSOC tumour samples per patient. (C)
PCA of ssGSEA-based analysis of hallmark gene sets. D) Principal component feature loadings (mag-
nitude and direction) of C are shown in the variables factor map. Vectors are coloured according to a
major biological classification of hallmark gene sets. Variation across classes in PC1 (p-value=3.2−16)
and PC2 (p-value=0.02) after Kruskal-Wallis H-test (Figure 8.1). Directionality of ESTIMATE’s
tumour purity is represented with the map compass. E) ESTIMATE immune score across patients and
samples. The Case Study samples were taken from (Jiménez-Sánchez et al., 2017). The bottom and
top edges of the box plots indicate the 25th and 75th percentiles. TCGA OV (n = 301).
Since immune related pathways explained a significant amount of variation between the sam-
ples, we further investigated the extent of intra-patient immune heterogeneity by computing
the ESTIMATE immune score for each sample. In addition, we included as a reference the
immune scores of the samples from a HGSOC case study with >9 years of clinical history we
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previously analysed (Jiménez-Sánchez et al., 2017) and the immune scores of ovarian cancer
samples from The Cancer Genome Atlas (TCGA), which comprises 307 treatment-naive
primary tumours (TCGA, 2011). Overall, the immune scores of our cohort fell within the
range expected at the population level (Figure 3.1E). Some patients (01, 04, 10, and the case
study) showed an intra-patient variation comparable to the inter-patient variation observed
at the population level by the TCGA ovarian cancer samples, which indicates that within a
single individual, complete distinct immune microenvironments can co-exist at diagnosis of
HGSOC. Also, all patients in the cohort had at least one sample with similar or lower immune
score than the progressing and immune excluded tumours of the case study, where distinct
tumour-immune microenvironments led to different clinical outcomes (Jiménez-Sánchez
et al., 2017). Importantly, consistent with our prior report, we recapitulate the observation
that tumours with high immune signalling and immunosuppressive Wnt signalling tend to be
mutually exclusive (Figure 3.1D).
3.5.2 Co-existence of distinct tumour-immune microenvironments in
treatment-naive HGSOC
To further characterise the tumour microenvironment of HGSOC, we performed multicolour
IF staining and quantification of CD4+, CD8+, and regulatory T cells (CD4+ FOXP3+) in at
least 10 tumour regions excluding stromal areas in each sample leading to a compendium of
440 imaged and digitally quantified tumour regions (Figures 3.2A-B, 8.2, and Table C3S2A).
This multi-region and multi-site IF analysis shows that treatment-naive HGSOC patients
present variation in T cell infiltration in tumour deposits, ranging from less than 1% (e.g.
patient 6) to T cells accounting for more than 10% of total cells in some areas (e.g. patient
01 and 10). Furthermore, some patients’ tumour deposits demonstrated marked variation in
T cell infiltration within the same tumour deposit across different habitats (e.g. patient 01).
We then performed a linear mixed effects model analysis (see Methods and Table C3S2B)
to statistically evaluate whether there is a difference of T cell infiltration between patients,
between tumours of the same patients and between habitats within tumours. We found a
remarkable difference in T cell infiltration across tumours within patients (DF=2, CD8+
F-value=8758; CD4+ F-value=58; Tregs F-value=657) and habitats within a tumour (DF=2,
CD8+ F-value=1184; CD4+ F-value=2870; Tregs F-value=2216). Sites and habitats also
showed an important level of interaction (DF=4, CD8+ F-value=5915; CD4+ F-value=4466;
Tregs F-value=142). This systematic T cell IF staining and computerised cell detection-
counting confirm the variation in T cell infiltration across patients, across tumour samples
within patients, within tumours and within habitats. Together with the transcriptome analysis,
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these data show that HGSOC is intrinsically characterised by the presence of heterogeneous
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Fig. 3.2 T cell infiltrate variation across patients, within patients, and within tumours. (A)
Multi-tumour sampling from 8 HGSOC patients are shown with each dot representing the percentage
of T cell subsets in a quantified area within a given tumour section stained with multicolour IF for
CD8+, CD4+ and CD4+FOXP3+. Stromal areas were excluded based on H&E stains. Patient cases are
indicated by different colours. Anatomical sites of tumour deposits are indicated by different markers
(circle, triangle and square). Habitats are defined by the Greek letters α , β and γ . Habitats from the
same tumour are indicated by connecting lines. Box-plots are sorted according to the median of CD8+
T cell infiltration across patients, sites and habitats accordingly. (B) Representative images of panel A.
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3.5.3 Consensus tumour microenvironment gene sets improve cell esti-
mation from bulk tumour mRNA
To estimate the relative abundance of different cell types in an unbiased manner using bulk
RNA data, various computational approaches have been developed during the last decade
(Finotello and Trajanoski, 2018). However, a comparison that objectively evaluates the
performance of these approaches against one another has not been conducted and no publicly
available data sets have been generated to serve as ground truths thus far (Zheng, 2017).
Therefore, to test the performance of cell-type specific estimation methods, we performed
a preliminary benchmark using the T cell IF quantification of the 440 regions from the 38
treatment-naive HGSOC samples as the ground truth. We used ESTIMATE for total T cell
infiltration (Yoshihara et al., 2013), and compared CIBERSORT (Newman et al., 2015),
TIMER (Li et al., 2016), MCP-counter (Becht et al., 2016) and xCell (Aran et al., 2017) for
cell type specific estimations. We also evaluated immune gene sets that were defined based
on gene expression of sorted immune populations (Bindea et al., 2013), as well as immune
gene sets based on the Immunological Genome Project database (Davoli et al., 2017; Heng
et al., 2008). Using ssGSEA (Hänzelmann et al., 2013), the Bindea et al. and Davoli et al.
gene sets were used to calculate normalized enrichment scores (NES) of the corresponding
cell types. To be able to evaluate the performance of ESTIMATE, which calculates a total im-
mune score but does not estimate immune cell types, total immune scores from the different
tools were generated (see Methods). Total immune scores and cell-type specific scores for
CD4+, CD8+ and Tregs were correlated independently against the aggregated T cells and the
corresponding cell type fractions (Figure 3.3A). Importantly, not all of the methods selected
estimate CD4+, CD8+, and Tregs; however, for the methods that estimate all three cell types,
none consistently outperformed the other methods in this independent benchmark analysis.
In addition, none of these methods was able to get a significant positive correlation with
Tregs, which may indicate a lower-limit threshold of sensitivity of detection, since Tregs
comprised, on average, less than 1% of cells in the tumour nests (Figure 3.2A, 8.2).
Since the cell-type specific estimation methods were developed independently of each other,
we reasoned that generating consensus gene sets by including the genes that fall in the
intersection of different cell types across the different tools could improve the cell estimation
performance. Since not all methods estimate the same cell types, we focused on cell types
that at least two methods estimate. We selected the union of genes, and finally removed
genes whose expression levels positively correlated with tumour purity using TCGA ovarian
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Fig. 3.3 Consensus tumour microenvironment cell enrichment method improves estimation
of tumour infiltrating T cells and leukocytes. (A) Spearman’s rank-order correlations between
percentage of T cells (immunofluorescent staining) and the corresponding scores for each method
using the treatment-naive ovarian cancer samples. Correlation coefficients (ρ) and q-values are
ordered from higher and more significant to lower and less significant. Scores were standardized
(z-score) to visually compare the different correlations in the same scale. IF immune score was
calculated by adding up CD8+, CD4+, and Tregs counts as an approximation, while immune scores
were calculated according to each tool (see Methods). (B, C) TCGA ovarian cancer Spearman’s
rank-order correlations between CD8+ T cell scores and leukocyte methylation scores. D) Multiple
linear regression analysis using leukocyte methylation score as response variable, and estimated cell
types as explanatory variables (see Methods). Adjusted R2, AIC, and BIC values were calculated
to compare goodness of fit and model simplicity. Arrowheads indicate best model for each method.
Inset in the AIC panel shows a magnification of the best ranked models.
We called this approach ConsensusTME version 1.0. We correlated the ssGSEA NES of the
ConsensusTME v.1.0 cell gene sets against the fraction of T cells quantified, and observed
that the ConsensusTME v.1.0 gene sets consistently showed higher positive correlations
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than the individual methods. In addition, the ConsensusTME v.1.0 Tregs NES was the only
score with a significant positive correlation with the fraction of Tregs, suggesting a greater
level of sensitivity obtained with ConsensusTME v.1.0 (Figure 3.3A, Spearman’s ρ=0.26,
q-value=6.2×10−07).
To further benchmark the methods and the ConsensusTME v.1.0, we employed TCGA ovarian
cancer leukocyte methylation scores (TCGA, 2011), which is an independent and larger
patient cohort. Leukocyte methylation measurements provide orthogonal means toward
estimating immune infiltration in tumours, and have been shown to significantly correlate
with histological purity estimates in primary HGSOC (Carter et al., 2012). Importantly, the
leukocyte methylation signature was generated by comparing methylation patterns between
HGSOC tumours, normal fallopian tube samples and buffy-coat samples of female individu-
als, making this data set ideal for benchmarking the different cell-type specific estimation
methods (Carter et al., 2012). We first performed a benchmark of all methods using the leuko-
cyte methylation scores and the CD8+ T cell scores (Figure 3.3B), as i) this sub-population
is a major component of infiltrating leukocytes, ii) all methods tested estimate CD8+ T
cells, and iii) overall the CD8+ IF estimations were the best correlations (Figure 3.3A).
Among the seven methods, ConsensusTME v.1.0 CD8+ gene signature correlated best with
the CD8+ T cell score (Figure 3.3C, Spearman’s ρ=0.82 p-value=3.9×10−16). However, as
the leukocyte methylation score does not count CD8+ T cells exclusively, we then compared
the different methods in an unbiased manner by fitting a multiple linear regression model for
each method using the leukocyte methylation score as a response variable and the different
cellular scores as explanatory variables, followed by unsupervised nested variable selection
(see Methods and Figure 8.3B). We compared the proportion of leukocyte methylation score
variance that is explained by the unsupervised selected estimated cells (adjusted R2), as well
as the relative quality of the models by considering goodness of fit and model simplicity
(see Methods). The ConsensusTME v.1.0 provided the highest adjusted R-squared with
fewer cell types selected (Adjusted R-squared=0.73, p-value < 2.2× 10−16, Figure 3.3D
left panel), as well as being selected as the simplest and most accurate model to explain
leukocyte methylation (Figure 3.3D middle and right panels). Finally, the ConsensusTME
v.1.0 gene sets that the systematic unbiased analysis suggested best explained leukocyte
methylation, were cells expected to be present in leukocyte infiltrates, with CD8+ T cells
and NK cells accounting for the vast majority of the variation explained (Table C3S3, CD8+
p-value=1.74× 10−07, and NK cells p-value=1.79× 10−11). In addition, we performed a
sensitivity analysis of the leukocyte methylation benchmark, and the ConsensusTME v.1.0
was also the best method with the same cells explaining leukocyte methylation selected
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(Figure 8.3C and Table C3S3). Together, these benchmarks show a consistent improve-
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Fig. 3.4 Unbiased analysis of tumour microenvironment heterogeneity in treatment-naive HG-
SOC tumours. (A) PCA of ssGSEA-based analysis using ConsensusTME v.1.0 estimated cell gene
sets. (B) Principal component feature loadings (magnitude and direction) of A. Vectors are coloured
according to cell types, for example monocytes and macrophages M0, M1, M2 (orange), B cells and
plasma cells (light blue), and CD8 and cytotoxic cells (yellow). (C) Differential expression analysis of
high purity and low purity classified tumours using the median purity score of the cohort as a cut-off
(see Methods). Vertical red lines indicate +/- 1 fold change of gene expression, and the horizontal
line indicates the corresponding 0.05 q-value on the y-axis. D) Gene ontology analysis of significantly
highly expressed genes on low purity tumours. Significantly highly expressed genes in pure tumours
are not significantly over represented in any gene ontology biological process. (E, F) ssGSEA analysis
of differentially expressed genes using hallmarks and ConsensusTME v.1.0 estimated cells, respectively
(see Methods). Gene sets on the x-axes were ranked according to their NES (Tables C3S4A and
C3S4B). Higher NES are indicative of higher purity scores. Dashed red lines indicate median and
± 1.96 median absolute deviations (modified z-score) to define outliers. Marginal density plots of
observed and values fitted to a normal distribution are shown.
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3.5.4 Tumour microenvironment cell decomposition and molecular com-
parison of high and low purity treatment-naive HGSOC
Having generated our own robust method for immune cell estimation, ConsensusTME, we
applied it to the treatment-naive HGSOC transcript data to systematically assess if specific
transcriptional programs were associated with variability in immune infiltration. We first
visualized the variation across samples using the NES of estimated ConsensusTME gene sets
of cells (Figure 3.4A, 8.4A). The gene sets explaining most of the variation were cytotoxic,
NK cells and fibroblast being negatively correlated with tumour purity; while endothelial,
monocytes and B cells positively correlated with tumour purity (Figure 3.4B, 8.4B). The
NES of estimated cells of this cohort were comparable to the NES obtained in the TCGA
ovarian cancer data set (Figure 8.5). Interestingly, the cells with highest NES in most sam-
ples were fibroblasts, highlighting the intrinsic low-immunogenic nature of HGSOC (Wang
et al., 2016).
To investigate genes associated with tumours with high cellularity (pure tumours), we used
the median tumour purity of the cohort to classify high and low purity tumours (see Meth-
ods), and performed a differential expression analysis leveraging sample-patient dependency
(i.e. considering that multiple tumours come from the same individual) to increase statistical
power. As expected, genes related to immune activation were significantly highly expressed
in low purity tumours, but only eleven genes were significantly highly expressed in the purer
tumours compared to the lowly pure ones (Figure 3.4C). Gene Ontology (GO) analysis
showed that genes with significant higher expression in low purity tumours are significantly
enriched in leukocyte proliferation and activation GO biological processes (Figure 3.4D),
whereas no significant GO enrichment was found with the genes significantly highly ex-
pressed in pure tumours. The genes with significantly higher expression in pure tumours
have been implicated in transcription [CPSF6 (Rüegsegger et al., 1998), FOXJ3 (Landgren
and Carlsson, 2004)], cellular growth [HOMER2 (Tu et al., 1998; Xiao et al., 1998), REPS1
(Cantor et al., 1995; Hu and Mivechi, 2003)], glucose transport [MFSD4B (Horiba et al.,
2003)], mitocondrial generation [PTCD3 (Davies et al., 2009)], aberrant proliferation [YBX1
(Frye et al., 2009; Weidensdorfer et al., 2009)], ovarian cancer initiation and progression
[ACP6 (Fang et al., 2002; Hiroyama and Takenawa, 1999), PARP2 (Amé et al., 1999; Gun-
derson and Moore, 2015)] and TGF-beta signalling down-regulation [FAM60A (Muñoz
et al., 2012; Smith et al., 2012)], which consequently can directly and indirectly promote
tumourigenesis through TME immunosuppression (Colak and ten Dijke, 2017; Mariathasan
et al., 2018; Tauriello et al., 2018).
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To further investigate which molecular signalling pathways are more highly enriched in
pure tumours, we performed ssGSEA using the adjusted p-values and changed the sign,
positive or negative, according to the differential expression direction (see Methods). As
expected, immune and stromal signatures were highly enriched in low purity tumours, in
addition to interferon (IFN)-γ response. In contrast, Myc and Wnt signalling appeared
to be highly enriched in pure tumours, both of which have been previously associated
with immune exclusion in pre-clinical models of lung cancer (Kortlever et al., 2017) and
melanoma (Spranger et al., 2015, 2016), respectively (Figure 3.4E). Not surprisingly, the
proliferation related hallmark G2M was highly enriched in pure tumours. Of note, little or
no overlapping between the G2M, Myc and Wnt hallmark gene sets was observed (Figure
8.4C and Table C3S4A; 6 out of 258 genes overlapped between G2M and Myc, and 2 out
of 242 genes overlapped between G2M and Wnt signalling gene sets). Considering the
TME, cytotoxic and NK estimated cells were preferentially enriched in low purity tumours,
whereas endothelial cells were highly prevalent in pure tumours (Figure 3.4F). Since all
genes in the cytotoxic gene set are included in the CD8+ T cell and NK cell gene set, this
suggests that a particular activation of NK cells is more prominent in low purity tumours
(Figure 8.4C), whereas pure tumours only showed enrichment of endothelial cells (Table
C3S4B). These observations suggest that Myc and Wnt signalling gene set enrichments in
pure tumours could be considered at least partially independent of tumour proliferation, and
may also contribute to immune cell exclusion as suggested by other studies (Spranger and
Gajewski, 2018).
3.5.5 Chemotherapy induces immune activation in HGSOC
To investigate the effect of chemotherapy on the TME and evaluate if there is a confounding
effect of the intra-patient TME heterogeneity described above, we studied the transcriptome
of site-matched (n=18) and site-unmatched (n=38) primary and disseminated tumours before
and after treatment with neoadjuvant platinum and taxane chemotherapy in 28 HGSOC
patients (Figure 3.5A, Table C3S5A and C3S5B). Using t-SNE dimensionality reduction
on the whole transcriptomes, we found that treated and untreated samples cluster separately
(Figure 3.5B), in contrast to the treatment-naive samples that cluster in a patient-specific
manner (Figure 3.1B). Using the ssGSEA NES of the hallmark gene sets of site-matched
and site-unmatched samples, we observed that treated and untreated sample groups were sep-
arated by the two first principal components with 63% and 50% of variation in site-matched
and site-unmatched groups, respectively (Figures 3.5C and 8.6A-B). Both site-matched and
site-unmatched groups showed that oncogenic and immune/stromal hallmarks contributed
significantly to the variation explained by the first principal components (Figure 8.6C-D).
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However, only site-matched PC1 reached statistical significance after paired comparison
between pre- and post-NACT samples (Figure 8.6E-F), while also explaining more than 50%
of the variation in the site-matched samples (Figure 8.6A-B). Interestingly, cellular stress
related pathways were more enriched in site-unmatched post-NACT than site-matched sam-
ples, potentially reflecting the cellular stress generated by therapy, whereas in site-matched
samples, immune related pathways dominate the variation signal (Figures 3.5C, 8.6C-D).
In addition, Wnt and Myc signaling showed a clear negative association to immune related
gene sets in the site-matched samples, whereas no clear clustering contribution of Wnt and
Myc gene sets is discernible in the site-unmatched samples (Figure 3.5C).
We then decomposed the TME cellular mixtures to investigate which cells were differentially
present in the pre- and post-treatment tumours. Pre- and post-treatment samples also clus-
tered separately both in site-matched and site-unmatched samples, with the first principal
components accounting for 64% and 43% of variation explained, respectively (Figures 3.5D,
8.7A-B). Eosinophils and cytotoxic cells showed a negative association with tumour purity
in site-matched samples, in contrast to fibroblasts, B cells and macrophages (Figures 3.5D,
8.7C). Interestingly, the only principal components that were significantly different between
pre- and post-NACT samples were the first two principal components of the site-matched
tumours (Figure 8.7E-F).
3.5.6 Tumour-immune microenvironment intra-patient heterogeneity
masks chemotherapy induced immune activation effect
To directly evaluate differences between pre- and post-treatment samples, we performed
an exploratory data analysis leveraging the possibility of performing paired comparisons
using the hallmark and ConsensusTME v.1.0 gene set NES independently for site-matched
and site-unmatched samples (Figure 3.6A). Site-matched samples showed a clear increase
of immune pathways and ConsensusTME v.1.0 gene sets in post-treatment samples, while
site-unmatched samples showed an increase of cellular stress pathways reflecting cellular
and metabolic stress after cytotoxic drug exposure, but no difference of ConsensusTME v.1.0
gene sets was detected in the site-unmatched cohort. Since we observed that cytotoxic and
NK cell ConsensusTME v.1.0 gene sets were mainly enriched in treatment-naive low purity
tumours (Figure 2.4F), and it is known that CD8+ T cells play a crucial role in ovarian cancer
recurrence and overall survival (Zhang et al., 2003), we performed a multivariate Student’s
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Fig. 3.5 Unbiased signalling pathway and tumour microenvironment cell decomposition anal-
ysis of chemotherapy treated HGSOC site-matched and unmatched tumour samples. (A)
Flowchart of sample acquisition, clinical study design, and analysis. TME = Tumour microen-
vironment. (B) t-SNE analysis of overall transcription profiles of multiple HGSOC tumour samples
per patient. (C, D) PCA and principal component feature projections (magnitude and direction) of
ssGSEA-based analysis of hallmark and ConsensusTME v.1.0 gene sets respectively. Arrows in the
principal component space indicate pre- to post-NACT directionality. Hallmark gene set vectors are
coloured according to a major biological classification. Angiog = Angiogenesis, Myog = Myogenesis.
ConsensusTME v.1.0 vectors are coloured according to cell types. Neut = Neutrophils.
We compared the difference between these 3 ConsensusTME v.1.0 gene sets in pre- and
post-NACT site-matched and site-unmatched samples (Figure 3.6B), and observed a signifi-
cant increase of these immune cell types upon chemotherapy in the site-matched samples
(p-value=0.0034), but no difference in the site-unmatched samples (p-value=0.92). To further
evaluate T cell infiltration and activation between pre- and post-NACT samples, we per-
formed in situ TCR sequencing. Since T cell activation leads to clonal expansion of particular
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T cell clonotypes, TCR clonality measures can be used as a surrogate for T cell activation
upon specific (neo)antigen recognition (Jiménez-Sánchez et al., 2017; Kirsch et al., 2015;
Pielou, 1966). TCR clonal expansion was significantly higher in post-NACT site-matched
samples (Figure 3.6C, p-value=0.001), but no significant difference was observed in site-
unmatched samples (p-value=0.2). T cell fraction was also significantly higher in post-NACT
site-matched samples (p-value=0.03), while a slightly lower T cell fraction was observed
in site-unmatched post-NACT tumours, potentially as a result of the variability of immune
infiltration between omentum metastases (pre-NACT biopsies) and primary tumours (post-
NACT debulking surgery). To test whether the biopsy intervention could be a confounder and
lead to an immune activation per se, we compared post-NACT site-matched and post-NACT
site-unmatched TCR clonal expansions, since the post-NACT site-unmatched tumours were
not originally biopsied. No significant difference was observed in TCR clonal expansion
(p-value=0.67), suggesting that T cell clonal expansion was independent of biopsy treatment
and likely induced by NACT. However, a significant increase of T cell density was observed
in site-matched compared to site-unmatched post-NACT tumours (p-value=3.59×10−05),
potentially suggesting that wound healing after the biopsy procedure could increase the influx
of T cells. Together, these results provide evidence that neoadjuvant chemotherapy induces
an immune activation in the local TME of HGSOC, and that intra-patient inter-site TME
heterogeneity can obscure this clinically relevant observation among tumour deposits within
patients.
Finally, we investigated whether hallmark pathways or ConsensusTME gene signatures cal-
culated from the pre-treatment samples could explain the increase of TCR clonality upon
neoadjuvant chemotherapy in site-matched samples (n=8, only 8 pre-treated samples with
both gene expression and TCR-seq data were available, see Figure 3.5A, Table C3S5B). To
perform the analysis in an unbiased manner, we employed LASSO regression analysis with
the change of TCR clonality before and after NACT as a response variable (see Methods).
The hallmark pathways that potentially have predictive value with positive association were
the hallmarks G2M checkpoint, Myc and Wnt signalling and UV response, while apoptosis
and PI3K-AKT-MTOR showed a negative association with TCR clonality increase (Figure
3.6D). We then performed the same analysis using the ConsensusTME gene signatures, where
B cells, M1 macrophages and endothelial cells showed a positive association with TCR
clonal expansion, while cytotoxic, CD4+ and plasma cells showed a negative association. In
addition, the LASSO analysis selected the ConsensusTME v.1.0 cytotoxic signature as rele-
vant for explaining T cell clonal expansion upon NACT, and a correlation analysis supported
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Fig. 3.6 Immune activation induced by neoadjuvant chemotherapy is evident in site-matched
but not site-unmatched sample analysis. (A) Exploratory pre/post NACT paired comparisons of
hallmark gene sets and ConsensusTME v.1.0 estimated cells (see Methods). (B) Multivariate T2 tests
comparing pre and post-NACT CD8 T cells, NK cells, and cytotoxic NES together. (C) Comparisons
of TCR productive clonality (top), and percentage of productive T cells (bottom) between pre and post-
NACT site-matched and site-unmatched samples. Paired and unpaired tests were used accordingly.
TCR clonality is expressed as 1-entropy with values near 1 representing samples with one or a few
predominant TCR rearrangements, while values near 0 represent more polyclonal samples (D) Least
Absolute Shrinkage and Selection Operator (LASSO) regression analysis using the pre-NACT matched
(n=8 samples) hallmark and ConsensusTME v.1.0 NES as explanatory variables, and the log2 of the
TCR clonality ratio of post/pre-NACT as response variable (see Methods). DF = Degrees of Freedom.
The variables selected by the LASSO regression are indicated with an asterisk. (E) Spearman’s rank
correlation of pre-NACT cytotoxic NES and log2 of the post/pre-NACT TCR clonality ratio.
Post-selection inference, taking into account for the uncertainty of the model selection and
multiplicity, corroborated that the pre-NACT NES of the ConsensusTME cytotoxic gene
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set is a promising variable to explain T cell clonal expansion upon NACT in these eight
samples (p-value=0.096, see Methods). Overall, we were able to detect T cell activation in
HGSOC site-matched but not in site-unmatched samples, further suggesting that different
local immune-microenvironments play a role in the response to chemotherapy treatment.
Also, pre-treatment samples with low T cell infiltration have a significant increase of TCR
clonality upon chemotherapy, while tumours with higher infiltration levels do not have such
a high clonal expansion, an observation that could not be addressed in unmatched tumour
samples, due to the intra-patient tumour-immune heterogeneity. This highlights the potential
confounding effects that intra-patient tumour-immune heterogeneity imposes on comparing
tumours not only from different patients but also from different sites within the same patient.
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3.6 Discussion
Despite advances in surgical approaches, chemotherapy and targeted therapies, the prognosis
for patients with HGSOC remains poor, with the near-inevitable development of resistance
to systemic therapy. Genetic and molecular analyses of asynchronous and disseminated
tumours within patients have recently started to shed light on tumour clonal dynamics and
evolutionary properties of different tumour types (Johnson et al., 2014; McPherson et al.,
2016; Yates et al., 2015); however, the extent of TME heterogeneity in advanced HGSOC has
only begun to be revealed (Jiménez-Sánchez et al., 2017; Zhang et al., 2018). We explored
the main sources of variation in the transcriptomic space among treatment-naive samples
and detected that transcriptomic pathway heterogeneity is mainly explained by presence or
absence of immune and stromal cells. Importantly, the degree of immune signature variation
within patients was similar to the extent we observed in a case study of metastatic HGSOC,
where different tumour immune microenvironments were associated with clinical outcome.
In the case study (see Chapter 2), tumours with high immune related pathways regressed
and presented evidence of T cell activation, while immune excluded tumours progressed
(Figure 2.1) (Jiménez-Sánchez et al., 2017).
In the present study, all patients presented at least one tumour with low immune infiltration,
suggesting that HGSOC is characterised by microenvironmental niches, which could underlie
primary and acquired resistance to therapies (Hirata et al., 2015; Sharma et al., 2017; Wang
et al., 2016). The transcriptional, imaged-based and immunofluorescence analyses show that
TME heterogeneity is an intrinsic feature of HGSOC, which spans across patients, tumours
within patients and within tumours. We also integrated data from different estimation and
regression methods, as well as cell type-specific gene signatures to generate a consensus
approach (ConsensusTME) which consistently improved the predictions on our data sets
and in TCGA ovarian cancer leukocyte methylation data (see Chapter 4). Application
of ConsensusTME to the treatment-naive samples showed that cytotoxic and NK cells are
the major populations present in low purity tumours, while endothelial cells are the main
TME cell type in high purity tumours. Pathway analysis of the differentially expressed
genes showed that Wnt and Myc signalling pathways were more prevalent in purer tumours,
consistent with emerging data in HGSOC and other tumours and models (Damsky et al., 2011;
Gounari et al., 2002; Spranger et al., 2015, 2017, 2016; Sridharan et al., 2016). Furthermore,
we found that intra-patient TME heterogeneity can mask the immune activation generated by
treatment with cytotoxic chemotherapy. These analyses provide firm evidence that the TME
affects the extent of immune activation generated upon treatment with chemotherapy.
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integration approach.
Highlights
• Development of an enrichment-based method that integrates genes used by other methods
in a cancer specific manner (ConsensusTME).
• Pan-cancer DNA, methylation, and H&E based benchmarks of tumour purity, leukocyte,
and lymphocyte infiltration.
• Side-by-side independent methods benchmarks using PBMCs and tumour samples.




The tumour microenvironment comprises complex cellular compositions and interactions
between cancer, immune, and stromal components which all play crucial roles in cancer.
To estimate the relative abundance of different cell types in an unbiased manner using
bulk tumour RNA data, various computational approaches have been developed during the
last decade. However, a comparison that objectively evaluates the performance of these
approaches against one another has not been conducted. Here we benchmarked six widely
used tools and gene sets: Bindea et al. gene sets, Davoli et al. gene sets, CIBESORT, MCP-
counter, TIMER, and xCELL. We also use ConsensusTME, a consensus approach that uses
the union of genes that the six tools used for cell estimation, and corrects for tumour-type
specificity. We benchmarked the seven tools using TCGA DNA-derived purity scores (33
tumour-types), methylation-derived leukocyte scores (30 tumour-types), and H&E deep
learning derived lymphocyte counts (13 tumour-types), and individual benchmark data sets
(PBMCs and 2 tumour-types). None of the seven tools outperformed the others in every
single benchmark, and ConsensusTME was overall the top performing method in all cancer-
related benchmarks. Computational methods that provide robust and accurate estimates of
non-cancerous cell populations in the tumour microenvironment from tumour bulk expression
data are important tools that can advance our understanding of tumour, immune, and stroma
interactions, as well as potential clinical application if high accuracy estimates are achieved.
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4.3 Introduction
The tumour microenvironment (TME) plays an active role in in tumour initiation, progression,
metastasis, and treatment response. Thus, studying the TME is a central paradigm of cancer
research. However, a great variety of stromal and immune cell types populate tumour tissues,
and the role of many of these cell types is still unclear or their effect in different tumour-types
is largely unknown. Traditionally, cells from the TME have been quantified using immunohis-
tochemistry (IHC), immunofluorescence (IF), and flow cytometry, and more recently using
time of flight cytometry (CyTOF). These methods, although accurate, are laborious, low
throughput and require pre-selected cellular markers and therefore their application in large
number of samples and measurements is challenging. Thus, their systematic application for
comprehensively investigating the various different cell types in the TME in an unbiased
manner is limited.
Estimation of non-cancerous cell proportions from bulk tumour samples has been performed
using whole-exome sequencing, RNA-seq, or DNA methylation data. During the last decade,
multiple computational approaches have been developed intending to calculate quantitatively
or semi-quantitatively distinct TME cell-type population estimates (Finotello and Trajanoski,
2018). A variety of statistical frameworks and algorithmic procedures have been employed,
and each method has used different benchmark data sets (Finotello and Trajanoski, 2018).
In general, two different algorithmic classes into which most methods can be classified
are deconvolution algorithms and gene set enrichment-based methods. Importantly, both
classes rely on cell-type specific markers that are selected according to prior knowledge. The
deconvolution algorithms use linear combinations of the expression values of the cell-specific
genes, while gene set enrichment-based methods rank the genes of a mixture sample and
compute enrichment scores as a function of the ranked selected genes. A problem, however,
is that each method has claimed to outperform others, and debates about which statistical
frameworks are better suited have arisen (Li et al., 2017a; Newman et al., 2017). Thus, the
need for independent and more comprehensive benchmarks has been pointed out (Zheng,
2017). Additionally, with the diversity of methods developed, cell-type marker specific genes
can be curated and consensus gene sets generated. Here, we developed a consensus approach
(ConsensusTME) for the selection of cell-type specific gene sets after overlapping six widely
used TME cell estimation methods. We performed pan-cancer benchmarks using publicly
available bulk RNA sequencing data from TCGA and side-by-side comparisons using the
methods’ independent benchmarks. Finally, since the ConsensusTME approach ensembles
genes selected by different methods for different cell types, this makes ConsensusTME an
evolvable method by design.
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Quantification and statistical analysis
Further information and requests for resources and reagents should be directed to and will be
fulfilled by Alejandro Jiménez-Sánchez (alejandro.jimenezsanchez@cruk.cam.ac.uk) and Dr
Martin L. Miller (martin.miller@cruk.cam.ac.uk).
Quantification and Statistical Analysis
Single-sample gene set enrichment analysis
⊙
Single-sample gene set enrichment analysis (Barbie et al., 2009), a modification of standard
GSEA (Subramanian et al., 2005), was performed on RNA measurements for each sample
using the GSVA package version 1.28.0 (Hänzelmann et al., 2013) in R version 3.5.0 with
parameters: method = ’ssgsea’, and tau = 0.25. Normalized enrichment scores were generated
for the hallmark gene sets (Liberzon et al., 2015), immune and stromal signatures (Yoshihara
et al., 2013), TME cell gene sets obtained from previous publications (Bindea et al., 2013;
Davoli et al., 2017), as well as the consensus TME gene sets (Figure 8.3A). Hallmark gene
sets were obtained from MSigDB database version 6.1 (Liberzon et al., 2015).
ConsensusTME cell gene sets
⊙
To generate the ConsensusTME gene sets we identified cell types that were deconvoluted
by at least 2 different methods, leading to 18 different cell types. We then intersected the
gene sets that the different methods considered for the deconvolution of such cell types. To
intersect genes used in CIBERSORT, we first filtered out genes whose weight was below
1.96 standard deviations of the mean for each of CIBERSORT cell types. In addition we
combined activated states into the corresponding cell type. The only activated stated included
was cytotoxic cells, which would include CD8 and/or NK cells in their activated stated. The
intersected genes were used to represent each cell type, and genes with a higher Pearson’s
correlation coefficient than −0.2 and a p-value ≤ 0.05 with tumour purity as defined by
TIMER were filtered out from the gene sets (Li et al., 2016). Finally, ssGSEA was employed
to calculate NES for each cell type as described above.
Comparison statistical metrics
⊙
The different estimation tools were compared against each other using either Kendall’s rank
correlation coefficient or the multiple linear regression goodness of fit metrics: adjusted
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R-squared, Akaike Information Criterion (AIC), and Bayesian Information Criterion (BIC).
AIC and BIC z-scores values were calculated to incorporate different tumour types in the
comparisons since AIC and BIC values are unit-less. Differences between groups of variables
were identified using one-way ANOVA with Tukey honest significant differences post-hoc
tests. All statistical tests were adjusted for multiple testing using the Benjamini-Hochberg
procedure to control for false discovery rate (FDR).
TCGA immune estimations
⊙
RNA-seq data was collected from cBioPortal (Cerami et al., 2012). Batch normalisation
had been applied and gene expression values calculated using the “RSEM” pipeline (Li and
Dewey, 2011). Four TME cell estimation methods and two published gene sets were used to
produce relative abundances of immune cell types across 33 tumour types. For each method,
a general immune score was also derived if it was not already provided, representing the total
level of immune cell infiltration in each tumour sample.
TME cell deconvolution methods
⊙
Cell deconvolution methods were used to estimate levels of non-cancerous cells in the TME.
The methods employed were CIBERSORT (Newman et al., 2015), MCP-counter (Becht
et al., 2016), TIMER (Li et al., 2016), xCELL (Aran et al., 2017), as well as gene sets
collected from two previous publications (Bindea et al., 2013; Davoli et al., 2017).
Bindea et al. and Davoli et al. gene sets
⊙
Gene sets provided by Bindea et al. and Davoli et al. were used with ssGSEA to pro-
vide enrichment scores for each of the immune signatures. To generate general immune




The “xCell” R package (version 1.12) was used to generate immune estimates for the xCell





Estimations for the MCP-counter method were produced using the “MCPcounter” R package
(version 1.1.0) (Becht et al., 2016). Immune scores for this method were produced in a
similar manner as the ssGSEA methods by creating a union of signature genes for each of
the cell types. The “MCPcounter.estimate” function was used to allow for the new signature.
CIBERSORT
⊙
CIBERSORT estimations were produced using the R source code, provided on request
from the web resource (Newman et al., 2015). CIBERSORT was run in “Absolute mode”
(under beta development) using 100 permutations and quantile normalisation disabled as
recommended for RNA-seq data. Absolute scores representing the “overall immune content”
is produced natively by the algorithm in absolute mode.
TIMER
⊙
TIMER estimations were produced using R source code, available from the web resource (Li




ConsensusTME selects cell types that are estimated by at least two methods and generates
a gene set for that cell type. The genes that other methods have considered as relevant for
that cell type are incorporated into the gene set. Genes whose gene expression does not
correlate negatively (Pearson’s correlation coefficient lower than -0.2) with tumour purity, in
a tumour specific manner using TCGA data, are filtered-out. Thus, each gene set represents
the consensus genes for a given cell type in a particular tumour type. General immune scores
for each tumour types were generated by combining the genes of the different immune cells
into one gene set.
Purity score benchmark
⊙
Pan-cancer purity scores were downloaded from the NIH Genomic Data Commons (Hoadley
et al., 2018). Purity scores were generated using ABSOLUTE (Carter et al., 2012) which
uses copy number, variant allele frequency, and tumour specific karyotype data to calculate
the cancer fraction of a tumour samples. To benchmark the immune estimation method-
ologies using purity of samples the immune scores were added to an independent stromal
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score; calculated through the use of ESTIMATE (version 1.0.13) (Yoshihara et al., 2013).
ABSOLUTE’s derived tumour purity and the different methods tumour purity scores were
correlated independently for each tumour type.
Leukocyte methylation benchmark
⊙
Leukocyte methylation scores were downloaded from the NIH Genomic Data Commons
https://gdc.cancer.gov/about-data/publications/PanCan-CellOfOrigin (Hoadley et al., 2018).
Leukocyte methylation and CD8+ T cell estimations were correlated, since CD8+ T cells
are estimated by all the methods. Multiple linear regression was then employed using all
leukocytes the methods estimate as explanatory variables and the leukocyte methylation
scores as response variable. Leukocyte methylation data was log transformed to meet the
normality and heteroscedasticity assumptions of the model. Adjusted R squared, AIC, and
BIC metrics were calculated to compare the goodness of fit between the methods considering
the number of variables included in the model.
Somatic single nucleotide mutation data
⊙
Somatic single nucleotide mutation data was downloaded from the Broad Institute GDAC
Firehose.
H&E deep learning lymphocyte fractions benchmark
⊙
Lymphocyte fractions were generated by Saltz et al. for 13 TCGA cancer types. Multiple
linear regression was applied in a similar manner as for the leukocyte methylation analysis,
instead using a hyperbolic sine transformation of lymphocyte fraction as a response variable
to meet normality and heteroscedasticity assumptions of the model. Models for each method
were fitted using only lymphocytes as explanatory variables.
Independent methods side-by-side benchmarks
⊙
The benchmarking validation experiments for each of the methods were replicated, where
possible, to match the parameters used in the original publications. Of the six methods there
were four benchmarking datasets available; either online or provided by the authors. Each
of the datasets contained samples with bulk gene expression values along with matched
“ground truth” values. The CIBERSORT benchmarking dataset, provided by the authors
on request (Newman et al., 2015), consisted of flow cytometry values of different immune
cell types from PBMC samples. The xCell benchmarking datasets, SDY311 and SDY420,
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were publicly available for download from ImmPort (Bhattacharya et al., 2014), and the
validation data consisted of matching CyTOF quantification of immune cells from PBMC
samples. The MCP-counter publication used gene expression profiles from GEO (accession
number GSE39582) and IHC counts of CD3+, CD8+, and CD68+ cells (available on request
from the authors) (Becht et al., 2016). TIMER benchmark consisted of H&E stained slides
from TCGA Adrenocortical Carcinoma (BLCA) study. Pathological estimations of these
slides were carried out to categorise each sample into one of three categorical levels for
neutrophil abundance: “Low”, “Medium” or “High”; estimations are available from the
TIMER online resource (Li et al., 2016). For all benchmarking experiments, except TIMER,
concordance was measured using correlation between “ground truth” values and the immune
estimations of each method. Due to the variation in the degree of specificity to which cell
subsets were defined, summations of subsets was required to allow accurate comparisons in
some cases. For the TIMER benchmark, the in-silico neutrophil estimations for each method
were grouped by low, medium and high pathological estimation, then compared through
ANOVA with Tukey post hoc.
Data and Software Availability
Further information and requests for resources and reagents should be directed to and will be
fulfilled by Dr Martin L. Miller (martin.miller@cruk.cam.ac.uk).
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4.5 Results
4.5.1 Consensus tumour-type specific superset of tumour microenvi-
ronment cell populations
Following the generation of large data sets of tumour genomic profiles, various computational
tools assessing TME cell populations have been generated, each using different algorithms,
gene markers, and validation benchmarks. To build on the knowledge of cell-type specific
gene sets represented in the diversity of these methods, we sought an integrative strategy that
incorporates cell types and genes from the collection of independent tools. ConsensusTME
integrates cell-type specific gene markers used by independent cell estimation methods,
then we employed single sample gene set enrichment analysis (ssGSEA) to compute TME
cell-type and tumour specific enrichment scores from bulk expression data (Figure 4.1A
and Figure 8.3A). The ssGSEA approach was selected because its treats microarray and
RNA-seq values in the same way, since it is based on the ranked genes rather than the actual
values. To generate ConsensusTME, we selected six widely used cell estimation methods
that use different statistical and algorithmic frameworks, estimate different cell types, and
use different genes for their estimation. The selected methods were CIBERSORT (Newman
et al., 2015), TIMER (Li et al., 2016), MCP-counter (Becht et al., 2016), xCELL (Aran et al.,
2017), and the gene sets generated and use in (Bindea et al., 2013; Şenbabaoğlu et al., 2016)
and in (Davoli et al., 2017) here called “Bindea” and “Davoli” supersets, respectively. In
brief, we first selected cells that are estimated by at least two methods. Second, we generated
a gene set for each cell type by using the union of genes used by the methods to estimate that
cell type, and remove genes that correlate (ρ > -0.2) with tumour purity as done before (Li
et al., 2016) (see Methods). Therefore, ConsensusTME aggregates cell-type specific genes
that have been independently considered relevant by different methods, and estimates their
abundance in a tumour type specific manner.
4.5.2 Pan-cancer stroma, leukocyte, and lymphocyte benchmarks
To benchmark the different methods in an objective and systematic manner, we used publicly
available data from between 13 and 32 tumour types comprising 9,142 tumour samples in
total. First, we correlated DNA-based tumour purity scores (Carter et al., 2012; Hoadley
et al., 2018) with purity scores generated by the different methods, or customly derived
when not generated by default (see Methods). Since tumour purity does not account only
for immune cell infiltration but also for other stromal cells (e.g. fibroblasts and endothe-
lial cells) (Binnewies et al., 2018), this would affect the correlation of methods that only
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estimate immune cells. Therefore, we inferred stromal non-immune related content of all
samples using ESTIMATE (Yoshihara et al., 2013) and added this value to all methods’
purity scores. We found that all six methods and ConsensusTME perform very similar to
each other, with CIBERSORT, ConsensusTME, and Davoli as the top 3 pan-cancer negative
correlations (Figure 4.1B). Across tumour types, the different methods performed similar
and very few correlations were not statistically significant. As expected, tumour purity and
leukocyte fraction show a negative correlation across tumours, however neither mutation load
nor leukocyte fraction associated with the purity correlations calculated. Thus, the ability
to estimate tumour purity using expression profiles is largely independent from the cancer
cellularity and mutation load in the sample for any of the methods.
We further evaluated the performance of the methods by using leukocyte fractions derived
from methylation data for 30 tumour types (Hoadley et al., 2018). For this analysis we
fitted multiple linear regression models using only the scores of leukocyte infiltration from
each method as explanatory variables and the leukocyte fraction as response variable. When
comparing the adjusted coefficients of determination (R2) of the different models, the best
performing methods were Bindea, ConsensusTME, and Davoli (Figure 4.1C). Since different
methods estimate different number of leukocytes, the coefficient of determination can be
artificially increased by the number of variables in a model (i.e. overfitting). Thus, to more
appropriately compare the models we used the Akaike Information Criterion (AIC) and
Bayesian Information Criterion (BIC) for model selection, which penalise model complexity
(i.e. number of leukocytes used in the models) less or more heavily, respectively (Figure
4.1D). The AIC and BIC scores showed that ConsensusTME, Davoli, and Bindea models per-
form significantly better than the other methods (models with lower AIC and BIC values are
preferred). We also implemented multiple linear regression analysis using tumour-infiltrating
lymphocyte counts derived from digitised H&E-stained images analysed through a deep-
learning convolutional neural network approach (Saltz et al., 2018). Although low coefficient
of determination values were obtained across methods, likely due to the very difficult task of
computationally discriminate leukocytes on H&E images, the methods that obtained a higher
coefficient of determination were Bindea, CIBERSORT, and ConsensusTME, while the lowest
AIC and BIC values were obtained by ConsensusTME, Davoli, and TIMER (Figure 4.1E).
Together, these broad pan-cancer benchmarks show a large variation in the performance
of the different methods when compared to each other, and no single method consistently
outperforms the others.
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Fig. 4.1 Benchmark of methods for estimating TME cell components using purity and leukocyte
data from TCGA data. (A) Bioinformatic tools benchmarked, and ConsensusTME development
strategy (see Methods). (B) Kendall’s correlation coefficients (τ) of DNA-derived ABSOLUTE purity
scores (Carter et al., 2012; Hoadley et al., 2018) and RNA-derived estimated purity by the different
methods. ESTIMATE’s stromal scores were added to all the methods to account for stromal quantities,
since not all methods analyse stromal cells. (C) Kendall’s correlation coefficients (τ) of methylation-
derived leukocytes’ scores (Hoadley et al., 2018) and RNA-derived CD8+ T cell estimations. (D)
Multiple linear regression models of leukocyte methylation scores as response variable (Hoadley
et al., 2018) and RNA-derived leukocyte estimations as explanatory variables. Column heatmaps are
sorted according to leukocyte methylation scores (Left: Low, Right: High), rows are sorted according
to median performance (Top: Best, Bottom: Worst). (E) Multiple linear regression models of deep
learning H&E-derived lymphocyte counts as response variable (Saltz et al., 2018) and RNA-derived
lymphocyte estimations as explanatory variables. Kendall’s correlation significance is shown with
small/large squares as indicated by the q-value multiple test corrected. Adjusted R2, AIC z-score, and
BIC z-score were compared across models generated by each tool cellular estimations. Lower AIC
and BIC values represent a better goodness-of-fit penalising the number of variables.
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Continuation of Figure 4.1 caption . . .
Median single nucleotide variants (SNVs), ABSOLUTE purity scores (purity), and leukocyte methy-
lation scores (Leuk.) per tumour type are shown in B, C, and D. Violin plots are sorted according to
median correlation coefficient (left: best, right: worst). ACC n=77, BLCA n=397, BRCA n=1052,
CESC n=293, CHOL n=36, COAD n=281, DLBC n=47, ESCA n=162, GBM n=154, HNSC n=509,
KICH n=66, KIRC n=498, KIRP n=285, LGG n=519, LIHC n=359, LUAD n=504, LUSC n=493,
MESO n=81, OV n=293, PAAD n=159, PCPG n=165, PRAD n=473, READ n=92, SARC n=246,
SKCM n=460, STAD n=403, TGCT n=155, THCA n=469, THYM n=103, UCEC n=175, UCS n=56,
UVM n=80.
4.5.3 Independent methods benchmarks
All methods tested, except Bindea and Davoli gene supersets, performed their own independent bench-
marks in the original publications. Thus, we collected benchmark data for CIBERSORT, xCELL,
TIMER, and MCP-counter to carry out a side-by-side comparisons. We used the CIBERSORT
benchmark data that consisted of peripheral blood mononuclear cell (PBMC) of 27 human subjects
and quantified by flow cytometry (Newman et al., 2015). Correlations between estimated immune cell
types and the flow cytometry fractions showed that the best performing methods were MCP-counter,
CIBERSORT, and xCELL (Figure 4.2A). However, most of the correlations lacked statistical signifi-
cance, and due to the different cell types estimated by the different methods it is difficult to reach a
conclusion. Similarly, the xCELL benchmark data set consisted of 16 PBMC leukocyte subsets from
two different studies with 61 and 104 human subjects each, where PBMCs were measured using Time
of Flight Cytometry (CyTOF) (Aran et al., 2017). Again, MCP-counter, CIBERSORT, and xCELL
were the methods that showed best performance in these PBMC benchmarks, however many cell
types did not reach statistical significance (Figure 4.2B).
Finally, we used cancer-related benchmarks from TIMER (Li et al., 2016) and MCP-counter (Becht
et al., 2016). For TIMER’s benchmark, 404 TCGA bladder cancer samples were analysed by a
pathologist who categorised them as low, medium, or high according to their neutrophil counts using
H&E stained slides. Here, ConsensusTME, Bindea, and TIMER obtained the best separation between
categories, but only ConsensusTME and Bindea separated significantly the three categories after multi-
ple test correction (Figure 4.2C). Interestingly, xCELL, CIBERSORT, and MCP-counter were unable
to differentiate the three categories, while Davoli does not estimate neutrophils. The MCP-counter
benchmark consisted of IHC digital quantification of CD3+ (T cells), CD8+ (CD8+ T cells), and
CD68+ (Monocytic lineage) cell densities from 38 colorectal cancer samples. Correlations between
the methods’ estimations and the cellular fractions were computed (Figure 4.2D). ConsensusTME,
MCP-counter, and Davoli methods provided the best correlations, with ConsensusTME out-performing
on the three cell types.
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MCP-counter IHC COADREAD cell densities benchmark
Fig. 4.2 Side-by-side benchmark using available datasets published by the individual methods.
(A) Kendall’s correlation coefficients (τ) of CIBERSORT PBMCs’ flow cytometry (n=20 samples)
and (B) xCELL PBMCs’ CyTOF benchmarks. SDY311 (n=61 samples) and SDY420 (n=104 samples)
are different benchmarks available from ImmPort (Bhattacharya et al., 2014). Since not all methods
estimate cell activation states, cell proportions were aggregated into the cell type and use for correlation
with the methods that do not estimate activation states. The grey box represents correlation coefficients
that have a q-value > 0.05 (BH method). Box plots are sorted according to median correlation
coefficient (Left: Best, Right: Worst).
4.5 Results 113
Continuation of Figure 4.2 caption . . .
(C) Comparison between low, medium, and high categories of BLCA (n=404 samples) neutrophil
haematoxylin and eosin pathology counts. One-way ANOVA with Tukey HSD post hoc tests were
employed to calculate q-values. Plots are sorted according to performance (Left-Top: Best, Right-
Bottom: Worst). (D) Kendall’s correlation coefficients (τ) of MCP-counter colon adenocarcinoma
(COAD) IHC (n=38 samples) cell densities (cellmm2). Plots are sorted according to median correlation
coefficient (Left: Best, Right: Worst).
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4.6 Discussion
With the recent generation of large publicly available molecular profiling of cancer samples, a variety
of computational tools for analysis of cell components of the TME have been generated. In principle,
the method of choice should be based on performance, however popularity and ease of use are often
reasons behind the method researchers select (Zheng, 2017). In the case of TME cell estimation from
bulk expression data, this problem is magnified by the lack of objective and independent benchmark
analyses, since most methods use their own benchmarks which may introduce biases and reliance on
one type of data. The tools that have been developed so far for the estimation of TME cell types using
tumour bulk expression data fall under two main statistical frameworks: enrichment analysis and
algorithmic deconvolution (Finotello and Trajanoski, 2018). Here we performed an independent and
objective benchmarking exercise comparing six of the most widely used and recent tools, and also
developed ConsensusTME: a gene set enrichment based method that integrates cells and genes from
these six different tools in order to generate a consensus gene superset that is tumour-type specific.
We performed pan-cancer benchmarks using orthogonal data types generated for TCGA samples.
While DNA-derived tumour purity scores correlated negatively and similarly with RNA-derived TME
estimations in all methods, leukocyte methylation scores showed some discrepancy across methods,
and some lack of correlation in some cases. Also, different tumour types showed different levels of cor-
relation with leukocyte estimations, which could be due to the leukocyte methylation signature model,
which was generated by comparing pure leukocyte cells and normal tissue methylation patterns with
tumour-type specific methylation patterns (Hoadley et al., 2018), and tumour infiltrating leukocytes
may have different methylation patterns. Furthermore, lymphocyte deep learning H&E quantifications
provided a lower association with lymphocyte RNA-derived estimations, an observation that has
been reported before and considered to be in part due to the RNA-derived estimates reflect more cell
counts, while spatial image-derived estimates reflect the fraction of lymphocytes per area (Saltz et al.,
2018; Thorsson et al., 2018). Thus, this benchmark is inconclusive due to the uncertainty of both
RNA-derived and imaged-based derived lymphocyte estimates, but it was included to achieve more
comprehensive and orthogonal benchmarks. Moreover, for the application of TME cell estimation
using bulk RNA tumour data, PBMC benchmarks may not be very informative as these are circulating
and not necessarily infiltrating immune cells. In contrast, both BLCA and COADREAD bench-
marks on neutrophils, CD3+, CD68+, and CD8+ cells showed significant associations for some tools,
particularly ConsensusTME. These benchmarks showed that no independent method is consistently
outperforming other methods. Nevertheless, overall ConsensusTME ranked among the top three best
performing methods in all cancer-relates benchmarks. Lastly, ConsensusTME is an evolvable method
by conception, which means that other genes used by new methods can be added to the gene sets and
tested with the already defined benchmarks, thus potentially improving its performance as different
and new methods are developed.
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4.7 Contributions
CRediT standard taxonomy: http://dictionary.casrai.org/Contributor_Roles
Conceptualisation
Ideas; formulation or evolution of overarching research goals and aims
AJS, MM
Data curation
Management activities to annotate (produce metadata), scrub data and maintain research data








Acquisition of the financial support for the project leading to this publication
MM
Investigation




Development or design of methodology; creation of models
AJS, OC
Project administration
Management and coordination responsibility for the research activity planning and execution
AJS, MM
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Resources
Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumenta-
tion, computing resources, or other analysis tools
MM
Software
Programming, software development; designing computer programs, implementation of the computer
code and supporting algorithms; testing of existing code components
OC, AJS
Supervision
Oversight and leadership responsibility for the research activity planning and execution, including
mentorship external to the core team
AJS, MM
Validation
Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of
results/experiments and other research outputs
OC, AJS
Visualisation
Preparation, creation and/or presentation of the published work, specifically visualization/data
presentation
OC, AJS
Writing original manuscript draft
Preparation, creation and/or presentation of the published work, specifically writing the initial draft
AJS
Writing review & editing
Preparation, creation and/or presentation of the published work by those from the original research




Genetic and molecular analyses of asynchronous and disseminated tumours within patients have
recently started to shed light on tumour clonal dynamics and evolutionary properties of different
tumour types (Johnson et al., 2014; McPherson et al., 2016; Yates et al., 2015). However, the
extent of TME heterogeneity and the degree to which TME may be driven by stochastic, cellular or
molecular processes is not well understood. Specifically in HGSOC, this has great relevance due
to the known intra-tumour genetic heterogeneity and the lack of therapeutic success in advanced
stages of the disease. Particular findings of the studies presented in this thesis may have important
clinical implications if they are corroborated in larger cohorts. First, in the patient case study and
then confirmed in the treatment-naive cohort, we observed coexistence of distinct TME with different
immune infiltration levels across metastases within single patients. We sought factors behind the intra-
patient TME heterogeneity, as these could serve as potential therapeutic targets, and also to understand
fundamental properties of TME dynamics. Second, we evaluated the effect of NACT chemotherapy
on the TME of HGSOC and found that intra-patient TME heterogeneity can be a confounder and has
to accounted for to achieve reliable interpretations. Third, we benchmarked state-of-the-art TME
cell estimation methods that use bulk tumour expression data as input, and generated a consensus
method that, unlike the other methods, provides consistent high accurate estimations in pan-cancer
benchmarks and individual experimental quantifications of cells in the TME. Together, these results
provide a framework for the study of the TME dynamics in cancer using bulk tumour derived data
and bioinformatics approaches.
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5.1 HGSOC case study
In the case study, where WES data was generated, we sought differences and similarities in somatic
mutations between progressing and regressing tumours. Since the patient of the case study had
received multiple chemotherapeutic treatments, it could be possible that progressing tumours had
acquired mutations that provided resistance to therapy. However, no specific mutations in progressing
tumours that could explain the observed dichotomous progression/regression status were found. Since
regressing tumours had a higher immune infiltration, we asked whether mutation or neoepitope
load, or specific neoepitopes were responsible for the differences observed in immune infiltration.
We found that the mutation and predicted neoepitope loads alone could not explain the different
regressing/progressing behaviour of the metastatic samples. Although, a single case, it is known that
HGSOC has a low mutation rate, thus the mutation load may play a less preponderant role in this
disease in respect to immune evasion compared to other tumour types. In addition, since the patient
of the case study did not receive immunotherapy, in principle, the selective pressure induced by the
immune system onto the mutation and neoepitope landscape would be lower than in patients that have
received immunotherapy treatments. Indeed, recent studies looking for mechanisms of immunotherapy
resistance, have detected mutations in the antigen presentation machinery (Giannakis et al., 2016),
β2-micro-globulin (Zaretsky et al., 2016), the IFN-γ pathway (Benci et al., 2016; Zaretsky et al.,
2016), or HLA-I genes (Tran et al., 2016) in resistant tumours. In pan-cancer studies, using thousands
of untreated primary tumours, only few mutations in the antigen presentation machinery (Rooney et al.,
2015; Shukla et al., 2015), β2-micro-globulin (Challa-Malladi et al., 2011; Rooney et al., 2015), and
HLA-I genes (Rooney et al., 2015; Shukla et al., 2015) were detected. Although, we cannot exclude
that mutations in these pathways may occur in patients with HGSOC, in this case study we did not find
mutations that could explain the dichotomous progression pattern of metastatic lesions. This result,
however, opened up other avenues of possible causes behind the differential progression/regression
and immune infiltrations observed. Indeed, instead of specific mutations or subclonal neoepitopes
present in the regressing samples of the case study, TCR clonal expansion and T cell reactivity against
clonal neoepitopes (i.e. present in all tumours) were detected. Strikingly, through an epitope T cell
challenge experiment, we found that all neoepitopes that elicited a CD8+ T cell response had higher
mutant to wild-type HLA-I predicted binding affinity. The lack of tumour-specific somatic alterations
in the regressing and stable tumours alone suggests that other factors in the tumour microenvironment
may have been playing a critical role in the immune response and overall fate of the tumours.
Transcriptional signatures can be highly informative as diagnostic/prognostic resources, as well
as provide insights on mechanistic underpinnings (Burel and Peters, 2018). Thus, we analysed the
transcriptional profiles of the progressing and regressing tumours of the case study. We found that
STAT1 and CXCL9 were highly expressed in the regressing metastases. CXCL9 is well known as a
potent T cell chemokine (Liao et al., 1995; Rainczuk et al., 2012), and high expression of CXCL9
and CXCL10 correlate with enhanced T cell infiltration of tumours and better survival of ovarian
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cancer patients (Bronger et al., 2016). In contrast, when looking at gene expression signatures, the
growing vaginal cuff metastasis had a higher ES in the Wnt pathway, which has been implicated as a
mechanism that impairs recruitment of dendritic cells and prevents T cell infiltration in autochthonous
mouse melanoma models via a CXCL9- and CXCL10-dependent mechanism (Spranger et al., 2015,
2017). Although a direct link between tumour fate and the observations found in this patient could
not be proved with the available samples, this case emphasises the importance of an integrative
approach to understand the molecular mechanisms governing the interaction between the tumour
and its immune microenvironment (Miao and Van Allen, 2016), and points to the importance of the
specific TME state, in addition to specific epitopes influencing the immune response.
As in any case study, the present work has notable limitations. It involves only one patient, and
thus further studies are needed to determine whether the principles discovered here apply to other
patients. Furthermore, the interplay between treatment, somatic mutations, the immune system, and
heterogeneous fates of the tumours could not be untangled in this clinical case. For example, it is
feasible that the multiple chemotherapy interventions for this patient contributed to shape the somatic
mutations and the microenvironment of the tumours, but due to the availability of samples and descrip-
tive nature of the study this could not be explored further. Despite such limitations, this case provides
evidence for differential tumour-immune responses existing in metastases of the same individual,
related not only to genetic alterations but also to the tumour-immune microenvironment, which to
our knowledge has not yet been demonstrated in patients with ovarian cancer. Also, most studies on
the tumour-immune microenvironment have been conducted in primary tumours (Teng et al., 2015),
with the exception of a study of matched primary and metastatic tumours, which concluded that the
immune con-texture globally recapitulates that of the primary (Remark et al., 2013). In contrast, the
case of recurrent HGSOC presented here, clearly shows the opposite: that tumour-immune microenvi-
ronments, between primary tumour and metastases, and between metastases, can be heterogeneous
within a patient. Studying the intersection between ITH and TME heterogeneity could be a path to
understand the reason behind these conflicting observations.
Previous genomic and immune profiling of multiple lesions in patients have also shed light on
tumour heterogeneity and its implications on tumour evolution (Gerlinger et al., 2012), disease
progression (Ascierto et al., 2017), and immune control (McGranahan et al., 2016; Sridharan et al.,
2016; Şenbabaoğlu et al., 2016). For example, tumours that are genetically more heterogeneous
have less immune infiltrates (Şenbabaoğlu et al., 2016) and less benefit from checkpoint-blockade
immunotherapies (McGranahan et al., 2016). It has been shown that T cell infiltration and gene
expression of immune-related genes correlate with response to checkpoint-blockade immunotherapy
in melanoma (Chen et al., 2016). Additionally, analyses of synchronous resected metastases with
differential progression in patients with melanoma has shown that intra-patient metastases present
not only genetic heterogeneity but also immune-infiltration heterogeneity of immune cell types and
T cell clonality between samples (Reuben et al., 2017). A rapid autopsy study of a patient with
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metastatic melanoma treated with anti-PD-1 therapy showed that resistant metastases over-expressed
genes related to extracellular matrix and neutrophil function (Ascierto et al., 2017). Interestingly,
association between Wnt signalling and lack of T cell infiltration was also observed in a patient with
adenoid cystic carcinoma where serial biopsies from the same patient were analysed, and different
expression profiles between primary and metastatic deposits were also detected (Sridharan et al.,
2016). Finally, a plethora of molecular mechanisms and types of cells influencing the tumour-immune
microenvironment have been described in different tumour types, leading to important advances in
immunotherapy (Joyce and Fearon, 2015; Melero et al., 2014; Sharma et al., 2017). Unfortunately,
the promise of immunotherapy has not been as successful in ovarian cancer as it has been in other
tumour types (Homicsko et al., 2016) despite the fact that it has been recognised more than a decade
ago that T cell infiltration is a key element for patient outcome in this disease (Zhang et al., 2003).
We believe that the growing evidence of differential genomic, transcriptomic, and immune profiles
between and within patients will eventually provide new key elements to target in ovarian cancer and
other tumour types. However, this task will require extensive and deep systematic analyses along
with longitudinal data, as the differences between metastases and coexistence of tumour-immune
microenvironments within a patient are likely to be dynamic and sensitive to intrinsic (e.g., mutations
and cell-cell communication) and extrinsic perturbations (e.g., prior treatment and microbiome) (Sivan
et al., 2015; Vetizou et al., 2015).
5.2 Treatment-naive HGSOC
Given the observations of the case study and the mentioned limitations, we set up a follow-up study
with treatment-naive HGSOC patients with metastatic disease to further evaluate intra-patient TME
heterogeneity. We performed an unbiased transcriptomic analysis of primary and disseminated
treatment-naive HGSOC tumours and detailed immunofluorscent quantification of T cell subpopula-
tions. We explored the main sources of variation in the transcriptomic space among treatment naive
samples and detected that transcriptomic pathway heterogeneity is mainly explained by presence of
immune and stromal cells, or lack thereof. Importantly, the degree of immune signature variation
within patients was similar to the one we observed in a case study of metastatic HGSOC, where
different tumour immune microenvironments were associated with clinical outcome: tumours with
high immune related pathways regressed and presented evidence of T cell activation, while immune
excluded tumours progressed (Figure 2.1). In addition, all patients presented at least one tumour with
low immune infiltration, suggesting that HGSOC is characterised by TME havens, which could under-
lie primary and acquired resistance to therapies (Hirata et al., 2015; Sharma et al., 2017). Through MR
image analysis we captured immune signature differences within tumours, which was confirmed by
immunofluorescence staining of T cells, and again variation of T cell infiltration within tumours was
observed. Together the transcriptional, imaged-based, and immunofluorescence analyses show that
TME heterogeneity is an intrinsic feature of HGSOC, which spans across patients, tumours within
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patients, and within tumours. Furthermore, we found different levels of general immune infiltrates
on different metastases within patients as in the case study. Having multiple tumour samples from
the same patient, we were able to perform differential expression analysis between high and low
purity tumours controlling for patient dependency. Pathway analysis of the differentially expressed
genes confirmed the previous observation that Wnt and Myc signalling pathways were more preva-
lent in purer tumours. This result supports the evidence we also observed in the case study, where
immune-excluded tumours showed an increase expression of Wnt signalling compared to infiltrated
tumours (Figure 2.2). In addition, accumulated evidence in different tumour types and murine cancer
models suggests that Wnt signalling can promote immune-exclusion (Spranger et al., 2015, 2017,
2016; Sridharan et al., 2016), and that the immune-exclusion was caused by a tumour cell-intrinsic
oncogenic Wnt signalling activation (Damsky et al., 2011; Gounari et al., 2002; Spranger et al., 2015).
Likewise, recently it was shown in a mouse model of lung cancer that Myc signalling overexpression
can reprogram the immune component of the TME to a more immunosuppressed state, which was
substantially dependent on NK cells (Kortlever et al., 2017). Previous work has also suggested that
Myc signalling can inhibit T cell activation and infiltration (Rakhra et al., 2010), as well as directly
regulating expression of immune checkpoint molecules in cancer cells (Casey et al., 2016). However,
more research is required to conclusively elucidate the potential molecular and cellular mechanisms
behind the association between Wnt and Myc signalling with low immune infiltration in HGSOC.
The evaluation of TME cell population in the tumours using expression data has been an area
of intense research in the last decade (Finotello and Trajanoski, 2018). Previous unbiased immune
enrichment and deconvolution studies have estimated relative abundances of immune cells in ovarian
cancer tumours (Newman et al., 2015), and calculated survival associations (Li et al., 2016); however,
no objective independent benchmarking has been performed to date, and discordant results make it dif-
ficult to judge these observations (Li et al., 2017b; Zheng, 2017; ?). We integrated data from different
enrichment/deconvolution methods and generated ConsensusTME, a consensus enrichment approach
that consistently improved the predictions on our 440 quantifications IF data set of T cell subsets,
and in TCGA ovarian cancer leukocyte methylation. We then evaluated which cell populations may
have a higher degree of infiltrates in impure treatment-naive HGSOC tumours. The analysis using
ConsensusTME showed that cytotoxic and NK cells were the major populations present in low purity
tumours, while endothelial cells were the main TME cell types in high purity tumours. A previous
pan-cancer analysis showed negative correlations between somatic copy number alterations (SCNA)
and estimated immune infiltrates, and that NK cells and CD8+ T cell receptor pathway were the
most differentially abundant immune factors between tumour samples with high versus low SCNA
(Davoli et al., 2017). Despite these associations, the molecular mechanisms underlying this negative
correlation between immune infiltrate and SCNA in HGSOC have not been elucidated. Interestingly,
NK cell infiltration appeared to be significantly higher in tumours with low SCNAs in HGSOC
(Davoli et al., 2017), and our results also showed that NK cells were more enriched than CD8+ and
CD4+ T cell infiltration in low purity tumours, which would have low SCNA according to the previous
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study (Davoli et al., 2017)), and have higher Wnt and Myc signalling. In addition, different studies
have observed association between loss of p53 function and decrease of NK cell infiltration in mouse
models (Xue et al., 2007) and T cell infiltration in human breast cancers (Iannello et al., 2013). In
fact, missense or nonsense mutations in p53 are the earliest and almost ubiquitous (96%) alterations
in HGSOC (Ahmed et al., 2010; TCGA, 2011). Altogether, these different lines of evidence help to
clarify why HGSOC is intrinsically non-immunogenic: beyond the low somatic missense mutation
load and the high SCNAs, the intrinsic oncogenic signalling of HGSOC seem to shape the TME and
hinder immune infiltration of T cells and NK cells in treatment-naive tumours.
5.3 Pre/post neoadjuvant chemotherapy HGSOC
Targeting the TME has proven to be extremely successful in some cases, and thus represents a
promising alternative to complement current therapeutic strategies in different tumour types including
HGSOC (Hansen et al., 2016). Since the standard of care treatment in HGSOC is primary debulking
surgery followed by platinum based chemotherapy or NACT followed by interval debulking surgery,
there are significant potential clinical implications from understanding the effect of chemotherapy
on the TME and the molecular drivers of the TME heterogeneity observed. While response rates
to initial treatment are high, acquired resistance and relapse occurs in 80 to 90% of cases (Bowtell
et al., 2015). A previous study investigated the effect of NACT on the activation of CD8+, CD4+ and
Tregs in HGSOC, as well as systemic levels of cytokines (Böhm et al., 2016). This study found that
patients who had good responses to NACT had a decrease of Tregs after treatment compared to poor
responders. In general, there was also a trend towards higher cytolytic activity in tumours after NACT
despite failing to detect significant changes on CD8+ T cell counts (Böhm et al., 2016). Therefore,
we applied the same unbiased approach we used with the transcriptomes of treatment-naive HGSOC
samples to explore the effect of chemotherapy on the TME of matched and unmatched pre/post-NACT
treated HGSOC samples. We found an increase of cytotoxic immunogenic activity after NACT in
matched tumour samples but not in site-unmatched samples from the same patient. Similarly, employ-
ing TCR-seq, we found a significant increase in T cells and TCR clonality in matched samples, but
no significant difference was detected in unmatched pairs. Comparing post-NACT site-matched and
post-NACT site-unmatched samples indicated that the observed change in TCR clonal expansions was
driven by chemotherapy and not by the biopsy itself, although we cannot formally exclude potential
immunogenic effects that the biopsy procedure may have in a neoadjuvant setting. Together, these
results show a clear confounding effect that spatial TME heterogeneity can cause when deriving bio-
logical interpretations if heterogeneity is not taken into account. In addition, these results indicate that
besides T cells, NK cells could be a potential TME cellular target in HGSOC. Further experimental
and clinical investigations would be required to evaluate this data driven hypothesis.
Having unmasked the immune activation generated by NACT, we used the matched samples to
5.3 Pre/post neoadjuvant chemotherapy HGSOC 123
investigate the factors in pre-treated samples that influence TCR clonal expansion induction upon
NACT. Interestingly, cytotoxic cells showed a significant negative association with TCR clonal expan-
sion, and the PI3K-AKT-MTOR pathway, which is part of the TCR signalling cascade, also showed a
strong negative association. Conversely, Wnt and Myc signalling appeared as positively associated
with TCR clonal expansion. Together, these results suggest that tumours with low levels of infiltration
have a higher potential for T cell activation upon NACT than tumours with a previous immune
presence. We hypothesise that this could be due to an already exhausted immune TME generated as a
consequence of chronic immune and tumour interaction, while immune excluded tumours present a
fresh environment where T cells can become active and expand. These results provide an argument for
rational use of checkpoint blockade immunotherapy after NACT that warrants further clinical study.
Importantly, our results also point towards NK cells being similar or more activated after NACT,
further suggesting NK cells as potential therapeutic cellular target for combination therapy. Finally,
this conclusion could only be drawn when intra-patient spatial TME heterogeneity was controlled for,
again highlighting the necessity to take TME heterogeneity into consideration in translational studies
and in clinical applications.
Taking all the clinical data together, here we have presented how TME heterogeneity is a com-
mon feature of HGSOC and how it can affect the interpretation of translational studies. We have
sought to uncover molecular and cellular mechanisms behind intra-patient and intra-tumour TME
heterogeneity. However, there are critical limitations to consider. Disentangling the actual mechanisms
using human tumour samples represents a formidable challenge since tissue samples are limited,
inter-patient variability is prominent, and mechanistic experimental validation on these patients is
prohibitive. Given these constraints, these studies are descriptive in nature and relies heavily on
independent observations derived by other studies that use murine tumour models to propose suit-
able explanations. Despite this main limitation, our unbiased analysis on human tumours not only
complements in vivo studies, but also provides new hypotheses to further explore in a pre-clinical
and clinical settings. Another major limitation is the small number of samples available compared
to the large parameter space to investigate in an unbiased systematic study, which poses a challenge
not only for achieving statistically meaningful results but also for the findings to be influenced by
confounding variables and biological/technical noise. However, the implementation of orthogonal
methods in combination with the independence of the case study, the treatment-naive, and NACT
cohorts provide solid evidence of TME heterogeneity at multiple dimensions in addition to reasonable
putative mechanisms behind it. Ultimately, we hope that the increasing scientific evidence would
lead to better designed clinical trials, where TME heterogeneity is further evaluated, data driven
combination therapies or novel therapies are tested, and tissue sections are systematically analysed
and stored for future integrative unbiased analyses.
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5.4 TME cell estimation from bulk tumour expression data
Beyond systematic unbiased analyses, it is important also to consider the inherent limitations and
opportunities with the data obtained from these samples. It is known that tumours comprise highly
complex cellular compositions and inter-cellular interactions. Thus, disentangling the underplaying
mixture of cellular and molecular interactions occurring in tumours and their microenvironment is
a challenging task, particularly when analysing bulk tumour data. Bulk sequencing analysis poses
inherent limitations such as the need to employ deconvolution or enrichment methods to estimate
cellular populations. These estimations are not 100% accurate and absolute cell counts have not been
estimated yet [reviewed in (Finotello and Trajanoski, 2018)]. However, the huge amount of publicly
available bulk data generated so far and the ever decreasing cost of sequencing has made the estimation
of TME cell populations in bulk expression data a data mining challenge worth pursuing. Multiple
computational approaches have been developed to estimate quantitatively or semi-quantitatively the
different TME cell populations, using different statistical frameworks, and different using their own
benchmark data sets. A problem however, is that each method claims to outperform previous ones,
which has created confusion and debates in the field (Li et al., 2017a; Newman et al., 2017). The
need for independent and more comprehensive benchmarks has then be rightly proposed (Zheng,
2017). After benchmarking six recently published TME cell population estimation methods using
bulk expression profiles and T cell counts from IF data, as well as TCGA HGSOC cancer samples
with leukocyte methylation data, we did not find a consistently outperforming method. Thus, we
generated a consensus enrichment approach that integrates marker genes form the other methods and
filters out genes that most likely are cancer related based on purity-gene expression correlations, we
called the tool: "ConsensusTME". Using ConsensusTME we found that it consistently outperformed
the other methods in our IF data set and in the TCGA HGSOC. Thus we performed an unbiased
pan-cancer benchmarks, and collected independent benchmarks data sets from the different methods
to comprehensively evaluate the methods performances.
Currently we are also evaluating whether we can add weights to the genes selected by ConsensusTME.
The reason behind adding weights to genes is based on the idea that genes can be expressed by
non-cancerous and cancerous cells, thus a "confidence score or weight" for each gene would poten-
tially increase the accuracy of ConsensusTME, by giving greater weights to genes that are most likely
expressed only by non-cancerous cells. One way to do it would be to calculate gene expression and
CNA correlations, since positive correlations are most likely to represent tumour derived transcripts,
while no correlation would most likely represent non-cancerous derived transcripts. We can then
transform the correlations to their additive inverse and convert to a positive scale to generate weights
for each gene in a tumour type specific manner using TCGA data. This also would compensate for
cellular gene expression collinearity, which is an obstacle in the estimation of TME cell populations,
as more genes with different weights would be added to each cell type and tumour type. Compensating
biological collinearity is crucial since it is challenging to differentiate true biological from statistical
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collinearity, as well as distinguish similar cell types in a complex sample (Li et al., 2017a). This
is work ongoing, but preliminary results (not shown here) suggest that a the weighted version of
ConsensusTME could improve its performance. Overall, these group of analyses show the utility
and need of independent comprehensive benchmarks to assess tool performances. Additionally, by
leveraging information from different tools and adding gene-specific and tumour-specific information
increased the consistency in performance on the different benchmarks. Lastly, ConsensusTME is an
evolvable method by conception, which means that other genes used by new methods can be added to
the gene sets and tested with the already defined benchmarks.
Despite the progress made with the different methods created for estimation of TME cell popu-
lations, it is foreseeable that given the amount of heterogeneity in tumours, an upper level limit in
accuracy will be reached at some point. Similarly, due to the difficult task of setting apart biological
and statistical collinearity, and the intrinsic biological and technical noise, the level of resolution
between cell types and activation states will be reached sooner or later. Moreover, these TME cell
estimation methods depend completely on prior knowledge of cell types and gene markers of them,
precluding the possibility of discovering new cell types or cellular states. Also, the integration of
bulk RNA sequencing data and image analysis is correlative and mechanistic insights are descrip-
tive in nature. An imminent consequence of these limitations together is that a large number of
samples is often required to observe significant associations, which is not trivial for phase I and II
clinical trials, since these usually recruit an order of magnitude of patients less than the required
for achieving statistically significant observations using bulk data. Novel ways to study the TME
with higher level of granularity and data types are required. As the fields of single-cell RNA-seq
and high-dimensional image analyses continue to progress, new advances and discoveries tackling
limitations of bulk genomic studies in cancer and TME dynamics are likely to be covered, discoveries
confirmed, completed, and complemented (Azizi et al., 2018; van Dijk et al., 2018; Zheng et al., 2017).
Overall, the studies presented in this thesis show that the TME of HGSOC is intrinsically heteroge-
neous within patients and within tumours, posing an important barrier for the successful application
of therapies in general, and in particular ones that target the TME, like checkpoint blockade im-
munotherapy. However, insights into potential mechanisms driving TME heterogeneity obtained
only after controlling patient dependencies, put forward new therapeutic strategies to be explored in
future studies. Furthermore, the induced immunogenicity upon NACT treatment was only unmasked
after taking into account the TME heterogeneity, which otherwise acts as a confounding variable.
Also, coordinating comprehensive benchmarks for TME cell population estimation methods, and
leveraging upon independent methods to integrate a consensus approach is a valuable strategy to
increase consistent accuracy of estimated proportions. Finally, increasing our understanding of the
TME composition and dynamics has the potential to change the current paradigm of treatment and




Here we showed evidence of divergent tumour genetics, TMEs, and immune activation within a
single patient with advanced HGSOC. We confirmed the coexistence of TMEs within treatment-naive
HGSOC patients, and reported intra-tumour levels of TME heterogeneity as well. Furthermore,
the induced immunogenicity upon NACT treatment was only unmasked after taking into account
the TME heterogeneity, which otherwise acts as a confounding variable. The intra-patient TME
heterogeneity described here bespeaks a profound clinical challenge for therapeutic success and
correct interpretations. By controlling patient dependency and accounting for intra-patient TME
heterogeneity, insights into potential mechanisms driving TME heterogeneity were obtained, putting
forward new therapeutic strategies to be explored in future studies. These observations, although
made in small patient cohorts, may explain the frequent heterogeneous responses seen clinically and
the lack of objective response to checkpoint blockade immunotherapy. In addition, we conclude that
comprehensive independent benchmarks should be performed more broadly to inform the community
and provide more accurate and reliable systematic analyses. Our benchmarks for TME cell population
methods showed no consistent outperforming method, which prompted us to generate a consensus
approach (ConsensusTME). Unlike the other methods, ConsensusTME consistently performed among
the top methods, sometimes even outperforming methods in their own data sets. ConsensusTME
was conceived to be an evolvable method which will incorporate other methods and provide the
benchmarks to the community for their own tests. Given the data presented in these studies, it will be
essential to understand not only how to therapeutically target ITH between and within metastases, but
also how to successfully mobilise an anti-tumour immune response able to control all metastases in
advanced cancers despite the broad intra-patient TME heterogeneity observed. We foresee this would
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Fig. 7.1 Non-silent somatic mutations and copy-number alterations, related to Figures 2.1 and
7.2 and Table S1. (A) Binary matrix of present/absent non-silent point mutations (n=188) used
for the phylogeny tree reconstruction in Figure 2.1D. (B) Relative copy-number alterations inferred
from WES data of the primary and metastatic samples using CopywriteR (Kuilman et al., 2015). (C)
Relative copy number profiles and tumour purity inferred after ABSOLUTE (Carter et al., 2012)
analysis. Amplified and deep deleted DNA segments were defined as copy number alterations with at
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Fig. 7.2 Gene set enrichment analysis of transcript abundance and somatic alteration patterns
across samples, related to Figure 2.2 and Table S2. (A–C) Gene-expression levels and genetic
alterations of the DNA damage, apoptosis pathways, and caspases. (D) Expression levels of the 50
most variant genes according to their coefficient of variation. (E) Differential enrichment scores and
enrichment q-values of down-regulated pathways between tumour samples. No significantly enriched
pathways (q-value < 0.05) with at least ± 1 log2 change relative to the median of the other samples































Fig. 7.3 Complete slide haematoxylin and eosin and immunofluorescent staining, related to
Figure 2.3 and Table S3. Hematoxylin and eosin staining of tumour samples. Immunofluores-
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Fig. 7.4 Neoepitope distributions and HLA-I neoepitope depletion analysis, related to Figure
2.4 and Table C2S4. (A) Number of unique and overlapping expressed missense mutations, HLA-I,
and II neoepitopes between samples. (B) Correlations between expressed missense mutations and
predicted HLA-I neoepitopes using NetMHC. KDE = Kernel Density Estimate. (C) Top: Estimated
neoepitope deviation from expected in the five tumour samples compared to TCGA ovarian cancer
samples (n=150) (see Methods). Bottom: Neoepitope depletion analysis of 150 random unique
permutations of the patient’s tumours (primary, spleen, RUQ, liver, and vaginal cuff) and their
mutations. Each sample was compared against its own 150 unique permutations to control for the
number of mutations. Two-sided empirical p-values were calculated from each distribution.
163
A































1 23 4 5 6 7 8 9 10 11


















IP cisplatin IV carboplatinPaclitaxel










































T cell - neoepitope recognition assay
PBMC intracellular staining gating strategy









































Lymphocytes Live CD45+ CD3+ CD45+








































Fig. 7.5 PBMCs sample time line and T cell-neoepitope recognition assay, related to Figures
2.4 and 2.6, and Table C2S5. (A) Blood samples obtained from the patient 550 and 978 days after
resection were used for TCR sequencing and T cell – neoepitope recognition assays respectively.
(B) Experimental set-up and flow cytometry gating strategy for the T cell–neoepitope recognition
assays (intracellular cytokine staining assay) with surface staining of CD3+, CD4+, CD8+, CD45+,
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Fig. 8.1 Principal component hallmark gene sets’ loadings of treatment-naive HGSOC samples,
related to Figure 3.1. (A) Principal components’ variance. (B) Kruskal-Wallis H-test p-values
calculated for hallmark classes (top), and loadings of hallmarks for each principal component sorted
in groups according to the gene sets’ classes defined (bottom). Significant Dunn’s Kruskal-Wallis
multiple comparisons with Bonferroni correction are indicated: adjusted p-value < 0.05 *, adjusted
























Fig. 8.2 Total counts of T cell subsets in treatment-naive HGSOC samples, related to Figure 3.2
and Table C3S2. Immunofluorescent total CD8+, CD4+, and Tregs counts. 440 different regions
were scanned and computationally quantified.
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Fig. 8.3 Flowcharts for consensus TME gene set generation and TCGA OV leukocyte methyla-
tion benchmarks, related to Figure 3.3 and Table C3S3. (A) Generation of ConsensusTME v1.0
gene sets by taking the intersection of genes used by other methods. (B) TCGA OV leukocyte





















































































































































Fig. 8.4 Principal component TME cell gene sets’ loadings of treatment-naive HGSOC samples
and gene sets’ overlaps, related to Figure 3.4. (A) Principal components’ variance. (B) Loadings
of hallmarks for each principal component sorted. (C) Overlap of genes between hallmark gene sets,
and between consensus TME cells gene sets. Gene sets that were differentially enriched between high
and low purity treatment-naive HGSOC samples (Figure 3.4E, F) are highlighted in colour.
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Fig. 8.5 Normalised enrichment scores of estimated TME cells in TCGA ovarian cancer and
the treatment-naive HGSOC cohort, related to Figure 3.4.
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Fig. 8.6 Principal component hallmark gene sets’ loadings of pre/post-NACT matched and
unmatched HGSOC samples, related to Figure 3.5. (A, B) Principal components’ variance. (C,
D) Kruskal-Wallis H-test p-values calculated for hallmark classes (top), and loadings of hallmarks
for each principal component sorted in groups according to the gene sets’ classes defined (bottom).
Significant Dunn’s Kruskal-Wallis multiple comparisons with Bonferroni correction are indicated:
adjusted p-value < 0.05 *, adjusted p-value < 0.01 **, adjusted p-value < 0.001 ***, adjusted p-value <
0.0001 ****. (E, F) Principal components’ paired comparisons. Significant differences after Wilcoxon
signed-rank tests are indicated: p-value < 0.05 *.
173
BA


















































































































































































Fig. 8.7 Principal component ConsensusTME gene sets’ loadings of pre/post-NACT matched and
unmatched HGSOC samples, related to Figure 3.6. (A, B) Principal components’ variance. (C, D)
Loadings of estimated TME cells for each principal component sorted. (E, F) Principal components’





Supplementary figures for Chapter 4:
Comprehensive benchmarking and integration
of tumour microenvironment cell
estimation methods
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